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ABSTRACT
This thesis considers the range of technological developments which are required in order 
to allow the creation of biosensors based upon keto reductases generated from microbial sources.
Using the oral anticoagulant warfarin as a model compound, a range of microorganisms were 
screened for an ability to reduce the aliphatic ketone group present in the drug to the 
corresponding alcohol. High performance liquid chromatography was used as the analysis method. 
Two successful microorganisms from the genus Rhodococcus were grown in a fermenter to produce 
lOOg quantities of cells for further study.
The electrochemical problems which occur when creating a biosensor based on a reduction were 
considered. The electrochemical regeneration of enzymatically active reduced nicotinamide cofactors 
is difficult. An high performance liquid chromatography technique was developed to allow the 
determination of the products formed when the electrochemical reduction of nicotinamide adenine 
dinucleotide was carried out at different cathodic potentials at a mercury electrode.
In order to attempt to prevent the formation of nicotinamide adenine dinucleotide dimers and 
other inactive products during electrochemical reduction, a number of organometallic rhodium 
compounds were considered as possible electron transfer mediators and reaction modifiers. The 
synthesis of these compounds, based on the nitrogen containing heterocyclic ligands 2,2/-bipyridine 
and 2,2/;6/,2//-terpyridine and analogues, was attempted.
Methods for the incorporation of bacterial keto reductases, cofactors and mediators in to 
amperometric biosensors are discussed.
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1 INTRODUCTION. AIMS AND SCOPE
1.1 The Amperometric Biosensor
There has been intense research and interest in recent years in the emergent Biosensor 
technologies. A wide range of techniques are available to create devices which combine the 
specificity of biological systems with the high sensitivity of modern transducers. Several 
books1,2,3 and many reviews of the subject have been published.4,5,6,7,8
A generic scheme for the construction of a biosensor is given in Figure 1.1
Many biosensors are based on the detection of products or reactants of an enzyme 
catalysed reaction. Device specificity is dependent upon the substrate specificity of the 
enzyme. Certain other sensors are based upon detecting the interaction between an 
antibody and its antigen. In theory, some of the available transduction methods should be 
able to detect almost any biological binding event.
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Figure 1.1 The generation of a signal in a generic biosensor
This introduction does not attempt to review all the different methods available for the 
creation of biosensors. It focuses its attention on the technological problems which have to 
be overcome in order to use enzymes for the creation of amperometric biosensors.
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The basic requirements for an amperometric biosensor are:-
a) an enzyme which acts on its substrate to produce (or consume) a molecule which is 
capable of being reduced or oxidised (directly or indirectly) at a suitable electrode.
b) a method for immobilising the enzyme in close proximity to the electrode which 
retains the activity of the enzyme.
c) an electronic system capable of controlling the potential of the electrode and 
measuring the current produced by the oxidation or reduction.
Oxidation-reduction reactions are performed by enzymes which the International Union 
of Biochemistry classifies as oxidoreductases.
An oxidoreductase which has been studied in great detail for the construction of 
biosensors is Glucose Oxidase (GOD) due to its relatively low cost, high activity, good 
stability and due to the potentially lucrative applications of a simple glucose sensor. The 
development of the glucose sensor is explained in some detail as it serves to illustrate the 
types of technological hurdles which need to be overcome in order to develop other 
amperometric sensors.
The action that glucose oxidase has on glucose can be represented as follows:-
GOD
GLUCOSE + 0 2 ------------------------- >  GLUCONOLACTONE + H20 2
The first glucose sensor9 used an oxygen electrode (cathode) with GOD entrapped at its 
surface, to measure the local decrease in the oxygen tension at the electrode surface, this 
being proportional to the concentration of glucose in the solution. The problem with this 
arrangement was the dependence of the output current on the dissolved oxygen 
concentration of the glucose solution being analyzed. Below a certain dissolved oxygen
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tension the current becomes proportional to the oxygen concentration rather than the 
glucose concentration.
An ingenious cylindrical sensor design10 was developed and successfully used for the 
cathodic detection of ’oxygen decrease’. This electrode allowed oxygen to diffuse into the 
enzyme layer from two directions, but only allowed glucose to enter from one direction. 
This enabled glucose detection at lower concentrations of dissolved oxygen than in the 
original glucose sensors.
Most later sensors have relied upon the electrochemical detection of the hydrogen 
peroxide produced by oxidising it at an anode.11
H20 2  >  2H* + 0 2 + 26-
Glucose oxidase contains two cofactor molecules of flavin adenine dinucleotide (FAD). 
These do not readily dissociate from the enzyme and therefore they are best described as 
prosthetic groups. Each group is capable of being reversibly reduced to give FADH2.
+  2 H






Figure 1.2 Oxidised and reduced forms of the isoalloxazine moiety of flavin adenine 
dinucleotide
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Therefore, the conversion of glucose to gluconolactone by GOD can be more fully 
represented12 by:-
GOD-2FAD + glucose GOD-2FADH2 + gluconolactone
^  GOD-2FAD + ’electron acceptor’
(reduced)
GOD-2FADH2 + ’electron acceptor’
(oxidised)
As seen earlier, the ’natural’ electron acceptor in solution is dissolved oxygen.
If glucose oxidase is immobilised at the surface of a suitable electrode which is poised at 
+0.7V (with respect to a Ag/AgCl electrode) a glucose sensor can be formed. The current 
flowing in a three electrode electrochemical cell, which has a glucose oxidase electrode as 
the working electrode, is proportional to the concentration of glucose in the cell solution. 
The reaction scheme for such a sensor is illustrated more clearly in Figure 1.3




C O D  (
G O D  ( r
G l u c o s e
G l u c o n o l o c t  o n e
s u r f a c e
Figure 1.3 The reaction scheme for an amperometric glucose oxidase electrode.
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GOD (red) and GOD (ox) are the reduced and oxidised forms of Glucose Oxidase. Med (red) 
and Med (ox) are the reduced and oxidised forms of the electron transfer mediator.
However such a scheme has severed problems
a) if the solution has a very low oxygen concentration, the reaction rate will be 
controlled by the oxygen level rather than the glucose concentration.
b) the electrode must be held at approximately +0.7V13. This potential is in the region 
where the current produced from anodic decomposition of H20 2 is proportional to its 
concentration, but is below the potential at which solvent breakdown occurs (details of 
experimentally determined potentials for the electrolysis of water at a range of different 
electrode materials can be found in the book by Adams14).
At such a high potential, other biological molecules are capable of reacting at the 
electrode surface, the most notable of these being ascorbic acid.
In order to overcome these problems, the use of small redox molecules as electron transfer 
mediators has been attempted by a number of workers. Ferrocene derivatives have received 
the most research attention for this purpose (see section 1.3).
1.2 Enzyme Im m obilisation M ethodology and E lectrode Types 
An area which is crucial to the production of a functional glucose sensor is the method 
used to immobilise the enzyme (and any electron mediators) at the electrode surface. Many 
different techniques have been proposed and a small selection of these will be outlined 
below.
a) The earliest examples of immobilisation involved the use of simple semi-permeable 
membranes (eg dialysis membrane) to enclose the enzyme. In the first glucose sensor9
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a membrane was also used between the platinum electrode surface and the enzyme to 
protect the platinum from contamination by the enzyme.
The currents produced by such designs are limited by the diffusion rates of 
substrates through these membranes. This can be a useful phenomenon as diffusion 
through such membranes is a concentration dependent process. Provided a sufficiently 
high concentration of the enzyme is present in the entrapped layer, a linearisation of 
the sensor response can be achieved15. If the membrane is thick however, it can take 
considerable time for a steady state to be achieved, leading to long response times. Also, 
detrimental changes to the local environment of the enzyme may occur due to the build 
up of products of the reaction within the layer enclosed by the membrane.
Some of the more recent designs of implantable sensor use membranes to entrap the 
enzyme layer16 for bio-compatibility reasons. Very few of the electron transfer 
mediators so far considered for use in biosensors (see section 1.3) have been assessed 
for their toxicity in mammals17,18.
b) Inert proteins such as albumin, have been cross-linked with glutaraldehyde, at the 
electrode surface, to form a matrix to entrap the enzyme. Synthetic gels, such as 
acrylamide / methacrylamide co-polymers have also been used19.
c) Chemical bonding of the enzyme to various electrodes has been attempted. The 
method used by Ianniello and Yacynych(FromRef 20) is shown in Figure 1.4
This method was used with both GOD and L-amino acid oxidase and produced 
electrodes which remained active for up to 30 days.
d) In an attempt to achieve direct electron transfer between the FAD moieties of 
flavoenzymes (such as Glucose oxidase) and an electrode, certain ‘conducting organic 
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Figure 1.4 Enz3 rme immobilisation using chemical modification of graphite surface.
Albery et a l23,24 have used tetrathiafulvalin ium  tetracyanoquinodim ethanide 
(TTFTCNQ - Figure 1.5) to construct sensors with five different flavoenzymes; xanthine 
oxidase, D-amino acid oxidase, L-amino acid oxidase, choline oxidase and glucose 
oxidase26.
Electrodes were constructed by forming a slurry of the salt and FVC in tetrahydro- 
furan. This was then used to fill a platinum cavity or used to coat a glassy carbon 
electrode. The enzyme (in an electrolyte solution) was then immobilised using a dialysis 
membrane secured with an 0  ring.
These sensors have the advantage of requiring no mediator at all (a mediator may 
be generated at the electrode surface by local dissolution of the electrode), and the
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reduced forms of the enzymes can be oxidised directly at the electrode surface at 







Figure 1.5 Structure of Tetrathiafulvaline (TTF) and Tetracyanoquinodimethane (TCNQ)
e) Recently, the use of polypyrrole as an enzyme entrapment matrix has generated a 
lot of interest.
It was found by Diaz and Castillo26 in 1980 that pyrrole, dissolved in a variety of 
solvents, would readily polymerise at the surface of an electrode poised at between 
+0.8V and +1.3V. Further papers have discussed the variation in the mechanical, 
chemical, and electrical properties of the films produced.27,28,29
The use of polypyrrole in biosensors began in 1986, and if an enzyme is present 
when the electrochemical polymerisation of pyrrole takes place, some of the enzyme will 
be trapped at the electrode surface.12,13,30
The film produced is electrically conducting in its oxidised form and has an overall 
positive charge (approximately one positive charge for each four monomer rings). It 
consists mainly of linear chains which are joined by the a  carbon atoms (Figure 1.6), 
although some cross-linking via the {$ carbons probably occurs.
The main advantages of polypyrrole film entrapment are:-
a) The immobilisation is a one step process.
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Figure 1.6 Diagrammatic representation of the conducting form of polypyrrole.
b) The film thickness is proportional to the amount of current passed, and can easily be 
controlled.
c) Electron mediators can be trapped at the same time as the enzyme.
d) The process should lend itself well to the production of very small sensors and to the 
production of multi-sensor probes.
e) It may be possible to construct multi-layer systems, with different enzymes in each 
layer, to produce coupled reactions. This may increase the range of substrates which can 
be measured.
f) It has been shown recently that direct electrochemical transfer is possible between 
the active centre of enzymes and conducting polypyrrole microtubules without the need 
for additional electron mediators31.
g) Polypyrrole can be used to improve the performance of conducting organic salt 
electrodes32.
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Other molecules can be electrochemically polymerised and have also been used for 
enzyme immobilisation including N-methyl-pyrrole, aniline, phenol6 and 1,3- 
diaminobenzene33.
In addition to its use as an enzyme immobiliser, polypyrrole has also been studied for 
use in conductimetric sensors. A change in the local environment of the pyrrole film due 
to an enzyme reaction (eg. change in pH) can lead to a change in film conductivity 
which can be measured34.
g) A novel and interesting technique involves the incorporation of the enzyme directly 
in to the electrode surface. By having the enzyme present during the electrochemical 
platinisation of a platinum metal electrode, Ikariyama et al35 were able to create 
biosensors for glucose.
This technique lends itself well to the construction of miniature sensors using 
semiconductor fabrication techniques36.
1.3 Electron Mediators 
In order to function effectively, any electron mediator must have the following properties:-
a) Be stable in both reduced and oxidised forms.
b) Have a redox potential which shows little or no change in conditions of varying pH.
c) Be readily immobilised at the electrode surface.
d) Be able to operate at a potential which is as low as possible, in order that potentially 
interfering molecules cannot oxidise at the enzyme electrode.
e) React readily with the FADH2 moiety of flavoenzymes.
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Molecules which have been used extensively for this purpose are the Ferrocene 
derivatives. The structure of ferrocene is shown in Figure 1.7
One of the earliest reports of the use of ferrocene derivatives in amperometric biosensors 
came from Cass et al37 in 1984. Since that time, many workers have studied the use of 
such electron mediation with a variety of degrees of success. In 1987 Matthews et al38 
published a paper describing a pen-sized amperometric blood glucose meter using ferrocene 
as a mediator.
Figure 1.7 The structure of Ferrocene
1.3.1 Im m obilisation o f Ferrocene
Cass et al37 deposited 1,l^dimethylferrocene onto a graphite foil electrode by the 
evaporation of a solution (in toluene) at the foil surface. Glucose oxidase was then attached 
to the foil surface using carbodiimide covalent linkage and covered with a polycarbonate 
membrane. This method relies on the very low aqueous solubility of the ferrocene to keep 
it at the electrode surface. Electrodes prepared by this method have probably been the 
most successful ferrocene mediated glucose sensors to date. The electrode is operated at 
+160 mV (vs. saturated calomel electrode) which is 60 mV positive of E0 for 1,^-dimethyl- 
ferrocene. Low variation in output current is seen with variation of the oxygen tension of 
the analyte solution (approximately 4% change in output between a glucose solution purged
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of oxygen and the same solution saturated with air). Addition of ascorbic acid at the 
normal level found in blood produced a current increase of around 4%, but a range of other 
possible interferents produced no observable change in current.
The ferrocene mediated glucose sensor described by Cass et al has been developed 
further39, using a much smaller piece of graphite foil and a final electrode coating of 
polyurethane, to produce a potentially implantable sensor. A two electrode system was 
used employing a Ag/AgCl wire as a pseudo-reference electrode. This showed a higher 
dependence on dissolved oxygen concentration, and in addition the sensor gave lower 
output currents when operated in plasma than in buffer solution containing an equivalent 
glucose concentration.
A second approach to the problem of how to contain the ferrocene at the electrode surface 
is to bind it covalently to the glucose oxidase40,41 (Figure 1.8 - from reference 40).
Page 13
y O H  ( C H e ) 3 NH
+  N pH 7 . 2 >  t f = ^ _ c/ C \ c
7 7  \  II 0 ^ \  II




c h 2 c h 3
E n z y m » ~ N H e ^  ^ y N H _ E n i y m e
C H a c h 3 
\ /
N
p H  7 . 2  '  < C H e >3
3n u r e a  >b— '  +  I









Figure 1.8 Steps involved in attaching electron relays to the protein backbone of an 
enzyme.
Atomic absorption spectroscopy showed that unmodified GOD contains two iron atoms 
per molecule, but after the covalent attachment of ferrocenecarboxylic add the enzyme 
contained fourteen iron atoms per molecule40. The modification of glucose oxidase by 
ferroceneacetic add and by ferrocenebutanoic add has also been considered41.
Chemical attachment of the mediator may be advantageous in the prevention of leaching 
of potentially toxic components from the biosensor42.
The final method which has been considered for immobilisation of ferrocenes is the 
incorporation of the ferrocene into the matrix of an electrochemically prepared polymer 
which is being used to entrap the glucose oxidase13,43.
Electron mediators could conceivably be incorporated into polypyrrole films in several 
different ways:-
a) Attachment of mediator to a pre-formed film.
b) Pyrrole will incorporate anionic electron mediators during electro-polymerisation.
c) Attach mediator to the pyrrole monomer covalently.
Option (c) has been attempted by Foulds and Lowe13,43 by synthesizing the ferrocene 
derivatives [(ferrocenyl)amidopropyllpyrrole (FAPP) and ([(ferrocenyl)amido- 
pentyl]amidopropyl)pyrrole (FAPAPP) (Figure 1.9).
i
k /
. N C H g C H g C H g N H C O
FAP P
( C H p N H C O  ( C H p ) , .  N H C 0 - / P ' V | -  F *
F A P A P P
Figure 1.9 FAPP and FAPAPP
Any attachment of side chains to pyrrole at the a position resulted in a molecule which 
would not polymerise. Side chains at the P position would probably stop any cross-linkage
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within the polymer and affect its mechanical strength. Therefore, the compounds were 
synthesised by N substitution of pyrrole.
When used to form homopolymers, these compounds gave very poor, thin films if prepared 
using constant potential deposition but more satisfactory films were produced by cycling 
the potential between OV and +1.0V at lOOmVs'1. However, sensors formed in this way 
were not independent of the dissolved oxygen concentration, and within two days of 
fabrication they showed no response in the absence of oxygen. In addition to this, a 
potential of +300mV was required to re-oxidise the bound ferrocene. Co-polymers of FAPP 
and FAPAPP with pyrrole were also considered.
1.3.2 Theoretical Aspects of Electron Mediation
In order to allow a mediated glucose sensor to operate at a potential which is sufficiently 
low, so that the oxidation currents produced by any interfering compounds are 
insignificant, the redox potential of the mediator (as indicated by the standard electrode 
potential [E0] or by the half wave potential [Ew] in cyclic voltammetry) should be as low as 
possible. Reported values from the literature13,37,44 are given in the table below (in order).
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E0 and Ew values for ferrocene derivatives from the 
literature.

















Even though the over potential required for a particular derivative to act as a mediator 
may be low, the rate at which the derivative is able to transfer electrons from the reduced 
GOD to the electrode may be poor.
A useful indicator of mediator efficiency is the second order rate constant for the reaction 
between GOD and the mediator (kg).
The second order rate constant can be derived from cyclic voltammograms obtained under 
specific conditions, and by applying the mathematical theory for an overall reaction scheme 
which consists of an irreversible catalytic reaction following a reversible charge transfer 
(Nicholson and Shain45;case vn).
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As seen before, the reaction scheme occurring at the surface of a ferrocene mediated 
glucose sensor can be represented by:-
GOD-2FAD + glucose  GOD-2FADH2 + gluconolactone
GOD-2FADH2 + 2FeCp2R+ ------------------------- >  GOD-2FAD + 2FeCp2R + 2H+
2 FeCp2 R — N 2 FeCp2 R+ + 2e‘
(FeCp2R represents the ferrocene derivative)
If the reaction of the ferrocene at the electrode surface is fast compared with its reaction 
with GOD, and there is sufficient excess of glucose in solution (in order that the enzyme 
is maintained in a fully reduced state) then the reaction scheme can be reduced to the 
equations given below and the mathematical theory can be applied.
kf
R - e ^  0; O + Z ------------------------- >  R
where R and O are the reduced and oxidised forms of the ferrocene, Z is the reduced 
enzyme and k* is the pseudo-first-order rate constant.
From experimentally determined parameters it is possible (using Figure 14 of reference 
45) to calculate k* for a range of glucose oxidase concentrations. kg is then found from the 
gradient of a plot of kf vs. GOD concentration.
The second order rate constants for some of the ferrocene derivatives are shown below.
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kB values for ferrocene derivatives from the 
literature
ferrocene derivative 10 5k. /L mol s 1
FAPP 6.70
FAPAPP 21.00










The second order rate constant kB for the reaction of reduced GOD with oxygen has been 
determined by Weibel and Bright46.
ks = 1.5 x 106 1 mol'1 s'1
Several interesting points can be observed from this and the data in the table:-
a) There is no correlation between redox potential (E0 or Ew) and the second order rate 
constant kB for the various mediators.
b) For the majority of mediators, their reaction rate with GOD is lower than that of 
oxygen.
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c) The highest value of k, is that obtained for 2-aminoethyl ferrocene. This mediator is 
positively charged at pH 7 (pKa=9.5) and suggests that the active site of glucose oxidase 
is negatively charged.
d) FAPAPP has a high rate constant (above that for oxygen) despite having a relatively 
bulky side chain attached to one of the cyclopentadiene rings of the ferrocene moiety.
1.4 Measuring Drug Levels Using Amperometric Biosensors
Amperometric biosensors are potentially ideal for the measurement of drug molecule 
levels in a variety of solutions. They have the major advantage over most other types of 
biosensor (excluding potentiometric systems) in that they can produce continuous readings.
Monitoring of clinically useful analytes in a variety of biological fluids by biosensors can 
be considered in a range of different situations listed below:-
a) Chronic conditions in which a routine test by the patient can allow adjustment of a 
drug dosage. The classic example of this is the measurement of blood and/or urine 
glucose levels by diabetics, enabling self adjustment of insulin dosage.
b) Chronic conditions where the ability to continuously monitor a drug level would allow 
control of a drug delivery system. This would create a feedback loop similar in principle 
to many of the regulatory mechanisms found in the body. Such a system would be 
extremely useful in treatments which require the use of drugs which have a low 
therapeutic index or in conditions where poor drug level control over prolonged periods 
can create additional problems. It may also be of use in monitoring of hormone replac­
ement therapy, especially when natural levels of the hormone would normally vary 
depending upon the time of day or time of month. This sort of variation could be pre­
programmed into such a system.
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c) Acute emergency situations where it is necessary to know the blood levels of a drug 
extremely quickly, eg. poisoning or overdosage.
d) Measurement of drug levels during operations and in intensive care situations, 
allowing feedback control of blood levels by direct regulation of drug infusion rates.
e) Single measurements, either by the patient or within a doctors surgery, for diagnostic 
purposes. A comparison can be made here to existing products such as pregnancy 
testing kits.
Many newer types of non-amperometric sensors are based on measuring a change in a 
physical property associated with the formation of an antigen-antibody complex. Whilst 
these methods have the ability to measure concentrations of substances at several orders 
of magnitude lower than current amperometric systems, they are generally single use 
methods. Once an antigen has bound to an antibody it is difficult to remove it. Dissociation 
of the complex is slow, so limiting the possibility of using such a device for dynamic 
measurements.
It is likely that some of the non-amperometric biosensors will be extremely useful for 
measurements in categories a), c) and e) above.
The best prospects for creating amperometric biosensors which are clinically useful are 
in areas which require continuous analyte monitoring.
Few enzymes exist which specifically act upon a drug molecule, and even fewer which are 
also redox enzymes. However, in the future, with advances in protein engineering it may 
be possible to tailor make specific enzymes47, or to increase the specificity of certain 
enzymes or synthetic chemical catalysts by linking them to antibodies48.
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1.4.1 Current Drug Biosensor Designs
Although progress is being made towards reliable in vivo measurements of clinically 
useful endogenous analytes49, fewer articles exist in the literature which demonstrate 
useful biosensors for the measurement of exogenous drug molecules. A recent review by 
Guilbault and Schmidt50 showed that much of the current research interest is being 
directed towards drugs of abuse.
One area which shows considerable promise is to link immunoassay to an amperometric 
detection system. Such a system has been developed for lidocaine by di Gleria et al.51 and 
a schematic diagram of this is shown in Figure 1.10
Ag  : A b
F c - A g :  A b
A b
G O D  ( o x )Fc-Ag G l u c o s e
+ GAg
2
E l e c t r o d e  
s u r f  o c  e
Figure 1.10 Schematic diagram of a homogenous amperometric immunoassay.
Ag refers to the antigen (in this case lidocaine);Fc-Ag is the ferrocene-drug conjugate;
Ab is antibody to lidocaine)
The assay relies upon the synthesis of a ferrocene-drug conjugate which retains the 
electron mediation properties of ferrocene. Glucose and a known quantity of antibody to 
the drug have to be added to a known volume of the solution being analyzed.
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When the antibody binds to the ferrocene-drug conjugate, electron mediation is inhibited. 
Free drug in the analyte solution competes for the antibody, releasing free ferrocene-drug 
conjugate and increasing electron mediation.
In theory, this sort of approach could be used for any small molecule to which an 
antibody can be raised, and which can be effectively attached to an electron mediator 
whilst retaining the mediator activity. However, this type of reaction scheme is unfor­
tunately subject to the same limitations as for the non-amperometric immunoassays. The 
technique is further limited by the necessity for accurate volume measurements and by the 
need to add further reagents to the analyte solution. These last two limitations can be 
partially overcome by the use of clever packaging of the biosensor (as demonstrated in 
capillary fill devices62), but the inability of such a device to perform continuous measure­
ments still remains.
1.5 Aims and Scope
A summary of amperometric biosensor development has been given in this introduction 
in order to familiarise the reader with the concepts involved. Many groups of researchers 
are working on improvements to immobilisation technology, electron mediators and 
electrode materials. Ideally, electrode materials will be developed which allow the concept 
of a mediator to become redundant one.
However, a whole sub-class of enzymes exist which have so far been poorly exploited for 
biosensor creation. This is because these oxidoreductases perform reductions which lead 
to oxidised nicotinamide adenine dinucleotide cofactors which cannot easily be regenerated 
at an electrode surface. The mechanisms behind this are given more fully in the 
introduction to chapter 5.
Research is being performed in other scientific areas which can provide useful 
information and materials for biosensor production. One of these areas is that of microbial 
biotransformations. When these biotransformations involve reductions or oxidations the 
microbe involved is worthy of study for the creation of biosensors.
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The direct aims of this research were therefore:-
1) to develop the necessary instrumentation and in-house electrode fabrication 
technologies required for the production of biosensors.
2) to review the literature and to screen microorganisms for their abilities to reduce or 
oxidise drug molecules with a view to using enzyme extracts for the creation of drug 
biosensors.
3) to look at ways in which it might be possible to regenerate enzymatically active 
reduced nicotinamide co-factors by electrochemical means, leading to an expansion in the 
range of enzymes available for the creation of biosensors.
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2 MATERIALS. STANDARD METHODS AND INSTRUMENTATION
2.1 General materials
2.1.1 Water
In all electrochemical, HPLC (high performance liquid chromatography) and synthetic 
chemistry experiments, the water used to prepare solutions had been purified using a Milli 
RO (Reverse osmosis) system followed by a Milli Super Q (ion exchange) system. This 
water is referred to in the text as "RO water". Laboratory distilled water was used in all 
other situations e.g. preparing bacterial growth media.
2.1.2 HPLC solutions
All aqueous fractions of HPLC mobile phase solutions were filtered through a 0.45pm 
pore size cellulose acetate membrane filter (Whatman Ltd, Maidstone, Kent) prior to 
mixing with any other HPLC grade solvent. Mobile phase solutions were sparged with 
argon or oxygen free nitrogen (through a metal HPLC solvent filter) for at least 10 minutes 
before use. Compressed gas cylinders were obtained from B.O.C. Ltd, Herts, England.
2.2 Standard Methods
2.2.1 Measurement of pH
pH measurements were taken using either a Radiometer PHM 64 research pH meter 
(Radiometer Ltd., Crawley, West Sussex) or a Philips 9410 pH meter (Philips Ltd. 
Cambridge). A new pH electrode was obtained (Russell CWL/NS14/15/85) which was 
designed to fit the Metrohm electrochemical cell (see later).
Calibration was performed using the most appropriate two solutions from the three NBS 
primary standards given below53:-
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1) Potassium hydrogen phthalate 0.05m in RO water (pH 4.002 at 20°C, pH 4.008 at 
25°C)
2) Potassium dihydrogen phosphate 0.025m with disodium hydrogen phosphate 0.025m 
in RO water (pH 6.881 at 20°C, pH 6.865 at 25°C)
3) Borax 0.01m in RO water (pH 9.225 at 20°C, pH 9.180 at 25°C).
Buffer salts of A.C.S. reagent grade were obtained from the Aldridge Chemical Co. Ltd. 
and were oven dried and stored in a desiccator as appropriate. Most of the pH 
measurements in this thesis were not critical (molar solutions were used instead of molal 
solutions) and the meters were calibrated to a second decimal place only.
2.2.2 Solution volum e m easurem ent 
Volumes were measured using class B glass pipettes or by Gilson automatic pipettes as 
appropriate. 5ml, 1ml and 200jil automatic pipettes with disposable nylon tips were used. 
These were periodically calibrated by weighing the volume of water given out by the 
pipette at 20%, 40%, 60%, 80% and 100% of maximum volume using a standardised 
pipetting technique. Five replicates were performed at each point.
Rather than try to adjust the pipettes to give the correct reading, a linear regression was 
performed. The resulting equation was used to work out the correct setting required on the 
pipette to give the desired volume for any critical measurements.
2.3 Electrochem ical Instrum entation
Electrochemical measurements were taken using
Metrohm 626 Polarecord (polarograph) with Metrohm 612 VA Scanner.
(Metrohm Ltd., Herisau, Switzerland).
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The Polarecord was used in its DC mode connected to a three electrode electrochemical 
cell. In this mode it behaves as a potentiostat, with the voltage at the working electrode 
being controlled by external input from the VA scanner.
The VA scanner could be used to apply a fixed voltage or it could be used to perform 
linear or cyclic sweep voltammetry (Figure 2.1).
F I X E D  VOL T A GE
LI  NEAR SWEE P
C Y C L I C  S WE E P
T i m«
Figure 2.1 Voltage / Time profiles produced by the Metrohm VA Scanner.
For the purpose of recording experimental results, the Polarecord gives a voltage 
output between -lv and +lv proportional to the current flowing a t the working electrode. 
This voltage, and the voltage of the working electrode were measured by using a 2 channel 
12 b it analogue to d ig ital converter in terfaced  to an Acorn Archim edes A310 
microcomputer. In addition to this, the microcomputer was used to control scanner 
function.
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The analogue to digital converter was designed and built by Sean Hagan (postgraduate 
student, School of Electrical Engineering, The University of Bath). Figure 2.2 is a 
schematic diagram of the equipment interconnections.
A fast X/Y recorder could have been used for recording of voltammograms up to scan 
rates of approximately 300 mVs'1, and a storage oscilloscope used for higher scan rates. 
However, computerisation of the system has the advantage of allowing easier data 
handling and the benefit of more precise marking of axis details.
The equipment described above had a selectable current sensitivity between ±25 
milliamps full scale deflection (f.s.d.) and ±6.25 nanoamps f.s.d. Careful screening of cables 
and shielding of the cell ensured that induced currents from external sources such as 
mains supplies were not a problem, even at high current sensitivities. However, analysis 
of the output voltage of the polarecord using an oscilloscope showed the presence of small 
spikes due to un-smoothed operational amplifier switching potentials within the unit. At 
most current sensitivities, and at slow scan rates these did not cause any significant 
problems.
The computer program for the Acorn Archimedes A310 microcomputer, to control and 
receive data from the Metrohm 626 polarograph and 612 VA scanner, is given in 
appendix 1.
The program is written in Acorn BASIC 5 and uses a short machine code routine to 
access the A to D converter. The mnemonic form of the routine (prior to assembly) is 
contained in a procedure called code, starting at line 6160.
The routine is called during a procedure called Read2 at line 3900. The routine takes a 
set number of samples from each channel and returns an additive value for each channel 
into variables X% and Y% at line 4020.
The number of samples taken during each call to the routine is controlled by the value 
contained in the variable VAR%, calculated at line 3930. The values contained in X% and
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Y% are then divided by YAR% to give an average. This averaging provides a filtering effect 
against background noise, but the degree of this 'software filtering’ depends upon VAR%.
The value of VAR% depends on the initial and final voltage for a sweep, and upon the 
sweep rate. At high sweep rates the value of VAR% is small in order that sufficient data 
points are collected to be able to plot a meaningful voltammogram.
Data from the program is written to floppy disk in a format which is recognised by a 
computer aided design (CAD) program (Design CAD, American Small Business Computers 
Inc.). This allows output of the voltammogram on a variety of printers or plotters at an 
accurate, specified scale. Output to disk in encapsulated postscript format was also 
included to allow direct incorporation of images into most currently available word 
processors.
The computer program was modified to allow it to capture data from high performance 
liquid chromatography experiments. The program listing for this is also given in appendix 
one.
2.4 Thin Film Electrode Development
In order for amperometric biosensors to become useful tools for monitoring clinical 
analytes in acute or chronic medical conditions, several advances in design need to be 
realised.
To enable devices to be made sufficiently small for such use, it is necessary for
1) optimisation of the interface between the biological recognition system and the
electrode (discussed in the introduction).
2) development of miniaturised potentiostatic circuitry capable of measuring very low
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3) electrode design compatible with the electronic components. If very low current is to 
be measured, it is important that the electrical connections to the electrodes do not pick 
up any induced currents. To achieve this, they should be as short as possible, or ideally 
not exist as all. This concept can be accomplished by placing the electrode on the same 
silicon wafer as the integrated circuitry for the potentiostat and has been addressed by 
several groups54,55,56.
For development work, it is necessary for electrodes to be macroscopic, but it was decided 
to investigate the use of integrated circuit fabrication technology to make them.
Electrode materials such as graphite or glassy carbon are not compatible with this sort 
of technology, however the coating of metals onto silicon can be done using a variety of well 
established techniques.57
Several recent reports of electrode construction using planar IC fabrication methods have 
been published.58,59,60,61,62 Although the metallisation procedures are well documented 
there is little information on the stability of such devices (and in particular, the stability 
of insulator materials) on exposure to aqueous systems. Many different materials have 
been used as insulators, particularly in the field of potentiometric devices based on the use 
of ion sensitive field effect transistors (ISFETs). Silicon dioxide63 has been used, but the 
m aterial most commonly used in more recent ISFET devices is silicon nitride 
(Si3N4).64,65,66 This may be due to its superior ion-selective properties rather than for 
stability reasons.
In the manufacture of planar amperometric electrodes polyimide58, Tantalum oxide 
(TaaOg)60, epoxy resin61 and negative photoresist62 have been used as insulators. With all 
of the above designs, with the exception of the design of Sansen et al5*, the electrode area 
is defined without surrounding it with an insulator. The metallic layers are simply 
patterned onto a substrate (silicon, sapphire or glass) using either a lift off technique or 
by using wet etching. Insulator is then placed over the areas of metallisation which can
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be considered to form the ’wires’ to the electrode. This sort of methodology has the disad­
vantage of producing more variable electrode areas, particularly when epoxy resin is used 
as an insulator because application of this material is a manual process. In addition, the 
edge of underlying metal layers, used to improve adhesion of the electrode metal, will be 
exposed to solution (admittedly tiny areas).
The design shown in Figure 2.3 is that of a platinum working electrode, the exposed 
platinum region having a geometric surface area of 3.6mm2.
P h o t o r e a i i t
Gal d
T i t on!  u m 
Si  I I e o n  Di  o i l  d o  
S i l i c o n
C r o n - i e c t i  o
Go i  d C e n t  o c t  
a r e a
Figure 2.3 Cross-sectional and plan views of the working electrode (not to scale).
It was constructed by coating successive layers onto a piece of silicon which had been cut 
to size. Brief details are given below:- 
Silicon wafer rejected by the electronics industry was made use of, the section to be used 
for the electrode being cut from a flawless area of the wafer. This had a layer of silicon 
dioxide already on its surface which had been produced under controlled conditions by the 
manufacturer of the wafer.
After cleaning of the surface, a positive photoresist was applied. This was then exposed 
to ultra-violet light after a mask, created using standard photolithographic techniques, was
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positioned over the wafer. The photoresist exposed to the UV light was then washed away. 
This left exposed the area of silicon dioxide to be coated with the layers of titanium, gold 
and platinum.
Titanium was coated onto the surface using a thermal evaporation technique. This layer 
was thin (approximately 30nm) and was only present to improve the adhesion of 
subsequent layers.
The next layer consisted of a 150nm coating of gold, again applied using thermal 
evaporation. This was used to form a conductor from the contact end of the electrode 
to the platinum.
The final metallic layer is a 150nm coating of platinum, applied using ion beam 
coating. This technique was used because the thermal evaporation of platinum is 
difficult to achieve. However, ion beam coating is a slow process, and only small areas 
(approximately 1cm2 with the available equipment) could be coated. This was the reason 
for using the thermally evaporated gold layer as a conductor. On a much smaller 
electrode, the gold layer would be unnecessary.
The final process was to dissolve away (lift off) the positive photoresist, then to apply 
a negative photoresist (using another mask) to act as an insulator (Kodak microresist 
752, Kodak Ltd, Hemel Hempstead). This photoresist layer covered the whole electrode 
apart from the required platinum area and the contact area.
All electrodes were fabricated by Trevor Ryan of the Department of Electrical 
Engineering, University of Bath.
Earlier designs of this electrode used a silicon dioxide layer as an insulator material. 
However, this soon broke down on exposure to dilute aqueous solutions of hydrogen 
peroxide in 0.1M potassium chloride. This could have been caused by poor adhesion of the 
silicon dioxide to metallic layers below, or it could possibly have been due to microcrack 
formation within the layer (Cohen et alei).
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The fabrication technique outlined (and available equipment) only allowed the production 
of one electrode at a time. With smaller electrodes envisaged in the future, many hundreds 
or thousands of electrodes with their associated electronic circuitry, could be produced from 
one silicon wafer. These would then be cut out from the wafer and packaged to produce 
discrete biosensors.
2.4.1 Testing the electrodes
The electrodes produced were examined using two electrochemical experiments to 
determine whether their response was equivalent to that of platinum wire, and to test the 
stability of the photoresist insulator.
2.4.1.1 Materials
Potassium chloride (99+ % A.C.S reagent), potassium ferricyanide (99+ % A.C.S. Reagent) 
and 0.5mm diameter platinum wire 99.99% were obtained from the Aldrich Chemical Co. 
Ltd., Dorset, England.
2.4.1.2 Other Electrodes
Reference electrode: Radiometer K401 Saturated Calomel (SCE) (Radiometer UK Ltd, 
Crawley, West Sussex)
Counter Electrode: 1cm2 Platinum Foil (one half of Metrohm EA 210 titration electrode)
2.4.1.3 Electrochemical cell
The orientation of the various electrodes within the electrochemical cell is shown in 
Figure 2.4
The working electrode holder consisted of a modified printed circuit board edge connector, 
in which the electrode was mounted, soldered onto a piece of Vero board. Epoxy resin was 
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Figure 2.4 Electrochemical cell design.
The air-tight lid of the cell had a two additional ports not shown in Figure 2.4. One of 
these had a dip tube fitted to allow de-aeration of the solution by bubbling with pre­
humidified nitrogen. The nitrogen was re-directed to flow over the solution during measur­
ements.
The temperature of the water re-circulating through the water jacket of the cell was 
controlled by a Grant SU6 water bath heater, working against a Haake EK12 refrigeration 
unit.
2.4.1.4 Electrode response to potassium ferricyanide 
The behaviour of platinum film electrodes was compared with the behaviour of a 
platinum wire electrode of a similar surface area by examining cyclic voltammograms of
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potassium ferricyanide (potassium hexacyanoferrate III). A solution of this compound at 
a concentration of lOmM.l'1, with 1M.1'1 of potassium chloride (background electrolyte) in 
RO water was prepared. 20ml was added to the electrochemical cell and was de-oxygenated 
by bubbling with nitrogen for 15 minutes. Once temperature equilibration had occurred 
(25°C) the working electrode potential was held at +600mV, and the background current 
allowed to decay to a low value. A cyclic voltammogram was then recorded by taking the 
electrode potential down to -lOOmv then back to +600mv at SOmV.sec'1.












3o - 1 0 0
- 1 5 0
- 2 0 0
- 2 5 0
0. 0 0. 10 . 6 0 . 5 0 . 4 0 . 3 0 . 2 0. 1
V O L T A G E
INITIAL VOLT. — 0.60 volto FINAL VOLT.- -0.10 volts 
S W E E P  RATC(S): SO mV p o r
P o l  o s  s i  u m I o r  r i  c y o n i  4 o  10 mM i n 1 M KCI -  P i  f i l m  ol  
F I L E N A M E :  C V C t O  D A T E :  T h u . 0 3  Ms y  I • • 0 . 2 0 : 4 • : 4 7
Figure 2.5 Cyclic voltammogram of potassium ferricyanide a t a thin film platinum 
electrode
The platinum wire electrode was constructed by sealing a short piece of 0.5mm diameter 
wire into the end of a piece of glass tubing (5mm external diameter). Soda lime glass was 
used because it has a linear expansion coefficient similar to that of platinum. The seal
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between the glass and the metal was examined microscopically for evidence of cracks. Once 
a good seal had been established the length of wire protruding from the glass was trimmed 
to 8mm leaving a geometric surface area of approximately 13mm2 (platinum film surface 
area = 3.6 x 3.6 = 12.96mm2). The cyclic voltammogram for the platinum wire electrode is 
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Figure 2.6 Cyclic voltammogram for potassium ferricyanide at a platinum wire electrode
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2.4.1.5 Insulator stability 
The stability of the photoresist used as an electrode insulator was assessed. The easiest 
way to do this was to monitor any change in the electrochemically measured surface area 
of the electrode with exposure to solution.
The peak cathodic current i^ (as recorded using cyclic voltammetry) for the reversible 
reduction of O to R
0  + ne' ^  N R
where only 0  is initially present in solution is given by:-
ipc = (2.69 x  105) n3l2AD01/2vll2C0 
(Bard and Faulkner.68)
where A  is the electrode area in cm2, D0 is the diffusion coefficient of O in cmV1, C0 is the 
concentration of ferricyanide in mol.cm'3 and v is the scan rate in V s1. Temperature of 
measurement = 25°C.
The diffusion coefficient of the species Fe(CN)63‘ has been accurately determined by von 
Stackelberg et al69. The above equation can thus be used to determine electrode surface 
area from a cyclic voltammogram of Potassium ferricyanide. (O = F e ^ C N ^ 3', R = 
Fe^CNJg4*)
It can be seen from the equation that the peak cathodic current is directly proportional 
to the electrode area.
Cyclic voltammograms were performed using the conditions stated above on a series of 
three electrodes (stored in RO water at 25°C), weekly for four weeks. During this time, 





Warfarin is 3-(a-acetonylbenzyl)-4-hydroxycoumarin. The structure of the sodium salt is 
shown in Figure 3.1.
0
Figure 3.1 The structure of the sodium salt of warfarin showing the chiral centre *
The molecule has a chiral centre as indicated, and the commercially available 
preparations of warfarin consist of racemic mixtures.
The pKg of warfarin is 5.0100
3.1.2 A ctions and Uses 
Warfarin is licensed in Great Britain for use as an oral anticoagulant and it is widely 
used in the treatment of, and prophylaxis against, thromboembolism.
In order to understand the mode of action of warfarin, it is necessary to consider the 
vitamin K cycle.
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1) A reduced form of vitamin K is produced by the action of vitamin K reductase on 
vitamin K
2) The reduced form of vitamin K is involved as a cofactor in the activation of various 
clotting factors (II, VII, IX and X and the anticoagulant protein C) under the influence of 
y-glutamyl decarboxylase. Vitamin K epoxide is produced during this reaction
3) Vitamin K is regenerated by the action of vitamin K epoxide reductase on vitamin K 
epoxide to complete the cycle.
The action of warfarin is thought to occur by the inhibition of vitamin K reductase and 
v ita m in  K ep ox id e re d u c ta se  a lth o u g h  ex a c t m ech a n ism s are s t i l l  to be 
established70,71,72.
3.1.3 Do we need a Biosensor for Warfarin
When administered, warfarin binds to plasma and hepatic proteins. Additionally, it 
undergoes a variety of metabolic conversions including reduction of the aliphatic ketone 
group and hydroxylations of the coumarin ring structure and the benzyl group. These 
metabolites are produced in the liver and in the main they have little pharmacological 
activity.
The dosage required to produce equivalent levels of anticoagulation is subject to 
considerable inter-patient variation. Because of this, the effects of warfarin are usually 
monitored by regular patient attendance at an hospital anticoagulant clinic. The clotting 
time of a blood sample (which can be expressed in a variety of ways) is measured.
It would be desirable to have a simple and reliable home test by which the patient could 
adjust their warfarin dosage. Because of a poor correlation between free (unbound) blood 
warfarin levels and the degree of anticoagulation, a warfarin biosensor blood assay would 
not provide such a test.
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A warfarin biosensor could be useful in the study of warfarin metabolism.
From the point of view of biosensor research, the development of a sensor for warfarin 
is of interest because if some of the technical hurdles can be overcome, the technology 
should be of use in the development of other sensors.
3.1.4 Microbial Models of Mammalian Metabolism
Micro-organisms are capable of using many varied molecules as carbon sources. In 
addition, they are able to produce or make changes to many complex compounds. They are 
used for the production of drug molecules such as antibiotics and can also be used to 
modify a variety of substrates, the latter being particularly useful if the modification is 
difficult to perform by in vitro chemical methods.
Many types of bacteria and fungi are able to modify drug molecules in ways analogous 
to mammalian metabolic systems. In a review article in 1975, Smith and Rosazza73 
described systems which they termed "Microbial Models of Mammalian Metabolism". They 
showed that there were many examples in the literature of microorganisms which 
exhibited the ability to biotransform compounds in ways analogous to Phase 1 (pre­
conjugation) reactions seen in mammals. Such microorganisms are being studied74 with 
the aim that a range of cultures could be used to reliably predict the likely mammalian 
metabolites of new drug substances (e.g. Jurgens and Clark75), and that the cultures could 
be used to "synthesize" sufficient quantities of such metabolites for structure elucidation.
3.1.5 Warfarin Metabolism by Microorganisms
Warfarin has been used as a "metabolic probe" in the study of hepatic mixed function 
oxidases in various mammalian systems76, and therefore much attention has been 
directed to finding micro-organisms which can metabolise warfarin in a similar manner to 
mammals.77,78
Davis and Rizzo77 screened nineteen different microbial cultures for an ability to 
metabolise warfarin and found two (namely Nocardia corallina [ATCC 19070] and
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Arthrobacter species [ATCC 19140]) which were able to perform the reduction of the 
aliphatic ketone group as the main transform ation (Figure 3.2). The fungus 
Cunninghamella bainieri (UI-3065) has been shown to produce 4/-hydroxywarfarin as its 
main conversion product. Another of the Cunninghamella species, Cunninghamella elegans 
(ATCC 36112) has been shown to produce all the known hydroxylated metabolites of 
warfarin produced in mammalian systems79.
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Figure 3.2 The structure of Warfarin Sodium showing the chiral centre (*). Also shown 
is the chiral centre created when the aliphatic ketone group (■) is enzymatically reduced.
3.1.6 A Previously Attempted Warfarin B iosensor
Fitzgerald et al80 attempted to create a biosensor for warfarin using the bacteria 
Nocardia corallina (which had been shown by Davis and Rizzo77 to reduce the aliphatic 
ketone group of warfarin). This organism was immobilised at the surface of a glassy carbon 
rod together with ferrocene as an electron transfer mediator. The current flowing when a 
potential of 400mV (vs S.C.E.) was applied was proportional to the dissolved warfarin 
concentration (between 0.26 and 3.0 x 10"4 Aidin'3) in a phosphate buffered saline solution.
By direct comparison with an amperometric enzyme electrode in which an oxidation is 
taking place (e.g. a glucose sensor based on glucose oxidase), if Nocardia corallina is
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reducing the aliphatic ketone group of warfarin, one would expect to see the concomitant 
oxidation of perhaps an enzyme cofactor (cf reduction of FAD to FADH2 in the glucose 
sensor) or the appearance of an oxidised co-substrate involved in the reaction (cf H20 2 
appearance when FADH2 is re-oxidised by dissolved oxygen). The electrode reaction would 
be expected to be a reduction (Figure 3.3), and the electrode potential would need to be 
more negative than the standard electrode potential for the reduction of the cofactor or co­
substrate. It is therefore unclear what was happening in this biosensor. It would have been 
useful to have seen the current generated over the same concentration range of warfarin 
but from an electrode constructed in the same manner but without the inclusion of the 
bacteria. If inclusion of the bacteria was demonstrated to be necessary for the generation 
of the current, then it may have been that the electrode was detecting the products of other 
types of metabolic activity of the bacteria.
3.1.7 Specificity of biosensors based on Reductases
The question arises:- will a biosensor based on a ketone reductase be sufficiently specific. 
Many drug molecules contain a ketone group. Many microorganisms can be found with an 
ability to reduce ketones to alcohols. Not all of these however will reduce the ketone group 
found in warfarin and the ones that do are therefore exhibiting a degree of specificity.
In mammals several enzyme systems exist for the reduction of aldehydes and ketones. 
Liver alcohol dehydrogenase is able to reversibly catalyse the reduction of aldehydes and 
ketones to alcohols. The reduction of aldehydes by this enzyme system is relatively 
unimportant because there are enzyme systems which will oxidise aldehydes to carboxylic 
acids which can be readily excreted.
Reduction of ketones by alcohol dehydrogenase is an important biotransformation which 
increases the polarity of the compound and provides a site for phase 2 (conjugation) 
reactions.
The ease with which an alcohol dehydrogenase is able to reduce a ketone depends upon 
the bulkiness of groups attached to it. In addition, when the alcohol is produced, a chiral
Page 43
C o - s u b s t r a t e  
( R e d u c e d )
e
C o - s u b s t r a t  e 
( O x i d i s e d )
Cof a c t  o r  
( R e d u c e d )
Warf a r  i n
C o - s u b s t r a t  e  
( R e d u c e d )
Cof a c t  o r  
( O x i d i s e d )
W a r f a r i n  A l c o h o l s
t e
Cof a c t  or  
( R e d u c e d )
Figure 3.3 The sequence of events at a biosensor based on the detection of the reduction 
of warfarin
centre is formed. All commercially available alcohol dehydrogenases, from microorganisms 
and from mammalian liver extracts, reduce ketones to alcohols with same spatial 
configuration with respect to groups originally attached to the carbonyl group. Recently, 
Shen et a /81 have screened microorganisms and found a Pseudomonas species which is 
capable of producing alcohols with the opposite spatial configuration.
The reduction of warfarin to warfarin alcohols in cytosolic fractions from the liver and 
kidney from humans and from rats has been studied by Moreland and Hewick.82 This 
study gave some important findings. Previous workers (cited in the above paper) had 
shown that in man, warfarin alcohols represent about 18% of the urinary metabolites of
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warfarin compared to about 7% in rats. When R-warfarin alone was administered, the 
proportion of warfarin alcohols in human urine rose to 37% suggesting that S-warfarin is 
not significantly reduced to the alcohol in humans. As mentioned earlier, when the 
reduction occurs, a second chiral centre is created and two diastereomeric alcohols are 
produced. Each diastereomer exists as an enantiomeric pair. These can be described as:- 
R-warfarin-S-alcohol and S-warfarin-R-alcohol 
S-warfarin-S-alcohol and R-warfarin-R-alcohol 
After R-warfarin administration the alcohol found in the plasma is almost entirely R- 
warfarin-S-alcohol. After S-warfarin administration the alcohol found in the plasma is 
mainly S-warfarin-S-alcohol. However, approximately five times as much warfarin alcohol 
was found in the urine after a single dose of R-warfarin when compared with a single dose 
of S-warfarin. This seemed to correlate with the product profile that would be expected 
from the reduction of warfarin by liver alcohol dehydrogenase, with the majority product 
being the S-alcohol.
Moreland and Hewick82 showed that the enzyme responsible for the reduction was 
NADPH dependent (NADH being only one tenth as effective as a cofactor) and therefore 
it was not alcohol dehydrogenase but a separate distinct ketone reductase. It is possible 
that the low level of activity seen when only NADH was present may have been due to 
there being a mixture of alcohol dehydrogenase and the ketone reductase in their 
preparations.
These results have important implications for the specificity of potential biosensors based 
on ketone reductases. Although the reductase described by Moreland and Hewick is 
probably not specific purely for warfarin it would appear that it has a much higher activity 
on the ketone group in warfarin than alcohol dehydrogenase does.
The results of Apanovitch et al83 are somewhat contradictory. They demonstrated the 
reduction of S-warfarin to the S-warfarin-S-alcohol (but little detectable R-warfarin 
reduction), and the reduction of the ketone group at the C20 position in progesterone 
(aliphatic) to the corresponding 20p-alcohol (R-Configuration), by an NADPH dependent
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system in rat hepatic microsomes. They also showed differences in the activity of this 
ketone reduction system dependent upon the age, sex and strain of the rats used and 
suggested that one enzyme might be responsible for the reduction of both compounds. They 
also demonstrated NADH dependent reduction of progesterone to the 20a-alcohol (S- 
Configuration).
By isolating ketone reductases from a number of different sources it may be possible in 
the future to create a multi-biosensor probe. This would consist of several discrete ketone 
reductase electrodes each with its own degree of specificity for different ketone containing 
analytes. It may be possible for such a probe to actually identify a compound from the 
current profile produced, and then to measure its concentration from the electrode 
producing the highest current. It is as yet unknown of course whether ketone reductases 
from different sources will exhibit different specificities or not, or whether it will turn out 
to be a ubiquitous enzyme system. The results of the work of Shen et alsl are encouraging 
in this regard.
3.1.8 Daunorubicin Reductase
When the literature was searched for other examples of the reduction of drug molecules 
which contain a ketone group in the liver, an interesting example came to light. The anti­
cancer drug Daunorubicin contains an aliphatic ketone group (Figure 3.4) and is converted 
in the liver to the corresponding alcohol84,86,86. The closely chem ically related  
compounds of doxorubicin, epirubicin and idarubicin are more widely used than 
daunorubicin (which is available in the United Kingdom on a named patient basis only). 
Although the stereochemistry is not described in these papers it was established that the 
enzyme responsible for the reduction was NADPH dependent.
Daunorubicin is an anthracycline antibiotic which inhibits DNA and RNA synthesis. It 
is isolated from Streptomycetes peucetius71 and it may therefore be possible to find 
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Figure 3.4 The structure of Doxorubicin and Daunorubicin
A biosensor for any of these compounds would be very useful as a research tool, and 
might also be clinically useful. This class of anti-cancer drugs exhibits a high degree of 
cumulative cardiotoxidty. Dosage is usually calculated on the basis of the surface area of 
the patient (which is a derived parameter calculated from a weight-height-surface area 
nomogram) but if a biosensor existed a more precise dosage determination might be 
possible from the results of measuring the plasma drug concentration-time profile during 
the first administration to the patient.
3.2 Experim ental details
3.2.1 Equipment
Gilson model 116 variable wavelength UV detector
LDC Constametric 3000 dual piston metering HPLC pump (two)
BBC Servogor SE120 chart recorder or - 
Servoscribe Is chart recorder
HPLC column water bath - Grant SU6 re-circulating water bath heater running against 
a Haake EK12 water bath cooling coil.
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Rotary evaporator, Biichi rotavapor 
Mettler AE163 4 or 5 decimal place analytical balance 
BBC model B microcomputer, Acorn Computers, England 
Polarimeter, Optical Activity Ltd. England.
Perkin Elmer A3B dual beam scanning UV/Visible spectrophotometer 
Matched 1cm path length quartz cells for the above
3.2.2 Materials
3.2.2.1 Chemicals
Racemic warfarin 98% (free acid), potassium chloride 99+ % (ACS Reagent), phosphorous 
pentoxide 98+% (ACS reagent), sodium borohydride 98% and acetic add 99.7% (ACS 
reagent) were obtained from Aldrich Chemical Company Ltd.
Hydrochloric acid solution, sodium hydroxide volumetric concentrates, quinine and 
quinidine (98%), magnesium sulphate (99+%) were obtained from BDH Chemicals Ltd., 
Poole, Dorset, England.
Chloroform and HPLC grade methanol, dichloromethane and heptane were obtained from 
Fisons scientific, Loughborough, England.
3.2.2.2 HPLC Column
Preparative column: 10pm particle size Zorbax Sil (Silica), 21.2mm internal diameter, 
250mm length)
3.3 Resolution o f Racemic Warfarin 
In order to study the metabolism of warfarin by microorganisms it was preferable to be 




Racemic warfarin was resolved according to the method developed by West et alsl. This 
involves preferentially forming the salt of S-warfarin with the alkaloid quinidine and 
preferentially forming the salt of R-warfarin with quinine (the naturally occurring 
enantiomer of quinidine).
The structure of quinine/quinidine is shown below (Figure 3.5).
C
H
0 —  CH
Figure 3.5 The structure of quinine/quinidine showing the chiral centre *
3.3.1.1 S-warfarin
This first section of the method was performed at 13/100 scale when compared to the 
above paper and is summarised below. Intermediate optical rotations were not performed.
Solution 1: 40g warfarin (0.13 mole) and 42.4g quinidine were dissolved by warming in 
650ml of solution consisting of 40% chloroform in acetone. This solution was then held at 
—10°C until crystals of S-warfarin quinidine were formed (36 hours).
The temperature of —10°C was achieved by running a water bath cooling coil against a 
water bath heater in a 4°C refrigerated room. The solution in the water bath consisted of 
distilled water containing approximately 30% of a commercially available automotive 
antifreeze solution. The water bath temperature was monitored using a thermistor based 
sensor linked to a BBC microcomputer which was used to switch the water bath heater on 
or off as appropriate. The details of the circuitry for this are given in reference 88
The solution was filtered and the filtrate was saved for later.
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Solution 2: The crystals of S-warfarin quinidine were redissolved in 450ml of gently 
wanned acetone. This solution was then cooled to 0°C using the same equipment described 
above. The crystals formed were collected by filtration and the filtrate was discarded.
Solution 3: The recrystallised S-warfarin quinidine collected from solution 2 was dissolved 
in 65ml of chloroform. This solution was then extracted by shaking with 130ml of 0.5M 
Sodium Hydroxide solution in a separating funnel. This stage of the process liberated free 
quinidine, which remained in the chloroform layer, and formed the sodium salt of S- 
warfarin which partitioned into the aqueous layer.
After separation of the aqueous layer, S-warfarin (free acid) was precipitated by the 
addition of excess 1M Hydrochloric acid. The free acid was then extracted from the solution 
by shaking with three 40ml aliquots of chloroform.
The chloroform layers were combined and the solution dried, firstly by shaking with 30ml 
of saturated potassium chloride solution which was then removed using a separating 
funnel, and secondly by shaking the solution with 3g of dried magnesium sulphate powder 
which was then removed by filtration through a cotton wool plug.
The resulting solution was then evaporated to dryness using a rotary evaporator.
Solution 4: The S-warfarin powder was dissolved in 78ml of warmed solution consisting of 
80% acetone in water.
Unfortunately, at this stage crystals did not form on cooling. The solution was taken back 
to dryness in a rotary evaporator then the powder was dissolved in a minimum amount of 
warmed 50% acetone in water (60ml). The crystals formed on cooling were collected by 
filtration (S-warfarin Crop 1).
A further 13mls of water was added to the filtrate which caused it to become cloudy. The 
solution was gently heated until it became clear. The second set of crystals formed on 
cooling were again collected (Crop 2). A further 13mls of water was added and the 
procedure repeated. (Crop 3)
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3.3.1.2 R-warfarin
The filtrate from section 1 (above) was concentrated to approximately 65ml and was 
diluted with an equal volume of acetone upon which the solution became cloudy. Gentle 
warming was used to redissolve the solid. On cooling a precipitate was formed which was 
removed by filtration. The filtrate was evaporated to dryness in a rotary evaporator, 
forming a glass.
Solution 5: The glass was redissolved in 130ml of chloroform and extracted using 260ml 
of 5% aqueous sodium hydroxide solution. The aqueous layer was taken and added 
dropwise to 70ml of 5.65M aqueous hydrochloric acid solution forming a precipitate of 
partially resolved R-Warfarin which was removed by filtration.
This powder was dried (over phosphorous pentoxide in a vacuum oven at 40°C) to a 
constant weight of 17.93g (0.058 mole). At this stage of the resolution, West et al87 had 
124g (0.405 mole) of powder which when scaled down to the quantities used above would 
represent the equivalent of 16.12g. From this point on, the quantities of chemicals used by 
West et al were multiplied by a factor of 0.143 (0.058 -s- 0.405).
Solution 6: 17.93g of the partially resolved warfarin (0.058 mole) was added to a boiling 
solution consisting of 122ml of absolute ethanol containing 18.87g of quinine (0.058 mole). 
Following the cooling of the solution to room temperature, 480ml of dry ether was added 
and the solution was cooled further and held at —10°C (as before) until crystallisation had 
occurred (24 hours).
The R-warfarin quinine was collected by filtration which was carried out as quickly as 
possible in the 4°C cold room.
This product was recrystallised twice by dissolving in 3ml per gram of hot absolute 
ethanol, then adding 12ml per gram of dry ether to the cooled solution, followed by cooling 
to —10°C. A final crystallisation was performed by dissolving in 2.5ml per gram of hot 
absolute ethanol and allowing to cool slowly to room temperature.
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Solution 7: The recrystallised R-warfarin quinine collected from solution 6 was dissolved 
in 140ml of chloroform. This solution was then extracted by shaking with 140ml of 5% 
sodium hydroxide solution in a separating funnel. This stage of the process liberated free 
quinine, which remained in the chloroform layer, and formed the sodium salt of R-warfarin 
which partitioned into the aqueous layer 
The aqueous layer was then added dropwise to 70ml of 5.65M aqueous hydrochloric acid 
solution forming a precipitate R-Warfarin which was removed by filtration.
Solution 8: The R-warfarin was dissolved in a minimum amount of warm 50% aqueous 
acetone solution and allowed to cool. The crystals formed were collected by filtration (R- 
warfarin crop 1). The filtrate had more water gradually added until it became cloudy. It 
was then warmed until the solution became clear. Further crystals formed on cooling to 
room temperature (crop 2).
3.3.1.3 Optical Activity, Melting Point and Assay 
The optical rotation produced by each crop of crystals was measured at the same 
concentration and in the same solvents as in the paper by West et al87 for comparison. 
The melting point of each sample was measured.
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3.3.2 Results





S-warfarin 1st crop 3.39 -148.9 -148.0 171-172
S-warfarin 2nd crop 2.01 -146.8 -148.0 171-173
S-warfarin 3rd crop 1.53 -47.9 — 160-164
R-warfarin 1st crop 4.80 +147.3 +149.0 171-172
R-warfarin 2nd crop 0.52 +97.2 . . . 155-160
Measurements were performed as solutions in sodium hydroxide solution 0.5M.dm'3.
S-warfarin solutions analysed contained 1.2% and R-warfarin solutions contained 2% 
warfarin.
Ultraviolet/visible absorption spectra and HPLC chromatograms of S-warfarin crops 1 
and 2, and of R-warfarin crop 1 (0.0015% solutions in methanol) were indistinguishable 
from each other or from that of racemic warfarin. Single peaks were seen on the HPLC 
system described in chapter 4.
Following these results, S-warfarin crops 1 and 2 were combined. R-warfarin crop 2 and 
S-warfarin crop 3 were not used.
3.4 Chemical synthesis of warfarin alcohols
In order to provide positional markers for the presence of "warfarin alcohols" (from the 




The method used sodium borohydride to perform the reduction as outlined by Trager et 
al*9.
lg  of racemic warfarin (3.24 x 10‘3mole) was dissolved in 25ml of 0.132M sodium 
hydroxide solution. lOOmg (2.64 x 10'3 mole) of sodium borohydride was added and the 
solution was allowed to react at room temperature (with magnetic stirring).
0.1ml samples were taken during the reaction and acidified with 0.3ml of 0.1M 
hydrochloric acid solution followed by dilution to 10ml with HPLC grade methanol. This 
solution was further diluted 1 in 10 with mobile phase (see HPLC methodology in chapter
4) and analysed using HPLC. The reaction was allowed to continue until the peak 
representing the residual warfarin had fallen to below 1% of its value at t^ . This took 270 
minutes.
Example chromatograms from the start of the reaction (Figure 3.6) and run during the 
reaction (Figure 3.7) are shown below.
On completion of the reaction, 0.1M hydrochloric acid was added dropwise until all the 
sodium borohydride had decomposed (as indicated when drops of acid no longer cause the 
liberation of bubbles of hydrogen). It was then added in excess in order to precipitate the 
warfarin alcohols.
The product was extracted by shaking with three 25ml aliquots of diethyl ether in a 
separating funnel. The etherial layers were combined and dried by shaking with 20ml of 
saturated potassium chloride solution. The aqueous layer was then removed using a 
separating funnel.
The etherial layer was dried further by shaking with approximately 4g of dried 
magnesium sulphate powder, which was then removed by filtration through a cotton wool 
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Figure 3.6 Chromatogram of the Warfarin starting solution prior to the addition of sodium 
Borohydride
3.5 Separation of the alcohols
It was hoped that the conversion of warfarin to the corresponding alcohols by the 
microorganisms (Chapter 4) would have been high enough for the process to be followed 
by looking at the decrease in warfarin in the growth media. This did not turn out to be the 
case, and it became apparent that it was desirable to obtain pure samples of the alcohols 
to act as standards.
This method for the preparative separation of the two enantiomeric pairs of alcohols was 
not developed in time for them to be used as analytical standards for the work in this 
thesis. It is included because it is significantly easier than the elution chromatography 
method developed by Chan et al90.
The majority of analytical HPLC methods in the literature have used reversed phase 
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Figure 3.7 Chromatogram performed during the reduction of warfarin by sodium 
borohydride (45 minutes sample)
Lee et a l91 used a mobile phase consisting of 75% H eptane w ith 25% (79.3% 
dichloroethane, 20% ethyl acetate, 0.7% acetic acid) with a silica column with a bonded 
cyano/amino moiety (Partisil). They also pointed out tha t there was little difference 
between this and a plain silica column.
Banfield and Roland have used two slightly  d ifferen t system s; hexane/ethy l 
acetate/methanol/acetic acid 74.75/25/0.25/0.392 and 74.75/25/0.25/0.493 on plain silica 
columns but with derivatisation of the sample prior to analysis with the second system.
A variety of solvent systems have been able to demonstrate separation of the alcohols on 
plain silica thin layer chromatography (TLC) plates77. The amount of acetic acid in the 
solvent system seems to be an important factor in achieving separation.
Page 56
3.5.1 Method
Although the optimisation of a four component solvent system is difficult to achieve, a 
mobile phase that worked for normal phase HPLC and was based on a combination of 
those used above was arrived at empirically.
Solution A consisted of dichloromethane/methanol/acetic add in the ratio 30/10/2 by 
volume. Solution B was heptane. The combination of these which gave the desired 
separation was 10% A and 90% B.
Solution A had dichloromethane and methanol in approximately the same ratio as in the 
paper by Lee et al91 but had a higher concentration of acetic add, bringing the overall 
concentration in the mobile phase to 0.476%.
The separations were carried out at room temperature using a plain silica preparative 
column (21.2mm internal diameter x 25cm containing Zorbax Sil, 10pm particle size), 
using ultraviolet detection at 305nm. Two HPLC pumps, each capable of providing 
lOml.min'1 of output, were used to provide the high flow rate required. A measured flow 
rate of 20.5ml.min1 was achieved with a back pressure of approximately 2800 p.s.i.
The sodium borohydride reduced warfarin sample was introduced onto the column as a 
200mg.ml'1 solution in solvent system A. A 0.5ml loop size was used, leaving to a column 
loading of lOOmg.
3.5.2 R esults
The chromatogram shown in Figure 3.8 shows almost baseline separation of residual 
warfarin (30 minutes), R-warfarin-S-alcohol and S-warfarin-R-alcohol (38 minutes) and 
R-warfarin-R-alcohol and S-warfarin-S-alcohol (51 minutes).
Peak assignments given are based on the reverse of the elution order given in the paper 
by Fasco et al76. Samples of the alcohols collected from this system were chromato- 
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Several microorganisms which have been reported in the literature to metabolise 
warfarin were obtained and were screened with the aim of re-establishing warfarin 
metabolism in our own laboratories. A range of other related microorganisms, which were 
held in the University of Bath pharmacy department stocks were also screened.
It was intended to attempt to produce large quantities of any microorganism shown to 
produce reduction of the ketone group of warfarin, by using a fermenter.
4.2 Experimental Details
4.2.1 Equipment
LDC Spectromonitor 3100 variable wavelength UV detector 
LDC Constametric 3000 dual piston metering HPLC pump 
BBC Servogor SE120 chart recorder or - 
Servoscribe Is chart recorder
Hewlett Packard 3390A integrator with integral printer
HPLC column water bath - Grant SU6 re-circulating water bath heater running against 
a Haake EK12 water bath cooling coil.
Chilspin Bench centrifuge - Fisons Scientific Equipment, Loughborough, England 
Bioflow  II B atch or continuous 61 Ferm enter and C ontrolled environm ent 
incubator/shaker - New Brunswick Scientific, Edison, N.J., USA.
8 Flask shaker - Griffin and George, England
4.2.2 Materials
4.2.2.1 Chemicals and growth media 
All salts used to make the chemically defined media were of standard laboratory reagent 
grade or above. All complex growth media were obtained from Oxoid, Basingstoke, Hants,
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England and were reconstituted according to the manufacturers instructions using 
laboratory distilled water.
HPLC grade Acetonitrile and ethyl acetate were obtained from Fisons Scientific 
Equipment, Loughborough, England.
Trizma (Tris) buffer salts were obtained from Sigma Chemical Co. Ltd. Poole, Dorset
4.2.2.2 HPLC Column
Jones Chromatography 5pm particle size spherisorb ODS 2, 5mm internal diameter, 
150mm length
4.2.2.3 Other Items
0.2pm cellulose nitrate 25mm diameter filters were obtained from Whatman Ltd., 
Maidstone, England
4.3 Reverse phase HPLC analysis of warfarin
In order to screen various micro-organisms for the ability to reduce warfarin’s aliphatic 
ketone group to the corresponding alcohol it was first necessary to set up an assay for 
these compounds. The reversed phase HPLC system developed by Fasco et al76 was used 
initially.
4.3.1 Preparation of solutions for HPLC
4.3.1.1 Mobile phase
The mobile phase composition was the same as the one used by Fasco et al76 and 
consisted of:- 69 parts: 1.5% acetic acid solution in RO water (adjusted to pH 4.7
using concentrated ammonium hydroxide)
31 parts: HPLC grade acetonitrile
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4.3.1.2 Racemic warfarin
For the initial calibration run racemic warfarin was dissolved in methanol/acetonitrile 
(1:1). The resulting solutions were then diluted 1 in 4 with mobile phase. This dilution 
procedure mimicked the dilution which occurred during preparation on samples extracted 
from the microorganisms growth media.
4.3.2 HPLC methodology
A water bath was used to keep the HPLC column temperature at 25°C. The mobile phase 
flow rate was 2.0 ml.min1 and a 50pm sample injection loop was used. Ultraviolet 
detection at a wavelength of 305nm was employed.
4.3.3 Calibration Curves
In order to check the correct functioning of equipment, simple five point calibration 
curves were performed (two injections at each point). A typical curve is given below 
(Figure 4.1)
This curve was constructed using dilutions prepared from one warfarin weighing. This 
demonstrated the linearity of the assay.
In order to assess the repeatability of the analysis system, five solutions of around 0.004% 
were prepared together with corresponding 1 in 10 dilutions. Each solution was injected 
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Standard Deviation 0.0175 
(0.66% of the mean)
0.0280 
(1.12% of the mean)
At each dilution, the solution which gave the peak area/concentration value nearest to 
the mean value was then used as a standard.
The assay of extracted samples was performed according to the following protocol.
High standard injected twice 
Sample A injected twice 
Sample B injected twice
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Low standard injected twice 
Sample C injected twice 
Sample D injected twice 
High Standard injected twice 
Sample E injected twice etc.
The concentration of warfarin in the unknown samples could then be determined.
4.4 The screening o f m icroorganism s for w arfarin reductase activity
The following microorganisms were screened for warfarin reductase activity:- 
FUNGI
Cunninghamella bainieri C43
Cunninghamella bertholletiae C l
Cunninghamella blakesleeana CMI 53585
Cunninghamella echinulata IMI 199844
Cunninghamella echinulata C7
Cunninghamella echinulata NRRL 3655
Cunninghamella elegans ATCC 36112
The top six of these had previously been used in studies on the N-dealkylation of drugs 
at the University of Bath by Sewell94.
Sources:-
C American Cyanamid Company, Lederle Laboratories, Pearl River, New York,
USA.
CMI/IMI Commonwealth Mycological Institute, Kew, Surrey, England
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NRRL U.S. Department of Agriculture Northern Regional Research Labs, Peoria,
USA.
ATCC American Type Culture Collection, Maryland, USA
BACTERIA
Rhodococcus ATCC 19140 (Arthrobacter species)
Rhodococcus ATCC 19070 (Nocardia corallina)
4.4.1 Nomenclature
The classification of the Nocardia Corallina and Arthrobacter species referred to by Davis 
and Rizzo77 has recently been changed. They are now considered to be of the genus 
Rhodococcus. For a full description of the properties which are required for this 
classification (mainly based on the cell wall composition) see Finnerty95 and Topley and 
Wilson96. Because of this confusion in the literature, the ATCC numbers will be used in 
this text.
4.4.2 Screening protocol
A two stage protocol was used, based on the use of chemically defined media used by 
Eady et a/97 and modified by Gibson98 and Sewell94
4.4.2.1 Culture maintenance 
Fungal cultures were maintained on refrigerated (4°C) malt extract agar slants and were 
transferred to fresh slants every three months to maintain viability. Bacterial cultures 
were maintained on tryptone-soya agar slants in a similar manner.
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4.4.2.2 Stage One Media 
The mineral composition of the stage 1 basal media (at single strength) is shown below:-
Compound Concentration (mg I'1)
Na2HP04.12H20 989.0
(NH4)2S 04 667.0










This solution was prepared at double strength. 100ml bottles of this solution and 100ml 
bottles of distilled water were sterilised by autoclaving.
A 5% solution of the Casamino acid (mixed amino acids) powder in distilled water and 
a 10% solution of glucose in distilled water were prepared. These solutions were sterilised 
by filtration through sterile 0.2pm pore size cellulose acetate membrane filters into sterile 
20ml plastic vials.
The vessels used for both stage 1 and stage 2 cultures were thick walled, wide necked 
Erlenmeyer flasks which had six baffles moulded radially into the glass. They were pre­
sterilised in a hot air oven.
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Each flask had the following added aseptically:- 
Double strength stage 1 basal media 25ml 
5% Amino acid solution 10ml
10% Glucose solution 5ml
Distilled water 10ml
After equilibration of the solution to the incubation temperature the flasks were 
inoculated with surface growth from the slants. They were sealed using pre-sterilised 
bungs which consisted of a cotton wool ball which had been wrapped in gauze. The purpose 
of this was to allow a degree of oxygen diffusion into the flasks whilst maintaining 
sterility.
The flasks were incubated at 27°C in a controlled environment incubator/shaker running 
at 250 r.p.m. Cultures were incubated in the dark.
All fungal cultures grew well in this media, forming pellets of growth by approximately 
36 hours from the time of inoculation.
The bacterial cultures grew fairly slowly on this medium but an adequate suspension of 
cells was produced by 48 hours.
4.4.2.3 Stage Two Media
The stage two media was similar to the stage one media but with the addition of further 
trace elements.
The composition of single strength solutions are given below:-
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Stage two basal media
Compound C oncentration (mg I'1)
k h 2 p o 4 3327.0
NaH2 P 0 4 .2H20 732.0




Compound Concentration (mg I'1)
(NH^M o^ ^ H jjO 93.0
CaCl2 .2H20 33.0
ZnS04 .7H20 5.5
FeS0 4 .7H20 3.5
MnS04 .4H20 0.75
CuS04 .5H20 0 . 2 0
Co(N03 )2 .6H20 0.125
Na2 B4 O7 .1 0 H2O 0.090
The stage 2 basal media solution was again prepared at double strength and sterilised 
in an autoclave. The trace element solution was prepared as 50x strength concentrate and 
was sterilised by filtration.
Each stage 2 flask has the following added aseptically:-
Double strength stage 2  basal media 25ml
5% Amino add solution 1 0 ml
10% Glucose solution 5ml
50x strength trace element concentrate 1 ml
0.5% warfarin solution (see below) 5ml
Solution from stage 1 flask* 1 ml
Distilled water to 50ml
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* In the case of the fungal cultures, the inoculum from the stage on flask consisted of a 
single pellet. The volume of this was ignored.
The stage two flasks were set up using stage one cultures which were 72 hours old. The 
inoculum was the last solution to be added to the stage two flasks, after the other solutions 
had been pre-incubated for 1  hour to allow for temperature equilibration.
4.4.2.4 Preparation of the warfarin solution
These initial studies were carried out using racemic warfarin and the 0.5% solution was 
prepared as follows
lg  (3.24 millimole) of warfarin powder was accurately weighed and was dissolved in 25ml 
of 0.132M sodium hydroxide solution (3.3 millimole), forming the sodium salt. A 0.1M 
hydrochloric acid solution was then added dropwise until the slightest cloudiness was seen 
in the solution. Distilled water was then added to 200ml, upon which the solution became 
clear again.
The pH of such a solution was measured and found to be 9.5.
In order to check that the stage two media was able to buffer the addition of this solution, 
two solutions were prepared:-
Measured pH
1) 50ml stage two media including 5ml 0.5% warfarin 7.36
2) 50ml stage two media with 5ml of water replacing the warfarin 7.35
4.4.2.5 Controls
The following flasks were set up as controls
1) Stage two media with warfarin but no microorganisms. This was used to check for 
chemical degradation of warfarin during the incubation period.
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2) Stage two media with each of the microorganisms but without warfarin. These flasks 
were used to check that the microorganisms were able to grow in the stage two media, 
and that they did not produce any compounds which interfered with the assay.
All flasks (stage one and stage two) were checked for contamination when they were 
finished with by preparing two tryptone-soya-agar streak plates and incubating one plate 
at 27°C and one plate at 37°C. If any contamination was apparent the experiment was 
repeated
4.4.2.6 Extraction Procedure
For this initial screening experiment, the following semi-quantitative extraction 
procedure was used:-
1 .0 ml of the growth media was transferred to a glass culture tube and was acidified with 
0.1ml of 5.65 M aqueous hydrochloric acid solution. 4.0ml of ethyl acetate (HPLC grade) 
was added and the solution was mixed for 15 minutes using a flask shaker. The tube was 
then spun at 4000 r.p.m. in a bench centrifuge (Chilspin) for 5 minutes to aid separation 
of the organic layer. 3.0ml of the ethyl acetate solution was then transferred to a 10ml 
class A volumetric measure, and evaporated to dryness using a gentle stream of filtered 
compressed air. The residue was then redissolved by adding 2.5ml of a HPLC grade 
methanol/acetonitrile (1 :1 ) mixture, and the flask was made up to volume using mobile 
phase.
4.4.2.7 Results
The second stage cultures were followed for a period of sixteen days. None of the fungal 
cultures showed any metabolism of warfarin to the corresponding alcohols. Both strains 
of rhodococcus showed some production of the warfarin alcohols (estimated at less than 5% 
conversion) with the first of the two alcohol peaks (S,S and/or R,R warfarin alcohols)
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predominating. It had been hoped that this assay would be able to track the disappearance 
of warfarin from solution but the levels of conversion to the alcohol were too low for this.
4.4.3 Improving the assay
A method for improving both the separation of the two warfarin alcohols was sought 
together with a suitable compound for use as an internal standard.
4.4.3.1 A different mobile phase
The mobile phase used by Tasker" was tried. This consisted of 1% acetic acid and 44% 
acetonitrile in water. This gave baseline separation of the two pairs of warfarin alcohols 
and warfarin. In addition, the total assay time was reduced.
Acetic acid has a pKj, of 4.81 0 0  and a 1% solution (in water alone) has a calculated 
theoretical pH of around 2.8. Such a low pH was likely to cause damage to the analytical 
column, and therefore an old ODS column was placed in line to act as a guard.
4.4.3.2 Internal Standard
Davis and Rizzo7 7  had used phenprocoumon as an internal standard, but this compound 
was not readily available. Two possible commercially available compounds for use as 
internal standards were D L-3-(a-acetonyl-p-chlorobenzyl)-4-hydroxycoum arin  
(subsequently referred to as chlorowarfarin), and the compound coumarin itself. When 
chlorowarfarin was injected onto the column using the HPLC system first described it had 
a retention time approximately twice that of warfarin. Coumarin, on the other hand, came 
off the column with the solvent front, but with the new mobile phase described above there 
was a significant delay before the peak. Also with this system, the coumarin peak (which 
comes off before the warfarin alcohols) was separated from any other peaks.
A chromatogram taken during the sodium borohydride reduction of a second batch of 
warfarin is shown in Figure 4.2. Peak identities:- R-warfarin-R-alcohol and S-warfarin-S- 
alcohol (5 minutes); R-warfarin-S-alcohol and S-warfarin-R-alcohol (7 minutes); residual
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Figure 4.2 Chromatogram performed during the reduction of warfarin by sodium 
borohydride (120 minutes sample - second mobile phase)
4.4.4 Validation of the extraction procedure
It was found that both rhodococci grew more vigorously on the complex media tryptone 
soya broth (TSB). The extraction of warfarin from this media was attempted, together with 
the addition of coumarin as an internal standard during the extraction procedure. The 
extraction procedure was also modified in order to increase the final concentration of 
compounds in the injection sample.
Seven solutions of warfarin (as the sodium salt) in TSB were prepared covering the 
concentration range 0.006% to 0.06%. 1.0ml samples of each were placed in glass culture 
tubes and the following were added; lOOpl of a 0.24% solution of coumarin in ethyl acetate,
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lOOpl of 5.65M hydrochloric acid, 3.9ml of ethyl acetate. This solution was agitated using 
a flask shaker for a period of 5 minutes, followed by centrifuging at 4000 r.p.m. for 5 
minutes to separate the aqueous and organic layers. 3.0ml of the supernatant was then 
evaporated to dryness. The residue was then dissolved by adding 0.5ml of methanol 
followed by 1.5ml of mobile phase. These samples were injected onto the column in a 
randomised order.
4.4.4.1 Results
The peak area ratio (warfarin peak area -r  coumarin peak area) has been plotted against 
warfarin concentration in the TSB solution in Figure 4.3
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r-squared 0.99886 Correlation 0.99694
Calculated Intercept 0.152 Standard Deviation 0.0426
Calculated Slope 32.357 Standard Deviation 1.134
From looking at this data, it is obvious that although the correlation is reasonable, the 
intercept is considerably above zero. The same data, but with a non linear regression line 
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Figure 4.4 Peak area ratio vs warfarin concentration calibration graph (non-linear 
regression line shown)
STATISTICS
r-squared 0.99999 Correlation 0.99996 
Equation of line:-
Peak Area Ratio = 0.02838 + (43.0273 x Warfarin Cone.) - (161.6696 x Warfarin Cone.2)
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Although the data is useable, the better non-linear fit suggests that solubility is having 
an influence, or that the warfarin (free acid) is not partitioning fully into the ethyl acetate 
layer.
4.4.5 The reduction of warfarin by Rhodococci against time
72 hour cultures of ATCC 19070 (37°C in TSB) and ATCC 19140 (26°C in TSB) were 
prepared (incubation conditions as before).
Nine flasks were then prepared:-
1) TSB 40ml, ATCC 19070 72hr culture 5ml, 0.5% RS-warfarin 5 ml
2) TSB 40ml, ATCC 19070 72hr culture 5ml, 0.5% S-warfarin 5ml
3) TSB 40ml, ATCC 19070 72hr culture 5ml, 0.5% R-warfarin 5ml
4) TSB 40ml, ATCC 19140 72hr culture 5ml, 0.5% RS-warfarin 5ml
5) TSB 40ml, ATCC 19140 72hr culture 5ml, 0.5% S-warfarin 5ml
6 ) TSB 40ml, ATCC 19140 72hr culture 5ml, 0.5% R-warfarin 5ml
7) TSB 40ml, ATCC 19070 72hr culture 5ml
8 ) TSB 40ml, ATCC 19140 72hr culture 5ml
9) TSB 45ml, 0.5% RS-warfarin 5ml
Samples were taken at lhour, then periodically over the next 1 2  days
4.4.5.1 Results
Streak plates were produced from all flasks at the end of the experiment to check for any 
contamination. All flasks were shown to be clear.
Flasks 7 and 8  demonstrated that the rhodococci grew strongly in the media under the 
stated conditions.
Analysis of flask 9 gave a single warfarin peak throughout the experiment (ie. no 
chemical degradation products were seen). The warfarin concentration at the end of the 
experiment (288 hours) was not significantly different from the sample taken at one hour.
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The amount of warfarin metabolism in flasks 1 to 6 was again disappointing when 
compared to that seen by Davis and Rizzo77. The levels were again too low to produce any 
significant reduction in the amount of remaining warfarin, but in the absence of warfarin 
alcohol standards (see section 3.5) the peak areas of the metabolites produced divided by 
the coumarin (internal standard) peak areas are shown below.
Flasks 1 to 3 ATCC 19070
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Figure 4.7 Flask three - R warfarin
Three additional peaks developed as the experiment progressed:-
1) tf = 5 minutes corresponding to R-warfarin-R-alcohol or S-warfarin-S-alcohol
2) t,. = 7 minutes) corresponding to R-warfarin-S-alcohol or S-warfarin-R-alcohol
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3) t,. = 8 minutes - identity unknown 
(t,. =retention time)
From the graphs for flasks 2 and 3 it can be seen that the peak occurring at a tr of 5 
minutes has been produced from S-warfarin (no peak at this retention time if only R- 
warfarin is present) and therefore must be S-warfarin-S-Alcohol (Figure 4.8).
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Figure 4.8 Production of S-warfarin-S-alcohol by ATCC 19070 
when incubated with S-warfarin or RS-warfarin
By a similar argument, the peaks at 7 minutes and 8 minutes must be produced from R- 
warfarin. The peak at t, = 7 must be R-warfarin-S-alcohol. It is interesting that in both 
flask 1 and flask 3, the quantity of this metabolite appeared to decrease after its initial 
increase (Figure 4.9).
These result show that ATCC 19070 preferentially metabolises S-warfarin (peak area 
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Figure 4.9 Production of R-warfarin-S-alcohol by ATCC 19070 
when incubated with R-warfarin or RS-warfarin
Flasks 4 to 6 ATCC 19140 
ATCC 19140 showed no significant reduction of R-Warfarin (flask 6). S-warfarin was 
reduced entirely to the S-alcohol (tr = 5 min) as shown in Figure 4.10
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Figure 4.10 Production of S-warfarin-S-alcohol by ATCC 
19140 when incubated with S-warfarin or RS-warfarin
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4.5 The growth of Rhodococci in a fermenter
In spite of the relatively low percentage conversion of warfarin to its alcohols shown in 
the previous section, it was decided to attempt to grow both microorganisms in a 
fermenter. The high cell masses generated by such growth could then be used to see 
whether the percentage conversion could be increased, and whether it might be possible 
to extract the enzymes responsible.
4.5.1 Method
A 24 hour culture of either ATCC 19070 or ATCC 19140 was prepared in shake flask 
(conditions as before) containing 250ml of pre-sterilised TSB (37°C or 26°C respectively)
A 6  litre capacity fermenter (Figure 4.11) was filled with 4750ml of TSB and steam 
sterilised by autoclaving at 121°C, 15 p.s.i. for 20 minutes. Once the solution had cooled, 
the various connections to the fermenter vessel were made using standard aseptic 
techniques. These included the acid (1M orthophosphoric acid) and base (1M Sodium 
hydroxide) solutions which the fermenter adds to the vessel (automatically using peristaltic 
pumps) as required to maintain the pH, and the silicon based anti-foam solution. The 
appropriate temperature was set and the solution allowed to equilibrate.
The dissolved oxygen sensor was calibrated according to the manufacturers instructions 
by:-
a) sparging the solution with nitrogen with the impeller speed set to 700 r.p.m. Once the 
reading from the probe had settled, this was defined on the fermenter control panel as 
being a solution with a dissolved oxygen tension of zero.
b) sparging the solution with air at a flow rate into the vessel of 3 litres.min' 1 with the 
impeller rate set at 400 r.p.m. This solution was taken to have a dissolved oxygen tension 
of 1 0 0 %
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Figure 4.11 The Bioflow II fermenter
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The air input flow rate was adjusted to 0.5 l.min ' 1 and the fermenter was set to 
automatically maintain (by varying the agitation speed) a dissolved oxygen tension of 50%. 
Initially, before the addition of any culture, the dissolved oxygen tension was around 80% 
with the impeller operating at its minimum speed (around 60 r.p.m.)
The fermenter was set to maintain the culture pH at 7.2.
Once the 250ml of inoculum had been added, growth was allowed to proceed until the 
fermenter was unable to maintain the 50% oxygen tension with the impeller operating at 
600 r.p.m. (42-48 hours)
Culture samples were taken periodically during the fermenter cycle and streak plates 
performed to check for contamination.
Cells were harvested by centrifugation at 2000 r.p.m. for 15 minutes in a 6  x 1 litre 
capacity centrifuge (School of Biochemistry). The supernatant was discarded then the cells 
were re-suspended in approximately twice the packed cell volume of a pH 7.4 tris(hydroxy- 
methyl)aminomethane (Tris) buffer. This served to wash the cells in order to reduce the 
concentration of any of the anti-foaming agent added during the fermentation.
Cells were re-harvested by centrifugation and this washing process repeated three times
The following wet cell masses of Rhodococci were obtained.
ATCC 19070 196g
ATCC 19140 134g
The cells were re-suspended at a concentration of 50% w/v in Tris buffer and stored at 4°C.
4.6 M etabolism o f warfarin by the ferm enter cell suspensions  
A quick in itial experiment with the cell suspension from ATCC 19070 showed 
encouraging results. 0.5ml of 0.5% S-warfarin solution was added to 4.5ml of the 
suspension. This was incubated in the incubator/shaker at a temperature of 37°C
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and samples taken periodically for extraction according to the method outlined above. The 
results are given in Figure 4.12.
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Figure 4.12 The production of S-warfarin-S-alcohol by a 50% 
w/v suspension of ATCC 19070 cells
Although this information is from a single flask, this system showed significantly more 
conversion than any of the previous experiments. This suggests tha t the degree of 
conversion is related to the cell mass present and that cells do not need to be actively 
growing in order for reduction of the aliphatic ketone group to occur.
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5 NICOTINAMIDE ADENINE DINUCLEOTIDE
5.1 Introduction
Glucose Oxidase (considered earlier) is an Oxidoreductase which has a prosthetic group 
based on the flavin moiety. There are in excess of 550 commercially available 
oxidoreductases. Approximately 250 of these use coenzymes which contain the nicotinamide 
moiety, namely nicotinamide adenine dinucleotide (NAD+) and nicotinamide adenine 
dinucleotide phosphate (NADP+). The reduced forms of these two coenzymes are referred 
to as NADH and NADPH respectively.
0
OH R
N A D :  R = OH
0
N A D P :  R = — p — OH
0 H
Figure 5.1 Structures of the coenzymes NAD+ and NADP+
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PLEASE NOTE: Where information in the text refers to both NAD+ and NADP+, this will 
be written as NAD(P)+. Similarly, the reduced cofactors will be collectively referred to as 
NAD(P)H.
Nicotinamide is the functional part of the coenzyme molecule in reduction/oxidation 
reactions.
R R
Figure 5.2 The oxidised and reduced forms of the nicotinamide moiety (NAD or NADP 
coenzyme)
The development of a biosensor based on an NAD(P)+ dependant oxidoreductase requires 
additional problems to be overcome when compared to existing biosensor technologies (for 
example glucose biosensors)
1) NAD+ and NADP+ are cofactors (rather than prosthetic groups) and are able to 
dissociate from the enzyme. It is therefore necessary to immobilise them at the electrode 
surface (as well as the enzyme), in order that sensor output does not decrease with 
time. Additionally, this immobilisation needs to be performed in such a way that 
enzyme activity is not dramatically affected, ie. any chemical modification made to the 
cofactor should not stericaly hinder its ability to access the active site on the enzyme.
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It should be noted though that it may be possible to modify the cofactor in order to 
allow it to have a secondary function as an electron transfer mediator between the 
active site of the enzyme and the electrode surface.
2) If the enzyme is acting to oxidise a substrate the NAD(P)+ will consequently end up 
in its reduced form NAD(P)H. In order to produce a biosensor the cofactor would need 
to be re-oxidised at an anode.
NAD(P)H ------------------  >  NAD+(P) + 2H+ + 2e
Unfortunately, although this reaction is feasible at an electrode, it requires a large 
positive potential (eg. + IV vs AgCl at a clean platinum electrode). However, several 
novel "conducting organic salt" electrode materials allow this reaction to proceed at low 
anodic potentials.
e.g. The oxidation of ethanol by alcohol dehydrogenase (ADH)
CH3 CH2OH + NAD+   >  CH3 CHO + NADH + H+
NADH -------------------------->  NAD+ + 2H+ + 2e
V
ANODIC CURRENT
This reaction can occur at 0.0V (with respect to a Ag/AgCl reference electrode) at a PVC 
bound NMP^TCNQ' electrode1 0 1  (Figure 5.3)
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Figure 5.3 Structure of N-methylphenazinium (NMP) and Tetracyanoquinodimethane 
(TCNQ)
The mechanism by which this occurs at such surfaces is not well understood. Some 
dissolution of the electrode surface may be occurring so that an electron transfer 
mediator is formed in situ.
3) If the NAD(P)+ dependent enzyme is performing a reduction the NAD(P)+ will end up 
in its oxidised form. This oxidised coenzyme will need to be reduced (either directly or 
indirectly) at the electrode surface in order to regenerate the active cofactor. However, 
this does not happen (Figure 5.4). Although a small amount of the active NAD(P)H is 
regenerated, a series of dimers and other reduction products are formed102,103,104.
Analysis of what happens when the cathodic reduction of NAD(P)+ is attempted is the 
subject of this chapter.
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Figure 5.4 Desired sequence of events at biosensor based on a NAD(P)H dependent 
reductase
5.1.1 The Regeneration o f NAD(P)H from NAD(P)*
If a method for the regeneration of 100% active NAD(P)H without using an enzyme were 
to be found, it would be useful in a variety of different scientific areas. For example, during 
the synthesis of compounds using biochemical reactors1 0 5  it is often necessary to add a 
second substrate (to force the equilibrium in the desired direction a large excess may be 
required) and possibly a second enzyme, in order to regenerate the active cofactor for use 
in the desired enzyme reaction (Figure 5.5). This incurs the additional difficulty of having 
to remove unwanted products and reactants from the mixture.
From the point of view of reagentless biosensor development, there is a need to find an 
electrochemical system by which active NAD(P)H can be regenerated at low negative 
potentials without producing inactive products. Various organometallic compounds of 
Rhodium are considered later as possible reaction-modifying mediators.
Much effort has been put into the identification of the various products from the 
reduction (either chemical or electrochemical) of NAD(P)+ 102,103,10\  Experiments which 
identify the exact identity of inactive products are less important at this stage than
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Figure 5.5 The regeneration of a cofactor in a biochemical reactor
experiments which can demonstrate a change in the profile of the products formed when 
a particular mediator is present.
5.2 HPLC A nalysis of NAD* and its Reduction Products
A reversed phase gradient HPLC system was used to separate NAD+ from its reduction 
products and is detailed below.
5.2.1 Equipment
LDC Spectromonitor III variable wavelength UV detector (TWO) or LDC Spectromonitor 
5000 photodiode array detector (capable of recording at more than one wavelength at 
the same time)
LDC Constametric III dual piston metering HPLC pumps (TWO)
LDC GM4000 gradient programmer 
BBC Servogor SE120 chart recorder (TWO)
HPLC column water bath - Grant SU6  re-circulating water bath heater running against 
a Haake EK12 water bath cooling coil.
Remote immersible magnetic stirrer (Rank Bros., Bottisham, Cambridge)
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Rotary evaporator, Biichi rotavapor
Wenking model LB75M potentiostat (UK distributor: Linton Instrumentation, Harlow, 
Essex, England) The external reference voltage source for the potentiostat was from a 
Metrohm 612 VA Scanner (Metrohm Ltd., Herisau, Switzerland) used in its fixed 
voltage mode.
Thandor TM356 Digital Multimeter (RS components LTD, Corby, Northants, England) 
Mettler AE163 4 or 5 decimal place analytical balance
5.2.2 M aterials
5.2.2.1 Chemicals
Ammonium bicarbonate (99%), sodium pyrophosphate decahydrate (A.C.S. Reagent) 
were obtained from the Aldrich Chemical Company Ltd., Gillingham, Dorset, England. 
Acetone and Methanol (HPLC grade) were obtained from Fisons Scientific, 
Loughborough, Leicestershire, England.
Mercury (triple distilled) was obtained from Belgrade Mercury Ltd, Belgrade, England. 
Any surface film was removed from the mercury allowing it to fall through a small pin­
hole in a piece of filter paper twice immediately before use.
5.2.2.2 Nicotinamide Co-factors
The following were obtained from the Sigma Chemical Company Ltd., Poole, Dorset, 
England.
P-Nicotinamide adenine dinucleotide (grade III-C, product No. N-1511)
P-Nicotinamide adenine dinucleotide (grade III, product No. 260-101) lm g (1.46 
micromole) pre-weighed vials
p-Nicotinamide adenine dinucleotide, disodium salt, reduced form, (Grade III, product 
No. 340-101) lmg (1.28 micromole) pre-weighed vials.
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5.2.2.3 HPLC Columns
Analysis column: LKB (Pharmacia) Ultrapack 5K ODS-120T column (5pm particle size 
ODS, 4.6mm internal diameter, 250mm length)
Mixing Column: An old Chromotech Hypersil column (5pm particle size ODS, 5mm 
internal diameter, 150mm length) scavenger/mixer column was used between the two 
pumps and the injection loop. The purpose of this was to ensure adequate solution 
mixing (high pressure) and to try protect the analysis column against the relatively low 
pH of the mobile phase.
5.2.2.4 Other Items
0.2pm 25mm diameter cellulose nitrate membrane filters and 0.45pm 47mm diameter 
cellulose acetate membrane filters were obtained from Whatman Ltd, Maidstone, Kent, 
England.
5.2.3 Preparation o f solutions for HPLC
5.2.3.1 NAD and NADH standard solutions 
These solutions were prepared immediately before use from commercially available lmg 
pre-weighed vials. For the isocratic test runs the cofactor was dissolved in mobile phase. 
For gradient HPLC, samples were reconstituted with a solution equivalent to the starting 
composition of the mobile phase. This solution composition is referred to as "Initial Mobile 
Phase" later in the text.
Two types of calibration method occurred:-
1) To establish the linearity of the assay, a set of seven solutions were prepared containing 
both NAD+ and NADH in concentrations ranging from 0.005mM to O.lmM of each 
compound. These were then put on to the column in a random order.
Page 90
2) For individual analysis of a reaction mixture, a solution containing a high concentration 
of each compound (O.lmM) and a solution containing a low concentration of each compound 
(0.02mM) were analysed before and after the reaction mixture. The concentrations of NAD+ 
and NADH in the reaction mixture were then calculated by extrapolation.
5.2.3.2 Electrolysis Buffer Solution
The buffer solution used for the electrochemical reduction experiments consisted of 
dipotassium hydrogen phosphate 0.1M and tetraethylammonium chloride 0.05M in RO 
water, adjusted to pH 7.00 using 5M and 0.5M hydrochloric acid in RO water. This solution 
was deoxygenated by bubbling oxygen free nitrogen through it (via a glass sinter) for 15 
minutes prior to use.
The purpose of the tetraethylammonium chloride is for this salt to preferentially adsorb 
at the mercury surface and therefore reduce the adsorption of NAD+.
5.2.3.3 NAD+ Stock Solution
In order to semi-quantitatively match the chemical reduction experiment to the 
electrochemical reduction experiments, a stock solution of 2mM NAD+ in the electrolysis 
buffer described earlier was prepared. The same solution was then used for all three 
reductions (chemical and electrochemical at -1.1V and -1.8V) on the same day.
5.2.3.3.1 Beer-Lambert plot for NAD+
In order to assay the starting concentration of NAD+ in the stock solution a Beer-Lambert 
plot was constructed. Quantities of NAD+ were accurately weighed directly into 50.0ml 
class A volumetric flasks and made up to volume with electrolysis buffer. A 5.00ml sample 
of each solution was then diluted to 50.0ml with "initial mobile phase". This 1 in 10 
dilution mimicked the dilution which occurred when electrolysis samples were diluted for 
HPLC analysis. A 10%v/v solution of electrolysis buffer in initial mobile phase was used
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as a blank. A bsorbances were m easured  using  a P erk in  E lm er A.3 dual beam
spectrophotometer using matched quartz cells with a 1.0cm path length.
Weight of NAD+ Concentration in solution Absorbance at 260nm
19.8mg 55.9 pM 0.989
15.6mg 44.0 pM 0.766
11.8mg 33.3 pM 0.591
7.9mg 22.3 pM 0.397
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Figure 5.6 Beer-Lambert plot for NAD+ at 260nm
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STATISTICS
r-squared 0.99992 Correlation 0.99987
Calculated intercept 0.0042 Standard deviation 0.0047
Calculated slope 0.01754 Standard deviation 0.00014
Using the equation A = E.c.l, where A = absorbance, c = concentration and 1 = path length 
in cm.
Calculated extinction coefficient = 17.54 (pH 8.2)
The manufacturers quote a value of 17.7 (pH 7.0) 1 0 6
5 .2 .3 .4 Electrochemically reduced NAD+
According to Jaegfeld1 0 3  the reduction of nicotinamide adenine dinucleotide proceeds in 
two steps. A one electron step at -0.9V vs s.c.e. an a mercury electrode which produces a 
radical which can dimerise to give enzymatically inactive products. A second step at -1.7V 
vs s.c.e which produces compounds with some enzymatic activity.
For the purpose of this study, reductions of NAD+ were carried out at -1.1V and at -1.8V 
vs s.c.e. electrode in the electrochemical cell shown below (Figure 5.7).
The air-tight lid of the cell had two additional ports not shown in Figure 5.7. One of these 
had a dip tube fitted to allow de-oxygenation of the solution by bubbling with pre­
humidified nitrogen. During the experiment the nitrogen was re-directed to flow over the 
surface of the reaction solution at a flow rate which produced a small depression in the 
liquid surface.
The electrochemical cell and all associated glassware was cleaned after each experiment 
by immersing in a chromic acid solution for 30 minutes followed by rinsing with copious 
amounts of distilled water. A final rinse of RO water was used prior to drying in a hot air 
oven.
3.0ml of mercury was used in the cell and this had a physical electrode surface area of 
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diameter No. 5 glass frit had been sealed. The tube was filled with a solution consisting 
of 3M potassium chloride in RO water which had been solidified by the addition of purified 
agar at a concentration of 1%W/V. A space was left unfilled in the top of the tube to 
accommodate the counter electrode. This was fabricated from a 2cm x 10cm piece of 
platinum gauze, which was rolled up and immersed in a 3M solution of potassium chloride 
in RO water. A radiometer K401 s.c.e. reference electrode was positioned just above the 
mercury surface. Electrical connection to the mercury pool was achieved using a piece of 
0.5mm diameter platinum wire which had been sealed into glass. This was then dipped in 
to the mercury pool.
Electrochemical reductions were all carried out at 10°C. The teflon coated magnetic 
stirring rod (3mm diameter x 10mm) was used to keep the solution well mixed and to help 
renew the mercury surface. It was rotated as quickly as possible in order to create standing 
waves on the mercury surface without causing the surface to separate into droplets.
5.2.3.4.1 Electrochemical Reduction Methodology
8.00cm3 of pre-cooled electrolysis buffer was carefully added to the cell avoiding getting 
any of the solution on the sides of the cell above the liquid level. The appropriate electrode 
potential was applied and the current allowed to settle until stable. The working electrode 
potentials were checked using a high input impedance calibrated multimeter and were 
found to be -1.101V and -1.800V respectively. The cell was disconnected from the 
potentiostat and 8.00cm3 of a 2mM solution of NAD+ (pre-cooled) was then added to the 
cell. After a 10 minute period to allow for mixing and temperature equilibration the cell 
was re-connected and the reduction allowed to proceed. During the -1.8V reduction a 
significant amount of gas evolution (presumably hydrogen) occurred at the mercury 
surface. When the current flowing had dropped to the same order of magnitude as the 
background current a 1.00cm3 sample was taken and diluted to 10.0cm3 with "initial mobile 
phase", and the sample analyzed immediately using the gradient HPLC system.
Page 95
5.2.3.5 Sodium Borohydride reduced NAD
5.2.3.5.1 Method One
The first time the reduction was tried 150mg (0.21 millimole) of NAD+ (as free acid) was 
reacted with lOmg (0.26 millimole) of sodium borohydride. Assuming the production of 
approximately 3 moles of hydrogen from each mole of sodium borohydride, there was an 
almost four times molar excess present. The compounds were dissolved in 5.0ml of RO 
water and allowed to react at room temperature.
Both NAD and NADH absorb at 259nm. Another absorption maxima is seen at 340nm 
for NADH. The reaction was monitored by taking a 40microlitre sample and diluting to 
10ml with further RO water (1 in 250). The absorbance was then measured at 340nm. 
Based on total conversion to NADH and on the manufacturers quoted extinction coefficient 
= 6.2, a diluted sample should have had an absorbance of approximately 1 when the 
reaction is complete. When this reaction was performed, a sharp rise in absorbance 
occurred (absorbance at t=0 was 0.007) followed by gradual decline (Figure 5.8). This 
served to illustrate the care needed when preparing such samples. NADH is unstable in 
acidic solutions107 and as well as forming various breakdown products it is likely that 
dissolved oxygen may have re-oxidised any NADH formed. Additionally, an un-buffered 
solution of NAD+ is acidic and will tend to decompose the sodium borohydride as it is 
added. Visually, when the sodium borohydride was added gas was evolved and the solution 
became a pale yellow colour which then faded over the next 30 minutes. This colouration 
has been observed by other workers108
5.2.3.5.2 Method 2
The experiment was repeated in 5ml of 0.1M sodium pyrophosphate solution in RO water 
which had been adjusted to pH 9.0 using a combination of 5.55M and 1M solutions of 
Hydrochloric acid in RO water. The solution was purged for 10 minutes with oxygen free 
nitrogen prior to the addition of the NAD+. Before the addition of the sodium borohydride 
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Figure 5.8 The absorbance of the reaction mixture against time for sodium borohydride 
reduction of NAD in water (unbuffered)
minute and remained at this value (Figure 5.9). 3ml of HPLC grade acetone was then 
added to react with any excess sodium borohydride. Oxygen free nitrogen was used to 
displace any air from above the reaction mixture and the flask was sealed using a balloon 
arrangement to allow for the expansion of any gas produced. 12 hours later the solution 
was evaporated to dryness in a rotary evaporator. The residue was dissolved in a small 
volume of RO water, which had been purged with nitrogen, and filtered through a 0.2pm 
membrane filter into a 20ml class A volumetric flask. The filter was washed with several 
aliquots of RO water and the flask was finally made up to volume and stored in a 
refrigerator. This solution (produced from the equivalent of a lOmM solution of NAD+ once 
sampling and dilution had been taken into account) proved to be very useful for the 
development of HPLC methodology. For injection onto the column it was diluted 1 in 100 
with initial mobile phase. The sizes of individual peaks from this solution varied however 
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Figure 5.9 The absorbance of the reaction mixture against time for sodium borohydride 
reduction of NAD in water (buffered, pH 9.0)
borohydride reduction of NAD+ method 3 was used.
5.2.3.5.3 Method Three 
For this third borohydride reduction method 5cm3 of a 2mM stock solution of NAD+ in 
electrolysis buffer (see section 5.2.3.3) was diluted with a further 5cm3 of electrolysis buffer. 
Oxygen free nitrogen was passed through the solution for 15 minutes prior to the addition 
of a large excess of sodium borohydride (15mg). The solution was allowed to react (with 
stirring) until hydrogen evolution subsided. 1.00cm3 of this solution was then diluted to 
10.0cm3 with initial mobile phase and analyzed immediately using HPLC.
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5.2.4 HPLC M ethodology
5.2.4.1 Methodology Development
Three different HPLC mobile phase/gradient combinations were tried. The gradients were 
achieved using two LDC Constametric III dual piston metering HPLC pumps controlled 
by a LDC GM 4000 gradient programmer (high pressure mixing). The output from the two 
pumps was combined using a T-piece connector then passed through a 10cm x 5mm 
internal diameter column containing 1mm diameter glass beads to ensure adequate mixing. 
Subsequently, this column was replaced with an old analytical column (5pm particle size 
ODS, 5mm internal diameter, 150mm length) in order to achieve good mixing and to try 
and protect the analytical column from the relatively high pH. There was a minimum of 
fine bore tubing between the sample injection loop and the analytical column. 
Jaegfeldt103 used a mobile phase consisting of 30% water, 1-6% ethanol and 0.1M 
ammonium bicarbonate to 100%. Each run was "started isocratically at 1% ethanol and 
continued with a linear segment of increasing ethanol concentration up to about 4% 
ethanol". Following elution of the peaks the ethanol was further increased to 6% in order 
to wash the column. Timings were not given.
Umeda et a l109 used the starting composition from Jaegfeldts gradient system  
isocratically but with ethanol replaced by methanol (ie. 30% water, 1% methanol, 69% 
0.1M ammonium bicarbonate).
Miksic and Brown104 used a 60% solution of methanol in water varying from 2% to 30% 
with 0.02M potassium dihydrogen phosphate (pH 7.0) 98% to 70%. This gave a methanol 
concentration varying between 1.2% and 18%. A concave gradient program was used.
After many isocratic test runs the first gradient system (which used the same overall 
variation of alcohol concentration as Jaegfeldt103) was tried:-
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GRADIENT 1
Mobile Phase A 30% water 70% 0.1M ammonium bicarbonate
Mobile Phase B 30% water 60% 0.1M ammonium bicarbonate 10% methanol
Time (minutes) % mobile phase A % mobile phase B % methanol
0 90 10 1
2.5 90 10 1
7.5 60 40 4
15 60 40 4
20 40 60 6
25 40 60 6




Because of the large dead volume before the analytical column (due to the mixing column) 
there was a considerable delay (3 minutes with the glass bead [short] mixing column and 
5 minutes using the old ODS [long] mixing column) before the set gradient occurred at the 
column (see 5.2.4.2).
When chromatograms obtained using gradient 1 were examined, the last peak from any 
analysis occurred as the methanol concentration increased towards 6%. Additionally, due 
to the 5 minute delay time once the long mixing column was in use, the initial isocratic 
section with 10% mobile phase B was un-necessary. Gradient 2 was devised to take these 
points into account.
GRADIENT 2
Mobile Phase A 30% water 70% 0.1M ammonium bicarbonate
Mobile Phase B 30% water 60% 0.1M ammonium bicarbonate 10% methanol
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Time (minutes)% % mobile phase A % mobile phase B Methanol
0 90 10 1
25 40 60 6




A gradient system based on the one used by Miksic and Brown104 was also tried 
GRADIENT 3
Mobile phase A 0.02M potassium dihydrogen phosphate adjusted to pH 7.0 with 1M 
sodium hydroxide 
Mobile Phase B 60% methanol in water
Time (minutes) % mobile phase A % mobile phase B % methanol
0 100 0 0
30 70 30 18




The program "EXP 2" was selected on the gradient programmer in order to give a concave 
increase in methanol concentration. This gradient worked less well than gradient 2 and 
was unable to provide full baseline separation of NAD+ and NADH. In addition, compounds 
were eluting before the gradient had really started (once the mixing column delay had been 
accounted for). In hindsight this apparent poor performance may have been due to 
deterioration of the column. When gradient 2 was returned to the column performance 
deteriorated within the next 8 hours of use to the extent that it was relegated to the role 
of mixing column (see 5.2.4.3).
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5.2.4.2 Mobile phase mixing efficiency and pump performance 
Because of the use of high pressure mixing and because of the design of the HPLC pumps 
available for this work the pumps were likely to be inaccurate if asked to supply at very 
low flow rates, e.g. if pump A was set to provide 98% of the flow and pump B was set to 
provide only 2% of the flow it was likely that pump B would provide no output at all.
To assess the performance of the pumps and the mobile phase mixing two short 
experiments were performed.
1) To assess the actual percentage of mobile phase provided by the pumps compared to the 
percentage requested by the gradient programmer.
Mobile phase A was pure water 
Mobile phase B was 1% acetone in water
Absorbance was recorded at 300nm. With the analytical column in place (in order to 
maintain the back pressure) the gradient programmer was set to decrease from 100% 
mobile phase A down to 0% mobile phase A in 10% jumps every 3 minutes. The Actual 
percentage of mobile phase being provided by the pumps was then calculated. The flow rate 
was set at a total of 1.5cm3min'1 and the solution was collected for each 3 minute period. 
This volume was not found to vary significantly from the 4.5ml expected.
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Figure 5.10 HPLC pump / mixing performance test
2) Gradient 1 was used to assess the performance of the short glass bead mixing column 
and the longer ODS filled guard/mixing column. The same mobile phase combination as 
above was used but this time the analytical column was removed and the UV detector 
placed where the column would have been. From this it was possible to see the difference 
in the delay time produced by the two columns.
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Figure 5.11 Mixing column performance showing the measured percentage of mobile 
phase B against the percentage set by the gradient controller
The results from this are shown in Figure 5.11. These results demonstrate adequate 
mixing and pump performance.
5.2.4.3 Analytical column life
On two occasions during this work the first analytical column used (Chromotech) started 
to give two peaks for each expected peak. On examination, the centre of the top of the 
column showed some erosion. The problem was cured by filling this depression with a 
slurry consisting of Lichosorb ODS powder mixed with a small amount of HPLC grade 
acetone and allowing it to dry. Once sufficient material had been added the column end 
cap was refitted.
Eventually, the column failed to fully resolve NAD+ and NADH and was replaced with 
the longer LKB Ultrapack column. The old chromotech column was then used as a 
mixing/guard column. It was hoped that this would help to protect the new column from
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being damaged by the high pH. When this was done the back pressure increased from 
approximately 2000 p.s.i. to nearly 3000 p.s.i. As can be seen from Figure 5.11 pump 
performance and mobile phase mixing were not adversely affected by this pressure 
increase.
The new column gave longer retention times due to its increased length. However the 
peaks produced were much sharper. Time limitations prevented the re-running of all 
samples on this column although this would have been desirable. Column details and 
gradients used are included in the results section.
5.2.4.4 Standard HPLC Conditions 
The mixing/guard column was at room temperature.
The analytical column was held at 30°C by immersing it in a controlled temperature 
water bath.
The mobile phase flow rate was l.Scm^iin'1 
The Sample injection loop had a volume of 50pL.
Absorbance was recorded at both 260 and 340nm.
5.2.5 R esults and discussion
5.2.5.1 Assay Calibration 
The results below are from the LKB Ultrapak column using gradient 2 and the long 
mixing column. The peak areas are those measured at 260nm.
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Integrator peak area (260nm)










calculated intercept -29820 24628
standard deviation 17199 7124
calculated slope 60793000 4611700
standard deviation 305930 12670
Page 107
These results (Figure 5.12) establish the assays of NAD+ and NADH. It should be noted 
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Figure 5.12 HPLC calibration curves for NAD7NADH at 260nm
5.2.5.2 NAD+ starting solution 
A typical HPLC trace of the NAD+ starting solution (nominally O.lmM) at 260nm is 
shown below. The one shown is using gradient 2 with the LKB ultrapack column. 
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Figure 5.13 NAD+ starting solution (260nm)
5.2.5.3 NAD+ and NADH High and Low Calibration Solutions 
Typical HPLC traces of the NAD7NADH High and low calibration solutions at 260nm 
are shown below. The high standard solution contained O.lmM.dm'3 of each compound and 
the low standard contained 0.02mM.dm‘3 Those shown are from using gradient 2 with the 
LKB ultrapack column (Figure 5.14 and Figure 5.15). These calibration samples also 
provided good markers for the positions of peaks in the reduction samples (timings of peaks 
are more prone to small variations with a gradient system). Two additional significant 
peaks (at around 3 minutes and 4 minutes on this system) as well as numerable tiny peaks 
can be seen prior to the NAD+ peak at around 11 minutes. These impurities were present 
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Figure 5.15 NAD+ and NADH Low Calibration Solution (260nm)
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5.2.5.4 Sodium Borohydride reduced NAD+
The results for the sodium borohydride reduction of NAD+ appeared to be pH dependent. 
Figure 5.16 and Figure 5.17 show chromatograms (using gradient 2 with the Chromotech 
column) from the sodium borohydride reduction of NAD+ using method 2 outlined 
previously (pH 9.0). Figure 5.16 shows the typical 3 peaks when the chromatogram is 
recorded at 340nm (as reported by Jaegfeld103 and Umeda et a l109) corresponding to the 
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Figure 5.16 Sodium borohydride reduced NAD+ (reduction method 2, 340nm)
The position of the 1,4 NADH was confirmed from the calibration chromatograms run 
under the same conditions (not shown). The chromatogram at 260nm (Figure 5.17) shows 
two additional peaks at t*=1.7 minutes and at t r=9.9 minutes. From calibration runs on the 
same system it was seen that the peak at tr=1.7 minutes was in the same position as the
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contaminant seen in the commercial samples of NADH mentioned earlier. The identity of 
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Figure 5.17 Sodium borohydride reduced NAD+ (method 2, 260nm)
No peaks (apart from the solvent front) were seen when reduction method 2 was 
performed in exactly the same way but omitting the NAD+.
When method 3 was used in which the reaction mixture was buffered to pH 7.0 
(chromatograms using gradient 2 with the LKB Ultrapak column) the trace at 260nm 
showed only three major peaks (Figure 5.18) together with the same small early peak (t,=4 
minutes). It is worth at this point referring back to the calibration chromatograms 
(Figure 5.14 and Figure 5.15) which were run during the same session as this one. These 
showed tr(NAD+)=11.3 minutes and tr(NADP)=14.2 minutes. The first major peak in 
Figure 5.18 is at 11.5 minutes and was also present on the 340nm trace. This demonstrates 
that the peak does not represent un-reacted NAD+ but is probably 1,6 NADH. The second 
major peak is at 14.2 minutes confirming its identity as 1,4 NADH. The third major peak
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occurred at 20.5 minutes and was not present on the 340nm trace. This peak was not 
identified, but it was not 1,2 NADH which has some absorbance at the higher wavelength. 
No detectable 1,2 NADH was produced at pH 7.0.
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Figure 5.18 Sodium borohydride reduced NAD+ (method 3, 260nm)
approximately 33% both at pH 9.0 and at pH 7.0 (calculated using integrator peak areas). 
Please note: The retention times given above are those calculated by the integrator.
5.2.5.5 -1.1V Reduction of NAD+
The electrolysis buffer background current before the addition of NAD+ was 0.004mA. On 
addition of the NAD+ the current rose to 2.25mA then proceeded to decline slowly. Samples 
were taken for HPLC analysis at 165 minutes (current = 0.04mA) and at 255 minutes 
(current = 0.022mA). It was not possible to perform a coulometric analysis for this
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experiment because the potentiostat being used required its current meter to be re-zeroed 
each time the current display range was changed. Re-zeroing could not be performed 
without disconnecting the cell.
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Figure 5.19 NAD+ Reduced at -1.1V 165 minute sample
Please note the difference in both the absorbance scale and the time scale between these 
two chromatograms. Figure 5.20 has had its peaks numbered. Additionally, in order to see 
if any more peaks were going to come off the column the gradient programmer was set to 
give 100% mobile phase B at t=40 minutes. As the last peak seen was at t r=31.1 minutes 
it was demonstrated that this need not have been done.
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Figure 5.20 NAD+ Reduced at - l.lv  255 min sample
Summary of peak positions from the Sodium borohydride reduction of NAD* and 
from the NAD71,4-NADH calibration solutions
Retention time (t,.) in minutes Peak Identity
4.1
impurity found in commercial NADH and 
generated during sodium borohydride reduction of 











Peak Identity (where known) 
and comments
1 4.1 see above table
2 6.4
3 8.5








Although many small ripples in the baseline can be seen between these main peaks, one 
of the most important features of this data is the complete lack of any peaks corresponding 
to 1,6-NADH or 1,4-NADH (and probably 1,2-NADH). The large number of other peaks 
supports the work of Jaegfeldt103 who suggested the reaction produced numerous dimers 
and who attempted semi-preparative HPLC in order to try and identify these peaks.
5.2.5.6 -1.8V reduction of NAD+
The electrolysis buffer background current before the addition of NAD+ was considerably 
higher than the -1.1V reduction, as might be expected, at 0.84mA. On addition of the NAD+ 
the current rose to 23mA then proceeded to decline at a somewhat faster rate than 
previously. The reaction was stopped when the current had reduced back to the
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background level (140 minutes). The chromatogram at 260nm shown below (Figure 5.21) 
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Figure 5.21 -1.8V Reduction of NAD+ (Gradient 1)
From the chromatograms of the sodium borohydride reduction of NAD+ and the 
NAD7NADH calibration solutions using gradient 1, the peak a t t r=6.8 minutes 
corresponds with 1,6-NADH and the peak a t 7=8.2 minutes corresponds with 1,4-NADH. 
A small amount of un-reduced NAD+ can be detected at t r=7.3. A range of other peaks can 
be seen on the chromatogram which were not identified. Ideally, the -1.8V reduction should 
have been re-performed and analysed using gradient 2 and the LKB Ultrapak column to 
allow direct comparison with the -1.1V reduction.
5.2.6 Conclusions
The reduction of NAD* at a mercury electrode produces a complex mixture of reaction 
products. The chromatographic method described, particularly using gradient 2 with the
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LKB Ultrapak column, provides a useful system for the investigation of the influence that 




Various organometallic complexes of rhodium have been used to try and mediate the 
electrochemical reduction of NAD(P)+ to NAD(P)H. The work in this area has been driven 
by the need to be able to regenerate this cofactor in biochemical reactors, and their use as 
potential mediators in biosensors has not really been considered in the literature.
The first evidence that certain polypyridine rhodium complexes might be able to mediate 
cofactor reduction came from Wienkamp and Steckhan110 who formed complexes of 
rhodium with 2,2/-bipyridine (bpy). The structure of bpy is given below (Figure 6.1).
Figure 6.1 The structure of 2,2/-bipyridine
They showed that rhodium(III)-tris(2,2/-bipyridine)3+ ([Rh(bpy)3]3+) was able to generate 
rhodium(I)-bis(2,2/-bipyridine)1+ ([Rh(bpy)2l1+) at a cathode poised at approximately -0.9V 
vs Ag/AgCl electrode. This secondary complex is able to transfer two electrons (together 
with a hydrogen ion supplied from the solution) to NAD+, generating NADH. Their 
proposed reaction scheme is shown in Figure 6.2.
They were able to regenerate NAD+ using horse liver alcohol dehydrogenase (HLADH) 
to catalyse the reduction of cyclohexanone showing that, in the main, the NADH produced 
was active (i.e. 1,4-NADH). They were able to measure the total quantity of cofactor dimer 
formed and calculated that 0.9% of the NAD+ ended up as dimer per cycle.
Rhodium has an atomic number of 45 and in its ground state it has 7 electrons in its d 
orbital. In its 3+ state it has a d6 configuration and will accept electron pairs from up to 
6 nitrogen atoms. Thus, rhodium is able to form an organometallic complex with three bpy
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[ R h ( b p y )3 ] 3  +
NADH
HLADH
C at h o d e
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Figure 6.2 Regeneration of NADH from NAD+ by electrochemically generated [Rh(bpy)2]+ 
as an electron transfer agent (from ref 110)
molecules.
When the rhodium atom is reduced to its 1+ oxidation state, one nitrogen must dissociate 
from the complex.
In the reaction scheme given above, the reduction leads to the dissociation of a complete 
bpy ligand and therefore the dissociation of two nitrogens. This set of events leads to some 
of the problems associated with rhodium(III)-tris(2,2/-bipyridine)3+ as an NAD+ reduction 
mediator. Other potential ligands in the solution will coordinate with the rhodium. It was 
reported in the paper by Wienkamp and Steckhan110 that eventually the current at the 
electrode reduces due to fouling of the graphite cathode used by [Rh(bpy)2(H20)2]Cl or 
[Rh(bpy)2(OH)2]Cl.
Umeda et al 111 attempted to improve the stability of this type of compound by using 
two terpyridine ligands (Figure 6.3) instead of three bipyridine ligands.
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S ’
Figure 6.3 The structure of 2,2/;6/,2//-terpyridine (terp)
This is a logical move because if the rhodium is reduced to Rh(I) and a nitrogen has to 
dissociate from the complex, because the ligand is attached by the coordination of two other 
nitrogens, the ligand as a whole may remain in place. If subsequently the rhodium is re­
oxidised to Rh(III) the dissociated nitrogen will be in the correct position to re-associate 
with the atom in preference to other potential ligands in the solution.
They examined this compound for its ability to catalyse the photochemical reduction of 
NAD+ and found it to be a good cata lyst for the production of 1,4-NADH. Its 
electrochemical behaviour was not examined.
Ruppert et al112 described a system where formate was used to supply the 2 electrons 
and a proton required to reduce NAD(P)+. This reaction was coupled using pentamethyl- 
cyclopentadienyl rhodium complexes formed with three different bpy based ligands (bpy 
itself or a dimethyl-bpy compound, either 4,4/-Me2bpy or 6,6/-Me2bpy). In this system it was 
postulated that reduction of the rhodium from III to I did not occur, but that the compound 
formed a hydride intermediate (Figure 6.4).
They suggested that the rhodium compound initially formed a complex with the formate 
anion which was then followed by the extrusion of C02. This interaction with formate 
would appear to be crucial for this compounds activity and use as an electrochemical 
mediator would seem unlikely (or would have to occur by completely different 
mechanisms).
From the reduction experiments of NAD* at mercury electrodes it has been demonstrated 
that at -1.1V vs S.C.E. the majority of the cofactor is converted into a range of dimers. At 
the more negative electrode potential of -1.8V, hydrogenation does occur but different
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NAD( P) HRh, u (C5Mes ) (bp y)
H - R h , u (C5Me5) (bp y)
NAD( P)
Figure 6.4 Reduction of NAD(P)+ with formate catalysed by the rhodium complexes 
described in the text (from reference 112)
positional isomers are produced (a mixture of 1,2 1,4 and 1,6 NADH) as well as the dimers 
seen at the less cathodic potential. At -1.8V, a mercury electrode will start to electrolyse 
the water in which the experiment is taking place and hydrogen gas is evolved from the 
electrode surface. It would therefore seem likely that both a hydrogen radical and a NAD 
radical are being produced at the electrode surface and the range of products produced is 
based on the probabilities of collision:-
Hydrogen radical + Hydrogen radical -» Hydrogen (gas)
Hydrogen radical + NAD radical NADH (1,2 1,4 or 1,6)
NAD radical + NAD radical —> Dimers
One of aspects of the mechanism by which rhodium compounds may help as mediators 
may be by lowering the potential required for the production of hydrogen radicals.
Cosnier et al 113 have used a pyrrole derivative of bpy as a ligand to form a complex 
with rhodium and pentamethylcyclopentadiene. The pyrrole was then electro-polymerised 
at an anodic potential on to either glassy carbon, carbon-felt or platinum. They were able
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to generate hydrogen gas at -0.55V us Ag/AgCl (pH 1.0) using coated carbon felt electrodes 
(a process which does not occur at un-modified electrodes).
It is important from the point of view of biosensor development that yields of active 1,4- 
NADH are as high as possible. With this aim in mind it is important that these compounds 
are examined using an experimental design which can detect all the products of the 
reduction. Some of the papers in the literature assess the success of the compound by 
examining the absorbance increase at 340nm. This does not give the complete picture 
because the inactive compounds 1,2-NADH and 1,6-NADH have some absorbance at 
340nm. It would be beneficial, when the percentage of active 1,4-NADH decreases with 
each cycle, to examine the inactive products of the reaction using techniques such as the 
HPLC system described in chapter 5.
With this aim in mind it was decided to synthesize some potential mediators and examine 
their behaviour at a mercury electrode.
6.2 Synthesis of Rhodium complexes
The two basic methods are available in order to form two different series of rhodium 
complexes. These are outlined below.
6.2.1 R eactions o f pentam ethylcyclopentadienylrhodium  chloride dim er
Pentamethylcyclopentadienylrhodium chloride dimer (Figure 6.5) will react with various 
nitrogen containing ligands, to form complexes of the form:-
[CpentRhIII(L1)(L2)]n+
where Cpent is cyclopentadiene, Lx is a ligand containing two nitrogens which have lone 
pairs capable of coordination with the rhodium, Lg is H20 , Cl', OH'. The overall charge is 















Figure 6.5 The structure of pentamethylcyclopentadienylrhodium chloride dimer
An attempt was made to form a range of compounds based upon the reaction methodology 
outlined by Kolle and Grutzel114, although the experimental details in this paper were 
not comprehensive. The method used was also influenced by the work of Cosnier el aln3, 
who reacted the dimer with a slight excess of [bis(pyrrol-l-ylmethyl)methoxycarbonyl-2-2/- 
bipyridine in ethanol.
6.2.1.1 Chemicals
2,2/-dipyridyl (Bipyridine), 1,10-phenanthroline, biquinoline, 4,4/ dimethyl-2,2/-dipyridyl 
and Pentamethylcyclopentadienylrhodium chloride dimer were obtained fron the Aldrich 
Chemical Company Ltd.
All solvents were of HPLC grade as listed earlier. RO water was used throughout
6.2.1.2 Method
For this work, 0.3mmol (185mg) of the dimer was reacted with 0.72mmol of the 
appropriate ligand in 10ml of methanol. Using this solvent, the dimer is practically 
insoluble (although it colours the solution deep red) but it dissolves as it reacts to form the 
more soluble product.
The ligands used were:-





Completion of the reaction was indicated by all the dimer dissolving and by a colour 
change (all solutions became orange). The solution was then evaporated to dryness in a 
rotary evaporator (at room temperature) and redissolved in a minimum amount of warm 
(35°C) 50% aqueous ethanol, followed by cooling to around 20°C.
In hindsight, it was a mistake to use such a large excess of ligand because whilst trying 
to crystallise the products (all water soluble) the excess ligand (low water solubility) came 
out of solution first. 0.3mmol of dimer should probably have been reacted with 0.6mmol of 
ligand.
Attempts were made to recover the situation by evaporating the solutions to dryness 
again followed by dissolving them in 2ml of methanol. Ether was then added until the 
product just began to precipitate (ligands ether soluble). Gentle warming was then used 
to re-dissolve, followed by leaving the solution for crystals to form.
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6.2.1.3 Results
Elemental analysis of the crystals collected were performed in the School Of Chemistry.

















As can be seen from this data, the elemental analysis of these compounds gave values 
which were a considerable way out from expected values. It would not even be possible to 
tell the compounds apart from this data.
The reasons for this presumably lie in the crystallisation technique which was probably 
inappropriate. The expected values in the above table are calculated on the basis of L2  
being H20. Although the compounds had all been exposed to water during the first attempt 
at crystallisation, the solvent system used for the second attempt was non-aqueous. In this 
solvent system, it may be possible that the lone pair of electrons on the oxygen of diethyl 
ether may be able to interact with the rhodium.
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It is believed that if these compounds were re-made with a lower excess of ligand, 
followed by crystallisation from an aqueous or part aqueous solvent system, the elemental 
analyses would have been better. Other methods of structure elucidation, such as XH-NMR 
or f.a.b. mass spectroscopy, were not considered appropriate until this had been done.
6.2.2 Reaction of rhodium chloride with the ligands bpy and terp
It was intended to attempt the synthesis of the following three compounds, according to 
published methods. This work was unfortunately not completed.
1) K h ^ p y ^ C l ,
2) Rhra(terp)2Cl3
3) Rhm(terp)(bpy)Cl3
The papers containing the intended methods are given for reference.
6.2.2.1 Method - Synthesis of Rhra(bpy)3Cl3 and Rhni(terp)2Cl3
In the past, rhodium chloride has been fused with these ligands (Harris and 
McKenzie115 and Martin and Waind116) in order to form appropriate complexes. More 
recently, a simpler method has been developed by Kirch et al 117 which involves heating 
rhodium chloride with the appropriate ligand in 50% aqueous ethanol in the presence of 
N-ethyl morpholine. The disappearance of the ligand during these reactions can be 
monitored (to determine an end point) by examining the UV spectra of a diluted sample 
of reaction mixture.
6.2.2.2 Method - Synthesis of Rhm(terp)(bpy)Cl3
The synthesis of this compound relies first upon the synthesis of Khra(terp)Cl3 according 
to the method developed by Bhayat and McWhinnie 118. This involves the refluxing of
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rhodium chloride and the ligand (at equimolar ratios) in a 20% water 80% ethanol solvent 
system.
Once this compound has been collected by crystallisation it can be reacted with the 
bipyridine ligand (reflux for 6 hours in 25% dimethylformamide 75% ethanol) as outlined 
by Frink et al 119
Page 128
7 FINAL DISCUSSION
7.1 Creating A Biosensor
This thesis has illustrated that considerable progress will be necessary in the future to 
enable biosensors based on microbial ketone reductases to work effectively. However, many 
of these advances may not be too far away. Some of the current problems which need to 
be overcome are discussed here by describing the components which will be required to 
create such a biosensor.
Firstly, a suitable electrode surface is required. Although it is difficult to chemically 
attach enzymes and mediators to thin film metal electrodes, the manufacturing advantages 
to be gained by integration of the sensor with the necessary electronics are worth pursuing.
As with biosensors based on oxidative reactions, it should be possible to use compounds 
which will undergo electropolymerisation to entrap the enzyme. The polymer chosen should 
be able to conduct at cathodic potentials.
Electrode platinisation35 provides another technique by which enzyme entrapment can 
be achieved and by which the effective electrode surface area can be dramatically 
increased, leading to enhanced current densities. This method should be compatible with 
thin film electrodes, but the low pH of the chloroplatinic acid used in platinisation may 
reduce or destroy enzyme activity.
Metal electrodes may have a considerable disadvantage though. The potential at which 
the electrolysis of water can occur is less negative at these electrodes than is necessary at 
some of the other electrode materials14.
Secondly, a keto reductase with suitable specificity for the analyte needs to be found and 
isolated. As has been seen, microorganisms can be screened for an ability to carry out the 
reduction of ketone containing compounds. If one is found, it ought to be possible to grow 
the microorganism in large enough quantities using a fermenter to allow enzyme
extraction. The extension to this is the possible determination of the structure of the 
enzyme and perhaps expressing the gene for the protein in a bacteria such as E. coli to 
allow large amounts to be produced. Although biosensors can be created using immobilised 
intact bacteria, these have poorer response times and biocompatibility problems. Sensors 
based on pure immobilised enzyme will prove to be much more effective devices.
The third requirem ent for such a sensor is  the developm ent of a reaction  
modifier/mediator which is able to be oxidised by the enzyme’s reduced cofactor 
(regenerating active cofactor), and is then able to be reduced at the electrode surface 
(regenerating itself).
7.2 Future Work
This thesis has outlined many of the developments in biosensor technology which will be 
required in order to create a warfarin sensor. In addition, some of the research 
methodologies which will be necessary in the quest for some of these advances have been 
developed. This section describes some of the work which was planned but not done due 
to lack of time, and some of the potential experiments which would have followed on from 
this.
7.2.1 Warfarin
An effective HPLC assay for warfarin and its metabolites in bacterial samples is essential 
to the continued work towards the extraction of any warfarin reductase. The HPLC of 
warfarin using the pH 2.8 mobile phase outlined in section 4.4.3.1 gave particularly good 
separation of the warfarin alcohols. However, this assay is likely to become more difficult 
to perform (due to interfering compounds) once the bacterial sample has been treated in 
order to attempt enzyme extraction.
In order to improve the assay, the normal phase preparative HPLC method given in this 
thesis should be used to provide individual samples of each of the four warfarin alcohols
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for use as standards. In addition to this, an internal standard should be found which elutes 
in between the warfarin alcohol peaks and the warfarin peak.
7.2.2 The Warfarin Reductase
It has been shown in this thesis that ATCC 19140 and ATCC 19070 are able to reduce 
the ketone group found in the warfarin molecule. The purification and extraction of the 
enzyme responsible would be the next goal.
From the high cell mass obtained using a fermenter, various cell disruption techniques 
would be tried in an attempt to liberate the enzyme120,121 whilst attempting to retain 
as much of the enzyme activity as possible. These might include the use of a French press 
or other homogeniser to break down the bacterial cell wall. Another approach might be to 
use enzymatic breakdown of the cell wall using lysozyme. The reductase activity remaining 
after each process attempted would need to be measured (probably with a standard blend 
of different cofactors added to the mixture) together with some estimate of the degree of 
cell disruption. Centrifugation of the homogenate followed by the measurement of enzyme 
activity in each of the fractions would then need to be performed. The methodology 
required from this point on would depend upon the location any enzyme activity.
If the enzyme were to be successfully isolated a whole set of experiments would need to 
be performed including the determination of the optimum pH and temperature for enzyme 
activity. The effect of the presence or absence of a range of cofactors would need to be 
studied in order to determine which cofactor is required by the enzyme. The specificity of 
the enzyme for warfarin would have to be tested.
7.2.3 NAD(P)H
This thesis has outlined a suitable method for the electrochemical reduction of NAD(P) 
and for the HPLC determination of the product profile from such an experiment.
If any potential reaction modifiers/mediators were to be tested, the HPLC methodology 
may need to be adjusted to take in to account the chromtographical behaviour of that
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mediator. As mentioned previously, the measurement of the amount of active NAD(P)H 
generated cannot be achieved by using simple absorbance measurements.
7.2.4 Rhodium based mediators
As has been seen, various rhodium complexes have been shown in the literature to be able 
to modify the products of electrochemical nicotinamide cofactor reduction. These compounds 
are not perfect however, and their mechanisms of action are unclear.
The synthesis and electrochemical testing of a wide range of rhodium compounds with 
nitrogen heterocycle ligands needs to be carried out. The methodology for such syntheses 
are becoming more widely published. Anyone attempting this type of reaction for the first 
time will come to appreciate that the high cost of rhodium compounds will mean that they 
will be trying to attempt recrystallisations from very small fluid volumes. Any methodology 
needs to take this into account. One suggestion is to form crystals in a small vessel which 
has a 0.2pm membrane filter incorporated in to its base. Such a filter will not allow liquid 
through it without the use of pressure, and once crystals have formed, the filtrate can be 
removed by applying a vacuum to the bottom of the filter.
Some encouraging articles on the use of rhodium compounds have appeared in the recent 
literature.
Substituted 2,2/-Bipyridyl complexes of pentamethylcyclopentadienyl rhodium chloride 
have been further studied by Steckhan et al122. This group have started to examine the 
influence that substituent groups (on the bipyridyl moiety) have on their ability to reduce 
nicotinamide cofactors.
Work on Rhodium compounds containing a pyrrole derivative of bipyridyl (which is 
subsequently polymerised at the electrode surface) has continued123 leading to the 
production of an electrode for the reduction of pyruvate. They were unable to detect any 
dimer formation during bulk electrolysis of pyruvate using this electrode.
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Umeda et a l12i have started to elucidate how NAD+ and Rh(terp)2+3 interact at a 
molecular level. The results of this work may lead to an improved series of compounds.
Ryabov et a l125 in a preliminary report, have succeeded in complexing NAD+ directly 
with pentamethylcyclopentadienyl rhodium chloride.
One of the problems to be overcome with the use of reaction modifiers/mediators in 
biosensors is whether one can be found which works at a sufficiently small negative 
potential (this problem does not affect these compounds ability to work in biochemical 
reactors to the same extent). If these compounds require a large negative potential, many 
other compounds will be able to be reduced at the electrode surface, producing a large 
background current. As mentioned earlier, this may include electrolysis of water and the 
reduction of dissolved oxygen. Although it may be possible to correct for some of the 
interfering compounds by subtracting the current from a second electrode which does not 
have the enzyme present, mediators with less negative E0 values are desirable.
E0 and ks values would need to be determined for all potential mediators in order that 
structure modifications can be fully assessed (analogous to the development work for the 
ferrocenes used in glucose sensors).
The synthesis of novel ligands which have side groups attached (perhaps with suitable 
spacing molecules - see FAPP and FAPAPP in figure 1.9) to allow chemical attachment to 
the electrode, to the enzyme or to the cofactor could be attempted.
Beley and Collin126 have already generated a pyrrole derivative of terpyridine and used 
this to form complexes with rhodium chloride. Electrodes modified with these complexes 
were able to produce 96% active NADH from NAD+ at -750mV.
Any successful compounds would need to be tested for toxicity if their use in any 
implantable sensors were to be considered.
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7.2.5 Other Mediators
Bergel and Comtat127 have managed to use the flavin cofactors FADH2 and FMNH2 to 
reduce NAD(P)+. This reaction is thermodynamically unfavourable but was achieved at a 
potential of -650mV by using a large electrode surface area together with a very small 
solution volume (conditions which can be achieved using capillary fill devices). An 
assessment of any other reduction products (e.g. using HPLC) was not made.
Davies et a l128 have looked at the possibility of generating synthetic compounds which 
will mimic the cofactor activities of NAD/NADH whilst removing the problems associated 
with the reduction of NAD. If such compounds can be realised, they might work as both 
cofactor and mediator.
7.3 The Future for Amperometric Biosensors
The amperometric glucose sensor was the first biosensor to make the headlines. The 
revolution in analyte measurement that appeared to be heralded by these sensors has not 
really happened. The reason for this is probably that in many ways the glucose sensor has 
proved to be the simplest sensor (technically) to create for a clinically useful analyte. Few 
molecules which you would wish to measure the levels of have enzymes which act upon 
them with such high specificity. Even fewer have enzymes which are readily available from 
biochemical suppliers.
The world of biosensor research also seems to have occupied its thoughts with cheapness 
of sensors and with mass production. This is perhaps because of comparisons with the 
needs of the glucose sensor marketplace. There are a variety of medical situations where 
biosensors would be useful and would be cost effective, even if the actual sensor cost were 
to be in pounds rather than in pence. These might include such measurements as drug 
levels by ambulance crews when presented with an overdose case, or the sensing of 
biochemical changes produced by the body in acute illness such as stroke or myocardial 
infarction, allowing the administration of disease modifying drugs appropriately and
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quickly. It might be possible to measure the level of drug molecules in intensive care 
situations with direct feedback to drug administration pumps. They could allow rapid 
monitoring of levels of drugs with narrow therapeutic indices, reducing possible toxicity.
One question which needs to be asked of the medical professions is; if you could measure 
the level of any compound what would you actually want to measure. There are a range 
of compounds which they would like to measure but are currently unable to measure at all 
or are unable to measure on a sufficiently short time scale for the measurement to be of 
any use.
Very few real breakthroughs in biosensor design appear to have been published recently. 
The reasons for this lack of progress have been addressed in a review article by Griffiths 
and Hall129. Organometallic rhodium compounds may provide a path towards the reliable 
electrochemical regeneration of reduced nicotinamide cofactors. This in turn may open up 
the world of amperometric biosensors to a much extended range of enzymes.
Most of the researchers in the field of rhodium chemistry are looking at these compounds 
with a view towards use in biochemical reactors. Only one of the papers on rhodium cited 
in this thesis makes any mention of a possible role in biosensor devices.
The search for compounds which will mediate the effective electrochemical regeneration 
of nicotinamide cofactors is worthy of considerable research effort.
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APPENDIX ONE




































200 REM MAIN MENU
210 REPEAT
220 CLS:
INPUT*(F)lxed voltage, (L)lnear sweep, (C)yclic sweep or (E)dlt* ;FS$ 











340 TYPE$= “CYCLIC SWEEP VOLTAMMETRY*
350 PROCsweep 
360 WHEN *E*,*e*







440 R E M ----------------------------------------------------------------------------








PRINT*PRESS ANY KEY TO START*:
IFGET
520 interval=(TS*60/199) *100:









INPUT * Do you want to reset variables Y or N*;YN$
590 UNTIL YN$=*Y* OR YN$ = *N*








INPUT*Save (D)ata, (S)can or (E)xit*;CS$
640 UNTIL CS$=*D* OR CS$=*S* OR CS$=*E*
650 IF CS$=*D* THEN 
660 GOTO 770





INPUT"Are you aura Y or N " ;YN$
710 UNTIL YN$ = "Y" OR YN$="N"
720 IP YN$="N" THEN 620 ELSE 790 
730 FOR A%=1 TO 10 




77 0 PROCaave 











890 *FX 200,1 
900 CLS:















IP hA<1 THEN 1030 




PRINT*Preso any key to START":
IPGET









1100 INPUT"Reset (A)ll variables. Sweep (R)ata, (S)cale or re-use (O)ld values";RS$ 
1110 CASE RS$ OP 
1120 WHEN "A","a"
1130 PROCsure




INPUT "NEW SWEEP RATE (mV per second) * ; MV%:
PRINT 
1180 UNTIL MVSaoO















1320 UNTIL U < > 0  




1350 INPUT'Save (D)ata, (R)eturn or (E)zit";CS$





1410 IP Y N $ o " Y "  THEN CS$=""
1420 ENDCASE
1430 UNTIL CS$="R" OR CS$="E"




1480 DEF PROCholdinput 
1490 REPEAT 
1500 CLS
1510 INPUT• HOLD VOLTAGE" ;HV:
PRINT
1520 UNTIL HV> = -1 AND HV< = 1 
1530 REPEAT
1540 INPUT "TIMESCALE OP HOLD PERIOD in minutes" ;TS:
PRINT





1590 DBF PROCzero 
1600 **=820205 
1610 CLS
1620 PRINT* Set the 626 off-hold-sweep switch to OFF - adjust Icomp until the reading* 
1630 PRINT* Is as close to zero as possible (with the potentiometer locked)*










1740 R E M -------------------------------------------------------------------------------
1750 DBF PROCscale 
1760 REPEAT 
1770 CLS:
INPUT 'CURRENT SCALE - (M) lcroamps or (N) anoamps* ; SC$
1780 UNTIL SC$=*M* OR SC$=*N*
1790 PRINT






1860 PRINT TAB(16);SCI?;• per mm*;:
INPUT SM 
1870 UNTIL S M o O  
1880 NApmm= SM:
IF SC$=“M* THEN NApmm=SM*1000 
1890 step=250*NApmm
1900 IF 4*step<1000 THEN SC2$=* nanoamps*
1910 IF 4*step>=1000 THEN SC2$=*microamps*: 
step=atep/10 0 0 




1950 REM --------------------------------------------------------------------- ---------












2020 FOR A=200 TO 1195 STEP DS 
2030 MOVEA,2 95:
DRAMA,305 
2040 N( 1, B + 2 ) =A 


















T ( 2 , B ) = 2 2 0  
2150 TT=B 
2160 9*=8020103












PRINT'Press 'BSC' to halt*
2260 LOCAL ERROR
2270 ON ERROR LOCAL PROCerrorlocal 
2280 REPEAT
2290 IF SET <> -1 THEN 2430










2390 IF B*<10001 THEN 2410
Page 149
2400 *FX 125 
2410 REPEAT
2420 UNTIL TIME>FINISHTIME 
2430 UNTIL SET <> -1 
244 0 B%=B%-1 






250 0 DBF PROCacan 
2510 OCOLOi
IF B%>19 9 THEN C%=B%-199 
2520 FOR D%=C% TO B%






2570 IF D%=C%THEN GOTO 2600 ELSE GOTO 2590
2580 IF D%=C* THEN MOVED ( 0, D%) -D (0, C%) +200, D (1, D*) :
GOTO2600
2590 DRAWD(0,V%)-D ( 0, C%)+200,D (1, V%)











267 0 REPEAT 
2680 CLS:
PRINT'Uae numeric pad keya to acan - Praaa 'S' to take SNAPSHOT* 
2690 PRINT* Preaa 'E' to exit and save data*
2700 IK$=GET$:
IK=ASC(IK$)






















2800 UNTIL Repeat%=FALSE 








2870 DEF PROCredraw 
2880 El%=El*+ofaet%:
IF EISk O THEN E1%=0 
2890 IF E1%>F% THEN E1%=F%
2900 F1%=E1%+199:
IF F1%>F* THEN F1%=F%
2910 IF F1%<0 THEN F1%=0
2920 PROCholdax1a
293 0 FOR D*=E1% TO Fl%






IF SF%(A%,l)-0 THEN A*=10:
GOTO 3020 
2980 FOR D%=SF*(A%, 0) TO SF%(AV 1)
2990 IF D%=SF9s(A%, 0) THEN MOVE2 0 0,D(1,D%):
GOTO3010






3050 R E M ----------------------------------------------------------------------
306 0 DEF PROCaweepinput
307 0 REPEAT 
3080 CLS 
3090 IV=0:
INPUT * INITIAL VOLTAGE* j IV:
PRINT 
3100 FV=0:
INPUT ‘FINAL VOLTAGE* ;7V:
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PRINT
3110 UNTIL ABS (IV) <=1 AND ABS(FV)<=1 
3120 REPEAT
3130 INPUT "SWEEP RATE (mV per second)■;MV*:
PRINT 
3140 UNTIL MV%<>0
3150 C L $ (2)="SWEEP RATE(S)t "+STR$(MV%)
3160 ENDPROC 
3170 I
3180 R E M -------------------------------- --- ----------------- -------------------------








3240 IF nd >10 THEN nr=dr*2 




3290 IF ioa>.001 THEN ivl=ivl-(ios*dr*ne)
3300 IF A B S (Cos)>.001 THEN fvl=fvl+(dr*ne)- (fos*dr*ne)










N ( 3 , 1 ) = 1 2 0 0 :
N(4,1)=300 
3380 B=0








PRINT A / 10 










PRINTT$ (B) i 
T(1,B)=620:
T ( 2 , B ) = 2 2 0  
3490 MOVE200,220:
PRINT" INIT. VOLT. = *; STR$ (IV) ; • volts"
3500 MOVE900,220:
PRINT "FINAL VOLT. = " ; STR$ (FV) ; ■ volts"
3510 C L $ (0)=TYPE$







3580 R E M -------------------------------------------------------------------------------





3630 M19b(3, 1) =200 
3640 M l % (4,1)=1000 




3680 M l % (1,A%+2)=195 
3690 M1%(2,A%+2)=B%
3700 M l % (3,A9&+2) =205 








3780 FOR A%=-5 TO 5 
3790 B%=A**70+650 







T 1 (2,A%+6)=B% - (texthe ight/2)
384 0 NEXT A%
3850 MOVE 5,662:
PRINT SC2$














PRINT*Preaa 'ESC' to halt- 
3930 OCOLO:
Sl*=10:
VAR*=ABS ( 55642/ (MV*/ABS (FV-IV)) -42)





3970 ON ERROR LOCAL PROCorrorlocal 
3980 TIKE=0 
3990 REPEAT
4000 IF SET <> -1 THEN 4150 
4010 CALL code*
4020 X*=I store*:
Y*=at ore*14 i 
S*=atore*18 
4030 X = ((X*/VAR*)-2048)/2048:
Y=Y*/(4096»VAR*)
4040 D(0,B*)=200+(((10*X-lvl)*1000)/(fvl-lvl))
4050 D (1,B*)=(Y*700)+3 0 0 
4060 IF TIME<10 THEN4100 
4070 IF S*=6 THEN 4140









4130 IF B*<30000 THEN 4150
4140 *FX 125





4200 R E M ---------------------------------------------------------- ---------------------
4210 DEF PROCredraw2 
4220 E*=B*(a*-l)+1 
4230 FOR D*=E* TO B*(a*)
4240 IF D*=E* THEN MOVE D (0,D*),D(1,D*):
GOTO 4260 





4300 DEF PROCpolnter_reset 









4380 INPUT-Are you sure Y or N - PREVIOUS GRAPH(S) WILL BE ERASED!-;YN$








4460 INPUT-Leave graphs (U)nchanged, erase (L)ast graph or erase (A)ll graphs-,-ERS
447 0 CASE ER$ OF
4480 WHEN -A-
44 90 PROCsure






IF B*<0 THEN B*=0 
4560 ENDCASE
4570 UNTIL ER$=-U- OR ER$=-L* OR ER$=-A- 
4580 ENDPROC 
4590 :
4600 R E M ------------------------- -----------------------------------------------------
4610 DEF PROCinterupt 
4620 SET=-1:




PRINT-PRESS 'R' TO RESET - ■;
4660 IF (FS$=-L* OR FS$=*C*) AND pread=l THEN








INPUT" PILE ALREADY EXISTS - REUSE" ;YN1$
5640 UNTIL YN1$="Y" OR YN1$="N"







INPUT'New data file name ";FILE$
5720 UNTIL PILE$<>"" AND FILE$oPILEl$
5730 PILE1$=*"
5740 WHEN 201 
5750 CLS:
PRINT’WRITE PROTECT TAB IS ON - PLEASE REMOVE"
5760 PRINT"PRESS ANY KEY TO CONTINUE":
IPOET 
5770 WHEN 67798 
5780 REPEAT 
579 0 CLS:




1 . $ . *
5820 PRINT:
PRINT"(1) Enter new filename"
5830 PRINT:
PRINT"(2) Change the disk- 
5840 PRINT:
PRINT:
INPUT "Please enter your choice: ■;selection$





INPUT'New data file name *;FILE1$




PRINT TAB(10,10)j"Press any key when disk has been changed": 
IFQET 
5940 "MOUNT 1 
5950 ENDCASE




PRINT • AT LINE";ERL;" (Error No. *;ERR;*)";







6060 IF ERR<>17 THEN 
6070 REPORT:
PRINT " AT LINE ";ERL;• (Error No. *;ERR;■)■
6080 PRINT"PRESS ANY KEY TO CONTINUE"
6090 IFGET 
6100 ENDPROC 




6150 R E M -----------------------------------------------------------------
616 0 DEF PROCcode
6170 osbyte*=6
6180 readbyte*=146
6190 DIM code* 400,store* 20









6290 MOV Rl, #0 
6300 SWI osbyte*
6310 ADDAL R4,R4,R2,LSL*8 
6320 MOV Rl, #1 
6330 SWI osbyte*
6340 ADDAL R4,R4,R2 
6350 MOV Rl, #2 
6360 SWI osbyte*
6370 ADDAL R5,R5,R2,LSL«8 
6380 MOV Rl,#3 
6390 SWI osbyte*
6400 ADDAL R5,R5,R2 
6410 MOV Rl, #5 
6420 SWI osbyte*
6430 ADD R7,R7,#1 
6440 TEQ R3,R7 
6450 BNE start 
6460 MOV Rl, #6 
6470 SWI osbyte*
6480 ADDAL R6,R6,R2 
6490 ADR R8,store*
6500 STMIA R8, (R4,R5,R6)
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6510 LDMFD R13I, (R0-R12,PC) 
6520 ]





6580 IF CL$(2)<>■■ AND RIGHTS(CLS(2),12)<>• mV per sec.' THEN CDS(2)=CL$(2) +* mV per sec. 
6590 FOR A*=0 TO 4 
6600 CLS
6610 PRINT'ENTER 'D' to delete comment, or 'RETORN' to leave comment unchanged*
6620 PRINT
6630 PRINT 'Comment line *;A*+1;': ';CL$(A*):
CL$="i
INPOT'COMMENT: ' ;CL$
6640 IF C L $ = "  THEN CLS=CLS (A*)
6650 IF CL$='D' THEN C L $ = "




YN$ = " :
REPEAT:
INPOT'OK. Y or N';YN$:
ONTIL YN$='Y* OR YN$='N'



















t o $ = "










6900 channelin= OPENIN FILE1S 
6910 INPOT* channelin, TYPES 
6920 INPOT# channelin, FS$
6930 INPOT* channelin, TS 
6940 INPOT# channelin, HV 
6950 INPOT# channelin, IV 
6960 INPOT# channelin, FV 
6970 INPOT# channelin, MV*
6980 INPOT# channelin, NApmm 
6990 INPOT# channelin, SC2$
7000 INPOT# channelin, step
7010 FOR count*=0 TO 4
7020 INPOT# channelin, CLS(count*)
7030 NEXT
7040 FOR count*=0 TO 10
7050 INPOT# channelin, SF*(count*,0)
7060 INPOT# channelin, SF*(count*,1)
7070 NEXT
7080 INPOT# channelin, countatore*
7090 FOR count*= 0 TO countatore*
7100 INPOT# channelin, m*(count*)
7110 NEXT
7120 INPOT# channelin, m*
7130 count*= 0: 
flag*=0 
714 0 REPEAT
7150 INPOT# channelin, D(0,count*)
7160 INPOT# channelin, D(l,count*)
7170 count*=countV»l
7180 ONTIL EOF# channelin
7190 CLOSE# channelin
7200 OSCLI('ACCESS '+FILE1S+' LR')
7210 RESTORE ERROR 
7220 'MOONT 0 
7230 :
724 0 REM OOTPOT FORMAT MENU
7250 REPEAT 
7260 CLS
7270 PRINT TAB(10,5);•(1) Produce DESIGNCAD file'
7280 PRINT TAB(10,10);*(2) Produce POSTSCRIPT file'
7290 PRINT TAB(10,15);•(3) Produce ENCAPSOALTED POSTSCRIPT file'
7300 INPUT TAB(15,22);'Please enter your choice: *;output_type$
7310 CASE output_type $ OF 
7320 WHEN '1*
7330 PROCoutput_filename 
















7490 DEP PROCoutput redraw 
7500 VDU 28,0,31,79,27 
7510 IP PS$='P' THEN 
7520 CLQ:
PROCholdaxls 
7530 FOR a%=0 TO 10 
7540 IP SP%(a%,1)=0 THEN a%=10:
GOTO 7560 
7550 C%=SP*(a%,0):
B%=SF*(a%, 1) i 
PROCscan
756 0 NEXT &%
757 0 ELSE 
7580 CLG:
PROCsweepaxis 







7660 DEP PROCoutput_filename 
7670 Disk_Printer$='D'







INPUT TAB(10,5);■ Output file to (D)lac or (P)rinter*;Disk_Printer$








7810 PRINT' Enter NEW OUTPUT FILENAKE, or press 'RETURN' to leave unchanged* 
7820 PRINT
7830 PRINT' PILENAXE: ■;output_filenaae$;:
INFUTedit_filaname$




REM unlikely filenane (POSTSCRIPT backwards)
7880 ENDIF
7890 LOCAL ERROR
7900 ON ERROR LOCAL PROCerror
7910 IP Dlsk_Printer$='D* THEN
7920 'MOUNT 1
7930 ELSE









8030 DEP PROCdesigncad 
8040 IP PS$='P' THEN
8050 PROCopenfile(-l)
8060 FOR a*=0 TO 10









YN $ = " :
INPUT'Do you want to save this screen Y or N';YN$
8110 UNTIL YN$='Y' OR YN$='N*
8120 IP YN$='N' THEN 8150





8180 FOR a*=l TO 
8190 CLG:





INPUT'Do you want to save this screen Y or N';YN$
8230 UNTIL YN$ = 'Y' OR YN$='N'




8280 OSCLI('ACCESS '+PILE$+' LR')





8330 DBF FROCpostscript_menu(ps or epa$) 
8340 :
8350 REM POSTSCRIPT FORMAT MEND
8360 CLS
837 0 pa_epa$=pa _or_epa$




8420 FOR a%=0 TO 10 
8430 IF SF%(a%, U = 0  THEN 
8440 snapshots%=a%-l: 
a%=10
8450 PRINT ■ Number of snapshots taken = ■; snapshots*.
8460 ENDIF 
847 0 NEXT a%
8480 PRINT ■ (1) Produce output of all SNAPSHOTS*
8490 PRINT • (2) Produce output selected SNAPSHOTS*
8500 PRINT ■ (3) Exit*
8510 PRINT
8520 INPUT ’Please enter your choice: *;psoutput_type$











8640 PRINT * Number of sweeps in current file = •;m%
8650 PRINT * (1) Produce output of all sweeps*
8660 PRINT * (2) Produce output of several selected sweeps*
8670 PRINT ■ (3) Produce output of single sweep (analysis and enlargement possible)*
8680 INPUT ■ (4) Exit*;paoutput_type$





874 0 WHEN *3*
8750 PROCpostBcriptCSINGLE*)
876 0 ENDCASE
8770 UNTIL psoutput_type$=*l* OR paoutput_type$=*2* OR psoutput_type$=*3* OR psoutput_type$=*4* 
8780 UNTIL psoutput_type$=*4*





8840 IF FS$=*F* THEN 
8850 PROCopenpafile(-1)
8860 FOR a*=0 TO 10




8890 C%=SF*(a*, 0) :
B%=SF%(a%,1)
8900 PROCscan




INPUT’Do you want to save this screen Y or N*;YN$ 
8940 UNTIL YN$=*Y* OR YN$ = *N*




8990 OSCLI("ACCESS *+FILE$+* LR*)
9000 OSCLI CSETTYPE *+FILE$+* POSCRIPT* )
9010 ‘MOUNT 0 
9020 ELSE
9030 CASE All_Select_Single$ OF 
9040 WHEN "ALL*
9050 PROCopenpaflie(-1)




9100 OSCLI('ACCESS *+FILE$+* LR*)
9110 OSCLI CSETTYPE *4FILE$+* POSCRIPT*)
9120 ‘MOUNT 0 
913 0 WHEN -SELECT*
9140 PROCopenpsfile(-l)







INPUT'Do you want to save this screen Y or N*;YN$ 
9200 UNTIL YN$=*Y* OR YN$=*N*




9250 OSCLI(*ACCESS *+FILE$+* LR*)
9260 OSCLI CSETTYPE *+FILE$ + * POSCRIPT*)










9350 PRINT * This Is sweep number out of sweeps':
PRINT
9360 PRINT ■ Use cursor keys to select required sweep then press 'RETURN" 
9370 IK$=QET$:
IK-ASC( IK$)
9380 CASE IK OF 
9390 WHEN 136 
9400 IF a4t>l THEN 
9410 a%=a%-l 
9420 ENDIF 
9430 WHEN 137 




9480 UNTIL IK=13 
9490 *FX4,0
9500 Selected_sweep%=a%




9550 OSCLI('ACCESS '+FILE$+' LR')
9560 OSCLI CSETTYPE '+FILES + ' POSCRIPT')






9630 IF Disk_Printer$='P' THEN 
9640 'MOUNT 0 
9650 CLS:
PRINT:
PRINT’ Printing - Please Walt........*
9660 OSCLI('ACCESS '+FILE$+' WR')







9740 ON ERROR LOCAL PROCerror
9750 IF vX=-l THEN
9760 OSCLI{'SPOOL '+FILE$)
9770 ELSE









9870 IF W % o - l  THEN 10300 
9880 FOR A%=1T027 
9890 PRINT H$(A%)
9900 NEXT
9910 PRINT *1 2 1 0 0 O':
PRINT '0 0'1 
PRINT '0 O'
9920 PRINT '1 2 1 0 0 O':
PRINT '0 1010':
PRINT '0 1010'
9930 PRINT '1 2 1 0 0 O':
PRINT '1280 1010':
PRINT '1280 1010'
9940 PRINT '1 2 1 0 0 O':
PRINT '1280 O':
PRINT '1280 O'
9950 PRINT '21 0 0 0 0 O'






9980 FOR A%=0 TO 4 
9990 PRINT *3 2 16 0 0 1*
10000 PRINT '300 ■+STR$(153-(34'A%))
10010 PRINT '1100 '+STR$(153-(34 *A%))
10020 PRINT CL$(A%)
10 03 0 NEXT
10 040 FOR A*=l TO NT 
10050 PRINT'1 2 1 0  0 1'
10060 PRINT STR$(N(1,A%) )+• '+STR$ (N{2,A%) )
10070 PRINT STR$(N(3,A%))+' ■+STRS(N(4,A%))
10 080 NEXT A%
10090 0%=fcO2OlO6 
10100 FOR A%=1 TO TT 
10110 PRINT'3 1 16 0 0 1*




10160 PRINT ' 1 2  1 0  0 1*
10170 PRINT STR$(Ml\(l,A9s) )+' ' + STR$ (Ml%(2, A%) )
10180 PRINT STR$(M1%{3,A%))+' • +STR$ (Ml*(4, A%) )
10190 NEXT
10200 FOR A%=1T011
10210 PRINT '3 1 16 0 0 1'
10220 PRINT STR$(T1(1,A%))+■ •+ STR$(T 1 (2,A\ ) ) 
10230 PRINT Tl$ (A%)
10240 NEXT
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10250 PRINT "3 2 16 0 0 1*
10260 PRINT STR$(T2(1))+■ ■+STR$(T2(2))
10270 PRINT STR$(T2(3))+■ •+STR$(T2(4))
10280 PRINT ■CURRENT (■+SC2$+*)*
10290 ENDPROC
10300 IP FS$="F" THEN
10310 PRINT *21 •+STR$(a%+l)+■ 0 0 0 0«
10320 PRINT EL$
10330 POR A%=C% TO B%









10430 PRINT *21 "+STR$(a%)+" 0 0 0 0*
10440 e%=m%(a%-l)+l:
IP a%>l THEN e%=a%*l 
10450 f%=m%(a%)-e%
10460 IP 199 THEN f*=200 ELSE £%=199 
10470 POR b%=e% TO m*(a%) STEP t%
10480 d%=199:
IP m%(a%)-b*<200 THEN d%=m%(a%)-b%
10490 PRINT *1 •+STR$(d%+l)+■ 1 0 0 1 *
10500 POR c%=b% TO b%+d%







10580 DEP PROCopenps £lie(v%)
10590 LOCAL ERROR
10600 ON ERROR LOCAL PROCerror





10660 IP v%<>2 THEN
10670 PROCpswrite(VA)
10 680 ELSE
10690 PRINT ‘state restore*







10770 RESTORE ERROR 
10780 ENDPROC 
10790 :
10800 R E M -------------------------------------------------------------------------
10810 DEF PROCpswrite(w%)
10820 REM - Postscript £ile writing routine -
10830 REM - if v%<0 = Write Header as follows
10840 REM - wA=-l = Standadrd sized plain drawing
10850 REM - v % = -2  = Enlarged drawing with comment box
10860 REM - v%=-3 * Standard size drawing with peak analysis
10870 REM - wA=-4 = Differentiated curve - enlarged with comment box
10880 REM - WA=-5 = Differentiated curve - Standard size drawing
10890 REM - if w%>0 = Write Curve Data
10900 REM
10910 IF w%>0 THEN 13160
10920 IP ps_eps$=*EPS* THEN
10930 PRINT'%IPS-Adobe-2.0 EPSF-1.2*
10 94 0 PRINT"W:reator: Cylic voltammetry program*
10950 PRINT"%%Pori WordPerfect input"
10960 PRINT"%%Title: ";PILE$
10970 PRINT’VfcCreationDate: ";TIME$





PRINT * *&EndComment s*
11030 ENDIF 
11040 PRINT
11050 PRINT •%------------------ Prologue----------------- •
11060 PRINT */_rm"
11070 PRINT • {rmoveto) bind def"
11080 PRINT */_rl"
11090 PRINT " {rlineto) bind def"
11100 PRINT */_s"
11110 PRINT • (show) bind def"
11120 PRINT
11130 IP w%=-3 THEN
11140 PRINT •%---------- Peak Current Text-procs-------- ■
11150 PRINT "/ispo"
11160 PRINT ■ {8 12 _rm _lf setfont (\(I) _s _sf aetfont (sp) _s"
11170 PRINT • _Xf setfont (\)) _• 0 -5 _rm _af setfont (o) _s"
11180 PRINT • -8 -7 _rm) def"
11190 PRINT 
11200 PRINT "/ipco"
11210 PRINT ■ {8 12 _rm ^lf setfont (\(I) _s _sf setfont (pc) _s"
11220 PRINT • _lf setfont (\)) _8 0 -5 _rm _sf setfont (o) _s"
11230 PRINT • -8 -7 _r») def"
11240 PRINT 
11250 PRINT "/ipao•
11260 PRINT ■ (8 12 _rm _lf setfont (\{I) _s _sf aetfont (pa) _s"
11270 PRINT • _lf setfont (V)) _s 0 -5 _rm _sf setfont (o) _s"




11310 PRINT ■ {8 12 _rm _lf aetfont { I) _a _a£ aetfont (pc
11320 PRINT • -8 -12 _rm) d e f
11330 PRINT
11340 PRINT */ipa*
11350 PRINT ■ {8 12 _rm _lf aetfont ( I) _a _af aetfont (pa





11410 PRINT '%------------------- SCRIPT------------------ •
11420 PRINT '/state aave d e f  
11430 PRINT
11440 PRINT ’% ----------------- Define Fonta-------------- ■
11450 PRINT *%large font If*
11460 PRINT * /_lf
11470 PRINT * /Times-Roman findfont 24 acalefont d e f
11480 PRINT
11490 PRINT '^medium font mf*
11500 PRINT * /_mf
11510 PRINT * /Times-Roman findfont 20 acalefont def*
11520 PRINT
1153 0 PRINT *%small font a f  
11540 PRINT */_af
11550 PRINT * /Timea-Roman findfont 16 acalefont def*
11560 PRINT
11570 PRINT ■% Move Origin and Scale-------- *
11580 IF w*--2 OR w%=-4 THEN
11590 PRINT '^Enlarged Drawing - Portrait orientation*
11600 PRINT *1.5 .566929 mul dup acale*
11610 PRINT Xoffaet**-l;■ ■;Yoffaet%*-l)• tranalate*
11620 PRINT 
11630 ELSE
11640 PRINT *%Normal Sized Drawing Landacape orientation*
11650 PRINT *20 792 tranalate*
11660 PRINT *-90 rotate*
11670 PRINT *.566929 dup acale*
11680 PRINT 
11690 ENDIF
11700 PRINT ---------- Draw--Main Comment Box-------- *
11710 PRINT *_af aetfont*
11720 PRINT *330 0 moveto*:
PRINT*1070 0 lineto*




11750 FOR \%=0 TO 4
11760 PRINT *350 *+STR$(108-(24*A%))♦■ moveto*
11770 PRINT •(■+CL$(A%)+•) _a*
11780 PRINT 
11790 NEXT
11800 IF W*<>-2 AND W%<>-4 THEN
11810 PRINT  Translation before drawing Axia ■
11820 PRINT *0 -40 tranalate*
11830 PRINT 
11840 ENDIF
11850 IF W % < - 1  AND w*>=-4 THEN
11860 PRINT •*------------Draw Comment Box--------------■
11870 PRINT STR$(CommentBoxX\)+* *+STRS(CommentBoxY%)+■ moveto*
11880 PRINT *%atore box poaition in poatacript variables Xpoa and
11890 PRINT *currentpoint■
11900 PRINT */Ypoa exch def*
11910 PRINT '/Xpoa exch def*
11920 PRINT S T R $ ( C o m m e n t B o x S i z e X % ) 0 _rl*
11930 PRINT *0 •+STR$(CommentBoiS i zeY%)+■ _rl*
11940 PRINT *-*+STR$(CommentBoxSizeX%)+• 0 _rl*
11950 PRINT ‘cloaepath*
11960 PRINT 
11970 CASE w* OF 
11980 WHEN -2,-4
11990 PRINT •%— Fill Comment Box (enlargement)------- •
12000 PRINT *Xpos Ypoa moveto*
12010 PRINT *6 22 _rm*
12020 PRINT * (*+CommentLinel$+*) _a*
12030 PRINT ’Xpoa Ypoa moveto*
12040 PRINT *6 6 _rm*
12050 PRINT * (*+CommentLine2$+*) _a*
12060 PRINT 
12070 WHEN -3 
12080 8%=S0102030A
12090 PRINT ■% Fill Comment Box (analysis)--------■
12100 PRINT 'Xpoa Ypoa moveto*
12110 PRINT *ipc 8 12 _rm _mf aetfont ( = *+STR$(Ipc)+*, ) _s 0 -
12120 PRINT *ipa 8 12 rm _mf aetfont ( = *+STR$(Ipa)+■, ) _a 0 -
12130 PRINT *iapo 8 12 _rm _mf aetfont ( = *+STR$(Iapo)+■ ) _a 0
12140 PRINT *Xpoa Ypoa moveto*
12150 PRINT *0 70 _rm*
12160 IF dr<0 THEN PRINT *ipa* ELSE PRINT *ipc*
12170 PRINT *40 0 _rm*
12180 IF dr<0 THEN PRINT *lpao* ELSE PRINT *ipco*
12190 PRINT *58 12 _rm _mf aetfont (0.485) _a*
12200 PRINT *10 10 _rm 10 -10 _rl -10 0 _rm 10 10 _rl 0 -10 _rm*
12210 PRINT *2 -12 _rm iapo stroke*
12220 PRINT 'Xpoa Ypoa moveto*
12230 PRINT *0 40 _rm*
12240 IF dr«0 THEN PRINT *ipc* ELSE PRINT *ipa*
12250 PRINT *40 0 _rm*
12260 IF dr<0 THEN PRINT *ipc* ELSE PRINT 'ipa*
12270 PRINT *95 0 _rm*
12280 IF dr<0 THEN PRINT *ipc* ELSE PRINT *ipa*
12290 PRINT *Xpoa Ypoa moveto*
12300 PRINT *15 72 _rm 30 0 _rl 15 3 _rm 14 0 _rl -14 -6 _rm 14 0
12310 PRINT *15 3 _rm 50 0 _rl 15 0 _rm 14 0 _rl -7 -7 _rm 0 14
12320 PRINT *15 0 _rm 130 0 _rl 15 0 _rm 14 0 _rl -7 -7 _rm 0 14
12330 PRINT *10 -7 _rm _mf aetfont (0.086) _s 10 7 _rm*
12340 PRINT *10 3 _rm 14 0 _rl -14 -6 _rm 14 0 _rl 10 -4 _rm*




12390 PRINT *%----------------Draw Axle------------------ *
) _a*






rl 7 -7 _rm* 
_ r  7 -7 _rm*
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12400 PRINT *_lf aetfont■
12410 FOR A%=1 TO NT
12420 PRINT STR$(N(1,A%))+• ■+ STR$(N(2,A%))+■ moveto*




12470 FOR A*=l TO TT
12480 PRINT STR$(T(1,A*)+16)+* *+STR$(T(2, A%))+• aoveto'
12490 PRINT •(•♦T$(A*)+*) _a*
12500 NEXT
12510 FOR A%=1TO23
12520 PRINT STR$(M1*(1. **))+* ■ + STR$ (Ml%(2, A.%) ) + ■ moveto*




12570 PRINT STR$(Tl(l,A%)+62)+* ■+STR$(T1(2,A % ) )+■ moveto*
12580 PRINT *(*+Tl$(A%)+*) _B*
12590 NEXT
12600 PRINT STR$(T2(l)+70)+* *+STR$(T2(2))+• translate*
12610 PRINT *90 rotate*
12620 PRINT *0 0 moveto*
12630 PRINT '(Current (*+SC2$+*)) _s*
12640 PRINT *-90 rotate*
12650 PRINT ■ +STR$(T2(l)+70)+* -*+STR$(T2(2))+■ translate*
12660 PRINT *0.5 setlinewidth*
12670 PRINT
12680 IF W%=-3 THEN
12690 PRINT •%------------- Analysis Legend--------------■
12700 PRINT STR$(D (0,Yminpos))*■ ■+STR$(D(1,Ymlnpos))+■ moveto*
12710 PRINT STR$(D(0,Ymlnpos))+■ 650 llneto stroke*
12720 PRINT *gsave*
12730 PRINT STR$(D<0,ymlnpos))♦• ■+STR$((D{1,ymlnpos)+650)/2)+• translate*
12740 PRINT *0 0 moveto*
12750 PRINT *0.7 0.7 scale*
12760 IF dr«0 THEN PRINT *ipc* ELSE PRINT *lpco*
12770 PRINT 'grestore*
12780 PRINT STR$(D (0,Ymaxpos))+• •+STR$(D(1,Ymaxpos))+* moveto*
12790 PRINT STR$(D (0,Ymaxpos))+■ 650 llneto stroke*
12800 PRINT *gsave*
12810 PRINT STR$(D (0,ymaxpos))+* *+STR$((D(1,Ymaxpos)+650)/2)+* translate*
12820 PRINT *0 0 moveto*
12830 PRINT *0.7 0.7 scale*
12840 IF dr<0 THEN PRINT *lpao* ELSE PRINT *lpa*
12850 PRINT 'grestore*
12860 PRINT STR$(D(0,Xmaxpos))+■ * + STR$(D(1,Xmaxpos))+* moveto*
12870 PRINT STR$(D (0,Xmaxpos)) + * 650 llneto stroke*
12880 PRINT 'gsave*
12890 PRINT STR$(D(0,Xmaxpos))+• ■+STR$((D(1,Xmaxpos)+650)/ 2 ) t r a n s l a t e *
12900 PRINT *0 0 moveto*





12960 IF w%=-4 OR w%=-5 THEN
12970 FOR count%=fas% TO fse*-step% STEP 1
12980 IF count%=fas% THEN
12990 PRINT STR$(F(0,count%-fssA))+■ •+STR$<F<1,count*-fssk)*Scale_factor+650)+■ 
13000 ELSE




13050 FOR oount%=ras*b TO rae%-atep% STEP 1 
13060 IF count%=rss9b THEN
13070 PRINT STR$(R(0,count9b-rssA) ) +* ■ +STR$ (R( 1,countk-raak) *Scale_factor+650) +* 
13080 ELSE




13130 PRINT *[10] 5 setdash*
13140 ENDIF 
13150 ENDPROC 
13160 IF FS$=*F* THEN 
13170 FOR A%=C% TO B%
13180 IF A%=C% THEN
13190 PRINT STR$(D(0,A*)-D(0,C%)+200)+* * +STR$(D(1,A%))+* moveto*
13200 ELSE










13310 R E M -------------------------------------------------------------------------------
13320 DEF PROCpa_aweepout 
13330 e%=m%{a*-l)+l 
13340 FOR b%=e% TO m*(a%)
13350 IF b%=e% THEN
13360 PRINT STR$(D(0,b%))+* *+STR$(D(1,b% ) )+• moveto*
13370 ELSE







13450 DEF PROCslngle_analysis 
13460 i













13510 PRINT TAB(10,5)>“ (1) Print"
13520 PRINT TAB(10,8); " (2) Print Enlargement■
13530 PRINT TAB(10,11);"(3) Calculate Peak Ratios*
13540 PRINT TAB(10,14);"(4) Print differentiated curve- 
13550 PRINT TAB(10, 17) ; " (5) EXIT*
13560 INPUT TAB(15,22);'Please enter your choices •;analyaia_type$














13660 OSCLI("ACCESS "+FILE$+" LR*)
13670 OSCLI(•SETTYPE "*FILE$+" POSCRIPT*)
13680 "MOUNT 0 
13690 WHEN "2"
13700 MODES:









PRINT" Select area to be enlarged using the mouse - Press the LEFT button to exit" 




REPEAT UNTIL TIME>50 
13780 CLS 
13790 PRINT:
PRINT* Position comment box using the mouse - Press the LEFT button to exit"
13800 CommentBoxSizeX*=250:
CommentBoxSizeY*=44








13870 OSCLI("ACCESS "+FILE$+" LR")
13880 OSCLI("SETTYPE "+FILE$+" POSCRIPT")














13960 FOR count*=m*(a*-l)+1 TO m*(a*)
13970 IF (D(1,count*) -650) <YJnin THEN Ymin= (D( 1,count*)-650) :
Ymlnpos=count*
13980 IF (D(1,count*)-650)>Yteax THEN Ymax=(D(1,count*)-650):
Ymaxposscount*




DRAW D (0,Ymlnpos),6 5 0 
14020 MOVE D (0,Ymaxpos),D (1,Ymaxpos):
DRAW D(0,Ymaxpos),650 
14030 MOVE D(0,Xmaxpos),D(1,Xmaxpos):
DRAW D (0,Xmaxpos), 650
14 040 Current_per_mm=NApmm
14050 IF 1000"Current_per_mm>=1000 THEN Current_per_mm=Current_per_mm/1000 
14060 IF 1000*Current_per_mm>=1000 THEN Current_per_mm=Current_per_mm/1000 
14070 Ipc=ABS((650-D(l,Ymlnpos))»1250»Current_per_mm/350)
14080 Ipa=ABS((D(1,Ymaxpos)-650)*1250*Current_per_mm/350)
14090 Iapo=ABS((6 50-D(1,Xmaxpos))•12 5 0"Current_pe r_mm/3 5 0)
14100 IF dr«0 THEN
14110 Analysia_Result=(Ipa/Ipc)+(0.485*Ispo/Ipc)+.086
14120 ELSE
14130 SWAP Ipa, Ipc




PRINT* Position comment box using the mouse - Press the LEFT button to exit"
14180 CommentBoxSizeX*=50 0 :
CommentBoxS1zeY*=110 







14240 OSCLI("ACCESS *+FILE$+* LR*)
14250 OSCLI(*SETTYPE *+FILE$+* POSCRIPT*)









14310 REM find point of sweep reversal 
14320 Xmax=0
14330 FOR count%=m4b(a%-l) +1 TO m%(a%)










PRINT* The number of Data Points for this sweep Is * -m%(a%-l)+1:
PRINT
14410 INPUT* Enter differentiation step size (1-3)*;Dlff_step$




14460 fse%=fsa% + Xmaxpos1% - (Xmaxpos1% MOD step*)
14470 rsa%=Xmaxpos*+1 
14480 Xmaxpos2*=m%(a*)-ras*
14490 rae%=rss*+XmaxpoB2*-(Xmaxpos2* MOD step*)
14500 lmax=0: 
lmin=0
14510 FOR count%=fas* TO fae*-step% STEP 1
14520 F(0,count%-fss*)=(D(0,count*+step%)+D(0,count%))/2
14530 F(l,counts-fas*)= (D(1,count*+step*)-D(1,count*))/(D(0,count*+step*)-D(0,count*)) 
14540 IF F(l,count*-fas*) > Imax THEN ImaxF=F(1,count*-fss*)
14550 IF F(l,count*-fas*) < Iain THEN IminFrF(1,count*-fart)
14560 NEXT
14570 FOR count*=raa* TO rse*-step* STEP 1
14580 R(0,count*-ras*)s(D(0,count*+Btep*)+D(0,count*))/2
14590 R( 1, count*-rse*) = (D (1, count*+step*) -D(1, count*) ) / (D( 0, count*+atep*) -D(0, count*) ) 
14600 IF R(1,count*-rsa*) > Imax THEN Imax=R(1,count*-raa*)
14610 IF R(l,oount*-ras*) < Iain THEN Imin=R(l,count*-raa*)
14620 NEXT
14630 IF Iaax < ABS(Imin) THEN Imax=ABS(Iain)
14640 Scale_factor=300/Imax
14650 FOR count*=fas* TO fse*-atep* STEP 1
14660 IF count*=fas* THEN
14670 MOVE F(0,count*-fss*),F (1,count*-fas*)*Scale_factor+650 
14680 ELSE
14690 DRAW F(0,count*-fas*),F(1,count*-fas*)*Scale_factor+650 
14700 ENDIF 
14710 NEXT
14720 FOR count*=rsa* TO rseX-step* STEP 1 
14730 IF count*=rssX THEN









INPUT* Do you want to change differentiation step size Y or N*;YN$
14810 UNTIL YN$=*Y* OR YN$=*N*





INPUT* Do you want to enlarge a section of the drawing Y or N*;YN$
14850 UNTIL YN$=*Y* OR YN$=*N*
14860 IF YN«=*Y* THEN 
14870 PRINT:





REPEAT UNTIL TIME>50 
14 910 CLS 
14920 PRINT:
PRINT* Position comment box using the mouse - Press the LEFT button to exit*
1493 0 CommentBoxSiz.eX%= 250:
CommentBoxS i zeYX=4 4











15030 OSCLI(‘ACCESS *+FILE$+* LR*)
15040 OSCLI("SETTYPE *+FILE$+* POSCRIPT*)
15050 ‘MOUNT 0 
15060 ENDCASE
15070 UNTIL VAL(analysia_type$)>0 AND VAL(analysis_type$)<6 
15080 ENDPROC 
15090 :




1513 0 REM BOX DRAWING PROCEEDtJRE - BOX IS MOVED USING THE MOUSE 
15140 REM boxaizeX4b=X dimension of box, boxaizeY4b=Y dimension of box 
15150 REM llx% and lly4b represent the X and Y co-ordinates of the lower left 
15160 REM hand corner of the area within which the box Is allowed to move. 
1517 0 REM urx4t and ury4b are co-ordinates of the upper right hand corner of 
15180 REM the same area.
15190 s
15200 •POINTER 0 
15210 MOVE 11x4b, lly4b 
15220 MOUSE ON 0
1523 0 MOUSE xpos*, ypos4b, button*
15240 IP xpoa4b<llx% THEN xpoa4b=llx4b
15250 IP xpos%> (urx4b-boxsizeX4b) THEN xpoa4b=urx4b-boxsizeX4b 
152 60 IP ypos4b<lly% THEN ypos4b=lly4b
15270 IP ypoa4b> (ury4b-boxsizeY4b) THEN ypoa4b=ury4b-boxaizeY4b 
15280 MOVE xpos4b, ypos4b:
PLOT £06, xpoa4b+boxsizeX4b,ypos4b:




15300 MOUSE xpos 14b, yposl4b,button4b 
15310 IP xposl4b<llx% THEN xpos 14b= 11x4b
15320 IP xposl%> (urx4b-boxaizeX%) THEN xpoal4b=urx4b-boxaizeX4b 
15330 IP ypoal4b<lly4b THEN yposl4b=lly4b
15340 IF yposl4b> (ury%-boxslzeY%) THEN yposl4b=ury%-boxsizeY%
15350 IP xpoal4b<>xpos4b OR ypoal4b<>ypos4b THEN 
15360 MOVE xpos4b,ypos4b:
PLOT £06, xpos4b+boxa 1 zeX4b, ypos4b:
PLOT £06, xpoB4b+boxsizeX4b,ypoa%+boxsizeY4b:
PLOT £06, xpos4b,ypoa4b+boxalzeY4b:
PLOT £06, xpos4b, ypos4b 




PLOT £06, xpoal4b, ypos 1%
15380 xpos4b=xpoa 14b: 
ypos4b=ypos 14b 
15390 ENDIF 
15400 UNTIL button4b=4 





15450 DATA *0 0 1280 1010 0*,*20 0 0 0 0 0a,16,1,32,1,3,16,0
15460 DATA 50, -2 . 54■ , 4, 0,1, 4, 0, 0, 1, 0,1, 1, 0, *0 0",1,0, •,■21 20 0 0 0 0*










: 0 . $ . HPLCNEW




90 ‘MOUNT 0 









120 DIM N(4,100),T(2,100),T $ (100),H $ (27),S (2,15),D(l,30000) 
130 DIM m4b( 100 ) , M14b(4, 23),T1$(12),T1(4,12),T2(4),CL$(4)
140 DIM F(l,1000),R(l, 1000)
150 PROCcode
160 ON ERROR PROCerror
170 PROCheader
180 :
190 R B K -----------------------------------------------------------




INPUT ■ (C)ollect Data, (E)dlt or (Q)uit*;PS$
230 CASE PS$ OP 
240 WHEN ■C*,*c*
250 PROCcollect 









340 R E N ------------------------------------------------------------------------

















INPUT* Do you want to reset variables Y or N*;YN$
480 UNTIL YN$ = *Y* OR YN$ = *N*




INPUT* Save (D)ata or (E)xif;CS$







INPUT* Are you sure Y or N*;YN$
590 UNTIL YN$=*Y* OR YN$=*N*






660 DEF PROCholdinput 
670 REPEAT 
680 CLS
6 90 INPUT ■ TIMESCALE o f  data collection in minutes*;TS:
PRINT








PRINT * Please enter AUFS*
770 PRINT* (NB. Detector output should be set to give lv full scale)*;
780 INPUT AUFS




















920 IF TS»=20 THEN DS=DS*2
930 IF TS»=40 THEN DS=DS*2
940 IF TS>=60 THEN DS=DS*2
950 FOR A=200 TO 1200 STEP DS
960 MOVEA,2 95:
DRAWA,3 05 
970 N(lr B+2)=A 
980 N (2,B+2)=295 
990 N (3,B+2)=A 







1040 IF TS>=60 THEN JOHN=8
1050 IF (TS>=40 AND TS<60) THEN JOHN=4
1060 IF (TS>=20 AND TS<40) THEN JOHN=2
















1170 R E M -------------------------------------------------------------------------






PRINT*Preaa 'ESC' to halt*
1220 LOCAL ERROR
1230 ON ERROR LOCAL PROCerrorlocal 
1240 REPEAT
1250 IF SET <> -1 THEN 1400
1260 IF BV<>0 THEN FINISHTIME=FINISHTIME + interval 









1350 IF B*<1023 THEN 1370 
1360 *FX 125 
1370 REPEAT
1380 UNTIL TIME>FINISHTIME
1390 IF TIME/100 > mul*»TS*60/4 THEN interval=interval*(2*0.5)i 
mul*=nul*+l 
1400 UNTIL SET <> -1 
1410 £iniah*=B*-l 




1460 DEF PROCdraw 













1590 Ml*(2,1)=30 0 
1600 Ml*(3,l)=200 
1610 Ml*(4,1)=1000 
1620 FOR A*=0TO12 
1630 B*=(A**700/12)+300 




1670 M l * (3,A*-f2) =205 




1720 FOR A*=-2 TO 10
1730 B*=(A**700/12)+300+(700*2/12)











1800 T 2 (1)=50:
T2 (2)=560:
T 2 (3)=50:





1850 DEF PROCaure 
I860 REPEAT 
1870 CLS:
YN$ = * ■
1880 INPUT*Are you aure Y or N - PREVIOUS GRAPH(S ) MILL BE ERASED 1 *;YN$ 





1940 IF ERR<>17 THEN 
1950 REPORT:
PRINT * AT LINE *;ERL;■ (Error No. *;ERR;*)*






2 0 2 0  :
2030 REM ------------------------------------------------------------------------
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2040 DEP PROCinterupt 
2050 SRT=-1:
Z? = **
206 0 Repeat%=TRUE 
2070 REPEAT 
2080 CLS:
PRINT*PRESS 'R' TO RESET - •»
2090 PRINT*■
2100 PRINT*PRESS 'E' TO EXIT AND SAVE DATA - PRESS 'X' TO EXIT PROGRAM *; 
2110 CASE GET$ OF 
2120 WHEN *R*,*r*
2130 Z?=*R*:












2190 UNTIL Repeat%=FALSE 
2200 SET=0
2210 IF Z?=*X* THEN END 
2220 ENDPROC 
2230 :
2240 R E M ---------------------------------------------------------------------------
2250 DEF PROCheader 




2300 H $ {8)=STR$(teztheight)
2310 ENDPROC 
2320 :
2330 R E M ---------------------------------------------------------------------------









2400 PRINT • Insert disc (with NAME-'Data') in drive 1*











2510 CL?(4)=*FILENAME: *+FILE?+* DATE: *+TIME?
2520 channelout= OPENOUT FILE?
253 0 PRINT# channelout, FS?
2540 PRINT# channelout, TS 
2550 PRINT# channelout, SCI?
2560 PRINT# channe lout, step 
2570 PRINT# channelout, AUFS 




2610 PRINT# channelout, D(0,count*)
2620 PRINT# channelout, D (1,count*)
2630 IF D (0,count*)=0 AND D (1,count*)=0 THEN flag%=l
2640 count%=count%+l
2650 UNTIL flag%=l OR count%=30001
26 6 0 CLOSE# channelout





2720 CASE ERR OF 
2730 WHEN 17 
2740 END 
2750 WHEN 195 
276 0 REPEAT 
2770 CLS:
PRINT:
INPUT* FILE ALREADY EXISTS - REUSE* ;YN1?
2780 UNTIL YN1?=*Y* OR YN1?=*N*







INPUT‘New data file name -;FILE?
2860 UNTIL FILE?<>** AND FILE?oFILEl?
2870 FILE1?=**
2880 ENDIF 
2890 WHEN 201 
2900 CLS:
PRINT*WRITE PROTECT TAB IS ON - PLEASE REMOVE*
2910 PRINT”PRESS ANY KEY TO CONTINUE*:
IFGET 








I .* . *
2970 PRINT:
PRINT*(1) Knter new filename*
2980 PRINT:
PRINT*(2) Change the disk*
2990 PRINT:
PRINT:
INPUT ’Please enter your choice: *;selection$





INPUT’New data file name *;FILE1$




PRINT TAB(10,10);'Press any key when disk has been changed*:
IFGET 
3090 ’MOUNT 1 
3100 ENDCASE




PRINT * AT LINE*;ERL;* (Error No. *;ERR;*)*;
3150 PRINT* - PRESS ANY KEY TO CONTINUE*:
IFGET 
3160 ENDCASE 






3230 DIM code* 4 00,store*. 20






3300 LDR R3, [R8,#12]
3310 MOV R0,treadbyte*
3320 .start 
3330 MOV R1,*0 
3340 SWI osbyte*
3350 ADDAL R4,R4,R2, LSL#8 
3360 MOV Rl,#1 
3370 SWI osbyte*
3380 ADDAL R4,R4,R2 
3390 MOV Rl, #2 
3400 SWI osbyte*
3410 ADDAL R5,R5,R2,LSL#8 
3420 MOV Rl,*3 
3430 SWI osbyte*
3440 ADDAL R5,R5,R2 
3450 MOV Rl, #5 
34 60 SWI osbyte*
3470 ADD R7,R7,#1 
3480 TEQ R3,R7 
34 90 BNE start 
3500 MOV Rl, #6 
3510 SWI osbyte*
3520 ADDAL R6,R6,R2 
3530 ADR R8,store*
3540 STMIA R8, (R4,R5,R6)














3 640 REPEAT 
3650 CLS:
FILE1$ = * *:









3720 ON ERROR LOCAL PROCerror
3730 * MOUNT 1
3740 PRINT:
PRINT
3750 OSCLI(* INFO *+FILEl$)
3760 PRINT
3770 channe1in= OPENIN FILE1$
3780 INPUT# channelin, FS$
3790 INPUT# channelin, TS
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380 0 INPUT# channelin, SC1$
3810 INPUT# channelin, step
382 0 INPUT# channelin, AUFS
383 0 INPUT# channelin, finish*
3840 count*= 0
3850 REPEAT
3860 INPUT# channelin, D (0,count*)
3870 INPUT# channelin, D(l,count*)
3880 count*=count*+1
3890 UNTIL EOF# channelin
3900 CLOSE# channelin
3910 OSCLI("ACCESS *+FILEl$+* LR*)
3 920 RESTORE ERROR 
3930 * MOUNT 0 
3940 :
3950 REM OUTPUT FORMAT MENU
3960 REPEAT 
3970 CLS
3980 PRINT TAB(10,5);*(1) Produce DESIGNCAD file"
3990 PRINT TAB(10,10);B (2) Produce POSTSCRIPT file*
4000 PRINT T A B (10,15);*(3) Produce ENCAPSUALTED POSTSCRIPT file*
4010 INPUT TAB(15,22);‘Please enter your choice: •;output_type$












414 0 PROCoutput_redraw 
4150 ps__eps$=*EPS*
416 0 PROCpoatscript 
4170 ENDCASE




4220 DEF PROCoutput redraw 
4230 VDU 28,0,31,79,27 
4240 CLG:
PROCholdaxia 
4250 FOR B*=0 TO finiah*
42 6 0 PROCdraw 





4320 DEF PROCoutput_filename 
4330 Diak_Printer#=*D*







INPUT TAB(10,5);■ Output file to (D)isc or (P)rinter*;Disk_Printer#








4470 PRINT* Enter NEW OUTPUT FILENAME, or press 'RETURN' to leave unchanged* 
4480 PRINT
4490 PRINT* FILENAME: •;output_filename#;:
INPUTedit_filename#




REM unlikely filename (POSTSCRIPT backwards)
4540 ENDIF
4550 LOCAL ERROR
4560 ON ERROR LOCAL PROCerror
4570 IF Diak_Printer#=*D* THEN




4620 OSCLI(* SPOOL *+FILE#)
4630 ‘SPOOL
4640 OSCLI(‘DELETE *+FILE$)




4690 DEF PROCdesigncad 
4700 PROCopenfile(-1)
4710 PROCopenfile(0)
4720 OSCLI(‘ACCESS *+FILE#+* LR*)
4730 ‘MOUNT 0 
4740 ENDPROC 
4750 :
4760 R E M ----------------





INPUT" (P)ortrait or (L)andscape";PL$




INPUT* Include the filename on the drawing Y or N";FIL$ 
4810 UNTIL FIL$="Y" OR FIL$=*N*
4820 IF FIL»="Y" THEN PROCcomment_bor 







4900 OSCLI("ACCESS "+FILE$+" LR")
4910 OSCLI("SETTYPE "+FILE$+" POSCRIPT")
4920 "MOUNT 0
4930 IF Disk_Printer$="P* THEN 
4940 "MOUNT 0 
4950 CLS:
PRINT:
PRINT" Printing - Please Wait........*
49 60 OSCLI("ACCESS "+FILE$+" WR")
4970 OSCLI("COPY *+FILE$+" PRINTER: -C-VDQ")
4980 ENDIF 





5040 ON ERROR LOCAL PROCerror












5170 IF W*<>-1 THEN 5520 
5180 FOR A*=1TO27 
5190 PRINT H$(A%)
5200 NEXT
5210 PRINT " 1 2  1 0  0 0":
PRINT "0 0":
PRINT "0 0"
5220 PRINT " 1 2  1 0  0 0":
PRINT "0 1010"«
PRINT "0 1010"
5230 PRINT " 1 2  1 0  0 0":
PRINT "1280 1010":
PRINT "1280 1010"
5240 PRINT " 1 2  1 0  0 0":
PRINT "1280 0":
PRINT "1280 0"
5250 PRINT "21 0 0 0 0 0"
5260 FOR A*=l TO NT 
5270 PRINT* 1 2 1 0  0 1"
5280 PRINT STR$(N(1,A*>)+■ "+STR$(N(2,A*))
5290 PRINT STR$(N(3,A%))+* "+STR$ (N(4, A%) )
5300 NEXT A*
5310 0%=AO2O1O6
5320 FOR AV=1 TO TT
533 0 PRINT"3 1 16 0 0 1"




5380 PRINT " 1 2  1 0  0 1"
5390 PRINT STR$(M1*(1,A*) )♦" " +STR$ (Ml%(2, A*) )
5400 PRINT STR$(M1*(3, A*) )+" "+STR$(Ml*(4,A%))
5410 NEXT
5420 FOR A*=0TO12
5430 PRINT "3 1 16 0 0 1"
5440 PRINT STR$(T1(1,A*))+■ ■+STR$(T1(2,K\ ) )
5450 PRINT T1$(A%)
5460 NEXT
5470 PRINT "3 2 16 0 0 1"
5480 PRINT STR$(T2(1))♦■ ■+STR$(T2(2))
5490 PRINT STR$ (T2 (3) ) 4-• ■ +STR$ (T2 (4) )
5500 PRINT "SCI"
5510 ENDPROC
5520 PRINT "21 1 0  0 0 0"
5530 f%=flnish%:
IF f%=199 THEN f*=200 ELSE f%=199 
5540 FOR b%=0 TO finish* STEP f*
5550 d*=199:
IP finish*-b*< 20 0 THEN d*= finish*-b*
5560 0*=4OA
5570 PRINT "1 "+STR$(d*+l)+" 1 0  0 1"
5580 FOR A*=b* TO b*+d*






5650 DEF PROCopenpsfile(V * )
5660 LOCAL ERROR
5670 ON ERROR LOCAL PROCerror






5730 IF v9s<>2 THEN
5740 PROCpswrite(v%)
5750 ELSE
5760 PRINT 'state restore' 











5880 DEF PROCpswrite (w9s)
Postscript file writing routine - 
if w9s<0 = Write Header as follows
w%=-l = Standadrd sized landscape drawing 
w%=-2 = Standadrd sized portrait drawing 








5960 IF w4s>0 THEN 7090
5970 IF ps_eps$='EPS* THEN
5980 PRINT'%!PS-Adobe-2.0 EPSF-1.2'
5990 PRINT'WIreator: HPLC data collection program* 
6000 PRINT'WbFor: WordPerfect input'
6010 PRINT'VfcTitlei *>FILE$
6020 PRINT* VkCreationDatei •;TIMES 
6030 IF W*=-l THEN
6040 PRINT'%%BoundingBox: 0 0 712 792*
6050 ELSE
6060 PRINT'VfcBoundingBox: 0 0 576 405*
6070 ENDIF

















■ /Times-Roman findfont 20 scalefont def*
*9ssmall font sf**/_ef•















624 0 PRINT 
6250 PRINT 
6260 PRINT
6270 PRINT •%-----------------Define Fonts-------------- ■
6280 PRINT *%large font If*
6290 PRINT */_lf*










6400 PRINT ■*----------Move Origin and Scale---------- •
6410 IF w4s=-l THEN
6420 PRINT '^Landscape orientation*
6430 PRINT *20 792 translate*
6440 PRINT *-90 rotate*
6450 PRINT *.566929 dup scale*
6460 ELSE
6470 PRINT '^Portrait orientation*
6480 PRINT *.45 dup scale*
6490 ENDIF 
6500 PRINT
6510 PRINT ■% Translation before drawing Axis ■
6520 IF W*=-l THEN 





6580 IF FIL$=*Y* THEN
6590 PRINT *9s-Draw Comment Box-------------- •
6600 PRINT STR$(CommentBoxX%)+■ •+STR$(CommentBoxY%)+■ moveto*
6610 PRINT *%store box position in postscript variables Xpos and Ypos* 
6620 PRINT "currentpoint*
6 63 0 PRINT ■/Ypos exch def*
6640 PRINT '/Xpos exch def*
6650 PRINT STR$(CommentBoxSizeX%)+* 0 _rl*

















6750 PRINT *Xpos Ypos moveto*
6760 PRINT *6 6 _rm*
6770 PRINT *(*+CommentLine2$+*) _S*
6780 PRINT 
6790 ENDIF
6800 PRINT *%----------------- Draw Axia--
6810 PRINT *_lf setfont*
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6820 FOR A9b=l TO NT
6830 PRINT STR$(N(1, A9b))+ • "+STR$(N(2,A%))+• moveto"
6840 PRINT STR$(N(3,A9b) )♦• •+STR$(N(4,K% ) )+■ llneto"
6850 PRINT "stroke"
6860 NEXT A9t
6870 FOR \%=l TO TT
6880 PRINT STR$(T(1,A%)+16)+" ■+ STR$ (T ( 2, A9b)) moveto"
6890 PRINT "("+T$(A%)+") _B"
6900 NEXT
6910 FOR A%=1T014
6920 PRINT STR$(M19b(l,AA))+• "+STR$(Ml%(2,A9b)) moveto"




6970 PRINT STR$(T1(1, A9b)+62)+• •+STR$(T1(2,A9s)) moveto"
6980 PRINT "("+Tl$(A9b)+") _B"
6990 NEXT
7000 PRINT STR$(T2( 1 ) + 5 0 ) • +STR$(T2(2))+• translate"
7010 PRINT "90 rotate"
7020 PRINT "0 0 moveto"
7030 PRINT *("+SCl$+") s"
7040 PRINT "-90 rotate-
7050 PRINT "-"+STR$(T2(l)+50)+" -*+STR$(T2(2))♦■ translate"
7060 PRINT "0.5 setllnewidth"
7070 PRINT 
7080 ENDPROC
7090 FOR A9b=0 TO finish*
7100 IF A%=0 THEN
7110 PRINT STR$(D(0,A9b)+200)+" ■+STR$(D(1,A9b)) moveto"
7120 ELSE




717 0 ENDPROC 
7180 i
7190 REX -------------------------------------------------------------------------------
7200 DEF PROCcomment box 
7210 CLS 
7220 PRINT:










INPUT" Please enter comment";CommentLlne2$
7290 PRINT:
INPUT • OK - Y or N " ; YN$




7340 DEF PROCmouse (boxsizeX9b, boxaizeY*, 11x9b, lly*, urx9b, ury9b)
7350 :
7360 REM BOX DRAWING PROCEEDURE - BOX IS MOVED USING THE MOUSE 
737 0 REM boxsizeX%=X dimension of box,boxsizeY9b=Y dimension of box 
7380 REM llx* and lly* represent the X and Y co-ordinates of the lower left 
7390 REM hand corner of the area within which the box is allowed to move.
7400 REM urrt and \iry% are co-ordinates of the upper right hand corner of 
7410 REM the same area.
7420 :
7430 "POINTER 0 
7440 MOVE 11x9b,lly*
7450 MOUSE ON 0
74 6 0 MOUSE xpos*,ypos*,button*
7470 IF xpos*<llx* THEN xpoa*=llx*
7480 IF xpos*> (urx*-boxsizeX*) THEN xpos*=urx*-boxsizeX*
7490 IF ypoa*<lly* THEN ypos*=lly*
7500 IF ypos*>(ury*-boxaizeY*) THEN ypoa9b=ury*-boxaizeY*
7510 MOVE xpos*, ypos*:
PLOT 406, xpoa*+boxaizeX*,ypos*:





7540 IF xposlVtllx* THEN xpos1%=11X*
7550 IF xpoal*>(urx*-boxsizeX*) THEN xposl*=urx*-boxs1zeX*
7560 IF yposl*<lly* THEN yposl*=lly*
7570 IF ypoal*>(ury*-boxsizeY*) THEN yposl*=ury*-boxsizeY*






7600 MOVE xposl*, ypos 1*:
PLOT 406, xpoal*+boXBizeX*,yposl*:
PLOT 406, xpos l*+boxs 1 zeX%, yposl*+boxs 1 zeY*:





7630 UNTIL button9b=4 





7680 DATA "0 0 1280 1010 0","20 0 0 0 0 0",16,1,32,1,3,16,0
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